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ABSTRACT	  
Eph and their membrane bound ephrin ligands represent the largest family of receptor 
tyrosine kinases (RTKs). Ephs interact with cell-surface ephrin ligands to direct cell 
migration and orchestrate developmental patterning during embryogenesis by 
modulating cell shape and adhesion. Members of the Eph/ephrin family of RTKs are 
expressed in adult life and have ongoing roles both in normal tissue homeostasis and 
in responses to pathological situations. Eph/ephrin proteins are also expressed on 
many tumours including leukaemia, prostate cancer, colorectal cancer and brain 
cancer. High expression in a number of cancers has been linked to progression 
through facilitation of invasiveness and metastatic spread.  
Some members of the Eph/ephrin family of proteins are expressed on normal and 
cancerous haematopoietic cells. Real time PCR analysis showed expression of all 
EphA proteins on the haematopoietic stem cell (HSC) population, except for EphA6 
and EphA8. I have used EphA1, EphA2 and EphA7 knockout mice to investigate the 
effect of these individual Eph proteins in normal haematopoiesis, and in particular 
haematopoietic stem cells in vivo. These studies showed that mice lacking EphA1, 
EphA2 or EphA7 have normal haematopoiesis and no significant defects were 
observed in HSCs. This suggests that if Eph receptors have a role in haematopoietic 
differentiation the presence of other Eph receptors may compensate for the absence of 
individual Eph proteins. 
EphA2 expression has been investigated in many different solid tumours and 
expression of this member of the Eph/ephrin family has been detected in mixed 
lineage leukaemia (MLL). The role of EphA2 in leukaemogenesis was investigated in 
a syngeneic, retroviral model of MLL-AF9 induced acute myeloid leukaemia (AML). 
When HSCs from wild type mice were transduced with the MLL-AF9 retrovirus and 
engrafted into recipient mice, the subsequent leukaemias showed significant 
expression of EphA2 on leukemic blast cells. However when EphA2 null HSCs were 
engrafted, the absence of EphA2 appeared to have no effect on the leukemic process, 
demonstrating that EphA2 is not essential for leukaemia progression. Analysis 
showing increased expression of EphA7 and other Eph proteins demonstrate a 
possible compensatory role for the lack EphA2 expression, if Eph signalling was 
required for leukemic evolution in this model. Following these observations, the role 
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of EphA2 as a therapeutic target for MLL-AF9 leukaemia was evaluated. Results 
showed that radiolabelled (beta particle-emitting lutetium) EphA2 was an effective 
therapeutic approach by significantly delaying the progression of MLL-AF9 
leukaemia. Given the poor prognosis of MLL-driven paediatric acute lymphoblastic 
leukaemia (ALL) this data raises the prospect of effective EphA2-targeted therapy for 
this disease. 
EphA3 is another member of the Eph/ephrin family of RTKs, which was originally 
described in leukaemia and has subsequently been described in many other different 
cancers including sarcomas, lung cancer, melanoma and glioblastoma. The EphA3-
specific monoclonal antibody, IIIA4, binds and activates both human and mouse 
EphA3 with similar affinities. High expression of EphA3 has been reported 
previously on LK63 pre-B ALL cell line which contrasts with lack of expression of 
EphA3 in the Reh, a similar pre-B ALL cell line. The effect of IIIA4 monoclonal 
antibody treatment on LK63 and Reh xenografts in SCID-NOD mice was examined, 
to explore both direct anti-tumour and potential effects of this antibody on the host 
cells. In this xenograft model of leukaemia, using the LK63 cell line, administration 
of the IIIA4 antibody led to inhibition of both tumour growth and spread from bone 
marrow to the spleen and other organs, hence increasing the latency of the disease. In 
contrast, there was no significant reduction in engraftment in the Reh xenograft 
model, suggesting that the anti-tumour effect was directed against the leukemic cells 
rather than the stromal and vascular elements.  
To further analyse the therapeutic targeting of EphA3, LK63 EphA3-knockdown and 
Reh EphA3-expressing cells were tested in the xenograft model. Similarly to the 
LK63 model of leukaemia, the EphA3-expressing Reh xenograft model showed a 
reduction in bone marrow engraftment and slowing of disease progression upon 
treatment with EphA3 monoclonal antibody. Consistent with the effect of EphA3 
monoclonal antibody treatment on Reh xenograft model, the LK63 EphA3 
knockdown xenograft, showed minimal differences between treated and control group 
but had a notably significant reduction in the splenic engraftment compared to the 
normal LK63 model. A more impressive anti-tumour effect was delivered by 
antibody-mediated targeting of a radio-active isotope to EphA3-positive leukemic 
cells, in this case radioactive bismuth (alpha particle emitting) isotope-linked to IIIA4. 
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More importantly, no toxicity to normal tissues was observed, consistent with EphA3 
being expressed at very low or being entirely absent on normal tissues. 
In summary, in this thesis I have shown that whilst individual Eph receptors do not 
have critical roles in normal and malignant haematopoietic cells, individual Eph 
proteins may be candidates for targeted, antibody-based therapies in blood cancers.	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1.1 Haematopoiesis and Leukaemia 
1.1.1 Introduction to haematopoiesis 
Haematopoiesis is characteristically described as a hierarchical developmental 
process in which all lineages of blood are continuously produced throughout life. The 
process of haematopoiesis initially occurs during embryogenesis in the extra-
embryonic yolk sac. The first site of haematopoiesis within the embryo is the aorta-
gonad-mesonephros (AGM) region, pluripotent haematopoietic stem cells generated 
in this region are believed to seed to other organs including liver, spleen, lymph nodes 
and bone marrow. Haematopoiesis eventually ceases in other organs as the bone 
marrow develops into specialised niche that support haematopoietic stem cell (HSC) 
and becomes the primary site of haematopoiesis throughout adult life 1.  
Haematopoietic stem cells (HSCs) give rise to all mature blood cells and comprises a 
small population of cells, constituting of up to 1 in 10,000 bone marrow cells and 1 in 
100,000 blood cells in adults 2.  Haematopoiesis is a multi-step process in which 
HSCs give rise to the cells that undergo lineage commitment, maturation, 
proliferation and eventual migration from the bone marrow. HSCs are capable of 
exponential proliferation and in response to appropriate stimuli give rise to 
progenitors of all blood lineages. They require growth factors for their survival, 
proliferation, maturation and differentiation into mature blood elements 3. In 
accordance with their role in maintaining haematopoiesis throughout life, these cells 
have the capacity to self-renew and the ability to give rise to all haematopoietic cell 
lineages termed multipotency. Self-renewal of the HSCs occurs in either symmetrical 
or asymmetrical cell divisions. In the symmetrical self-renewal the cells divide into 
two identical daughter cells both with HSC properties and thus expanding the 
population of HSCs, however in the asymmetric self-renewal one daughter cell keep 
the HSC property while the other will initiate differentiation and expansion and 
eventually produce mature blood cells 4-6. All mature blood lineages and their 
progenitors originate from HSCs, self-renewing HSCs can be divided into long-term 
HSCs (LT-HSCs) with the most extensive self-renewing capacity, these cells give rise 
to short-term HSCs (ST-HSCs) with a lower self-renewal capacity. LT-HSCs and ST-
HSCs can both generate multipotent progenitor cells (MPPs) with no self-renewal 
capacity and a multilineage differentiation capability 7-9. These cells give rise to two 
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types of oligopotent progenitors known as the common myeloid progenitors (CMPs) 
and the common lymphoid progenitors (CLPs). CMPs generate the more restricted 
granulocyte-macrophage progenitors (GMPs), which develops in to mature 
granulocytic or monocyte macrophage cells, and megakaryocyte/erythrocyte 
progenitors (MEPs), which can terminally differentiate into either megakaryocytes or 
erythrocytes 10,11. CLPs will differentiate into progenitors of the mature B-
lymphocytes, T-lymphocytes and natural killer (NK) cells 12. Both CMPs and CLPs 
have been proposed to give rise to distinct subsets of dendritic cells (Figure 1.1) 13. 
 
Figure 1.1. Haematopoietic heirachy (Adapted from 13). 
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1.1.2 Transcription factors in haematopoiesis 
Several factors are responsible for maintaining haematopoietic stem cell homeostasis, 
including the balance between self-renewal and differentiation, loss through apoptosis 
and migration to other sites. Regulation of self-renewal, differentiation and migration 
within the haematopoietic system is controlled by a variety of both extrinsic and 
intrinsic factors. Transcription factors are important intrinsic regulatory factors in the 
haematopoietic system, governing stem cell self-renewal and lineage commitment 
decisions through regulation of gene expression 1.  
Some transcription factors, including stem cell leukaemia/T-cell acute lymphoblastic 
leukaemia 1 (SCL/Tal1), LIM domain only 2 (LMO2) and GATA binding protein 2 
(GATA-2), are essential for both primitive (embryo-restricted) and definitive (adult) 
haematopoiesis, while others including mixed-lineage leukaemia (MLL) and runt-
related transcription factor 1/ Acute Myeloid Leukaemia 1 (Runx1/Aml1) are 
necessary only for definitive haematopoiesis and therefore they are essential for the 
survival and proliferation of HSCs 14. 
The SCL/Tal1 transcription factor is critical for initiation of haematopoiesis during 
early stages of foetal development 15. It is also important but not essential for the 
development and function of adult HSCs and all blood cells, SCL1/Tal is also 
involved in specification of the erythroid and megakaryocytic lineages 16. The LMO2 
transcription factor is essential for both primitive and definitive haematopoiesis and 
mice lacking either SCL/Tal1 or LMO2 die in embryonic development due to a lack 
of haematopoietic progenitor cells in the early embryo, thus no blood is generated 
leading to embryonic loss 1. LMO2 is also important in regulation of lineage 
specification in erythropoiesis 16.  
GATA-1 and GATA-2 are both important definitive and primitive factors in 
haematopoiesis and loss of either of these can lead to embryonic lethality. In normal 
haematopoiesis GATA-1 is necessary for erythroid and megakaryocytic 
differentiation and GATA-2 is required for development of mast cells and regulation 
of HSCs 17,18. Runx1 is required for development and function of HSC and Runx1 
knockout mice lack definitive haematopoiesis and die during the mid-gestational 
period 19,20. MLL is another transcription factor with an important role in early 
haematopoietic development 21, it has been reported that this gene lies upstream of 
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HOXB4 and is therefore involved in regulation of the HoxB4 gene, which is needed 
for specification of HSCs 1.  
A number of other transcription factors, including Ikaros, activated nuclear form of 
Notch1, cell cycle inhibitor P21, members of the TGF/BMP-4 family, TNFα receptor 
and p55, are also involved in HSC survival and self-renewal 1,14. Some of the 
transcription factors, including PU.1, C/EBP and GATA-1, have the ability to 
“reprogram”, resulting in a switch of cell lineage when they are over expressed in the 
cells with a specific lineage fate 22. In summary, the above transcription factors are 
important intrinsic regulators of HSCs and also in determining the pathway of lineage 
commitment 14 (Figure 1.2).  
 
Figure 1.2. Transcription factors involve in haematopoiesis (Adapted from 1,13). 
LT-HSC
ST-HSC
MPP Multi-Potent 
Progenitors
CLPCMP
MEP GMP
Erythrocytes Platelets Granulocytes Macrophages
Dendritic cells
T-CellsNK-Cells B-Cells
Pro-DC
Oligo-Potent 
Progenitors
Self-renewal
Lineage-restricted
Progenitors
Differentiated
Cells
Self-renewal
PU.1 c-Myc
Gata-1
FOG-1 Gata-1
PU.1
C/EBP
Ikaros IkarosC-myb
Ikaros
C-myb
Pax-5
Runx-1
Scl/tal-1
LMO-2
MLL
Ikaros
PU.1
Notch
Chapter	  1	  
	  
	  
	  
	  
6	  
1.1.3 The extrinsic regulators of HSC 
Cytokines are a group of regulatory proteins with important functions during 
haematopoiesis and in blood cell function. They are involved in regulation of 
quiescence, self-renewal, differentiation, apoptosis, and cell migration, partly by 
inducing alterations in gene transcription 23. Cytokines work by binding to specific 
hetero-dimeric cytokine receptors (e.g. Granulocyte-macrophage colony stimulating 
factor (GM-CSF) binds to the GM-CSF receptor a/b complex) and thus triggering the 
receptor to initiate a process, which mediate the downstream cellular response. In 
particular, the cytokine receptors signal by activation of Janus kinases (JAK), which 
are members of the tyrosine kinase family. These in turn activate downstream 
molecules and in particular signal transducer and activator of transcription (STAT) 
proteins 24.   
Several cytokines act on progenitor cells and influence differentiation, proliferation, 
survival and functional activation of HSCs. Some of these cytokines are interleukins 
(IL-3, IL-5, IL-6, etc), granulocyte-macrophage colony stimulating factor (GM-CSF) 
and granulocyte colony stimulating factor G-SCF 25. Other important cytokines are 
erythropoietin (EPO) and thrombopoietin (TPO), which are members of the IL-2 
subfamily. IL-3 is one of the most important members of interleukin family in early 
haematopoietic cell function; it is involved in survival, proliferation, differentiation 
and maturation of HSCs 26. GM-CSF drives differentiation towards the granulocyte 
and macrophage lineages and G-CSF has a specific role in the production of 
neutrophils 27. Thrombopoietin (TPO), a ligand for the c-mpl cytokine receptor, is the 
primary regulator of megakaryocyte differentiation and functions as a modulator of 
platelet production and release 28. Erythropoietin (EPO) binds to the erythropoietin 
receptor and stimulates red blood cell development 29. 
Receptor tyrosine kinases (RTKs) also mediate extrinsic signals that regulate 
haematopoiesis. Stem cell factor or steel cell factor (SCF) is a cell bound protein 
expressed by stromal cells, which binds to the c-kit receptor tyrosine kinase, 
expressed on HSC. This interaction has a key role in the survival, mobility and 
possibly self-renewal of HSCs. Fms-like kinase 3 (FLT3) is a member of the PDGFR 
family of RTKs and is involved in the development of multipotential stem cells and B 
cells. Macrophage colony-stimulating factor (M-CSF/CSF-1), binds to the c-
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RTK, and is another lineage specific cytokine important in differentiation of 
monocyte progenitors and regulation of mature macrophages 30. Members of the Eph 
family of RTKs, and their ephrin ligands, are also expressed in haematopoiesis and 
their role will be discussed later in this review. 
1.1.4 The bone marrow niche and regulation of HSCs  
Bone marrow is the main site of haematopoiesis in adults and within the bone marrow 
interactions with HSCs regulate the maintenance, proliferation, differentiation and 
migration of the cells into the blood stream. As alluded to in discussion of extrinsic 
factors, the fate of the HSC is controlled by influences within specific niches in the 
bone marrow microenvironment.  There are currently believed to be two distinct 
niches, defined anatomically and physiologically. The endosteal region, or 
osteoblastic niche, is composed of non-haematopoietic bone-forming cells and other 
mesenchymal-derived stromal cells such as reticular cells, fibroblasts and adipocytes. 
This niche is remote from the vasculature and thus is relatively starved of oxygen, 
consequently it is often described as the hypoxic niche; this site has properties, which 
maintain the haematopoietic stem cells in a quiescent or dormant phase of the cell 
cycle. The other bone marrow HSC niche is known as the vascular niche. HSCs 
within this peri-vascular niche are close to the outer surface of the vascular sinusoids 
and thus can proliferate, differentiate and migrate through the sinusoidal wall.  
In summary, whilst these functions form a continuum, the hypoxic, osteoblastic niche 
is believed to be biased towards maintaining the undifferentiated LT-HSCs while the 
vascular niche is more involved in differentiation and release of the mature HSCs 
5,6,31,32. Whilst most of the LT-HSCs in the bone marrow remain in the osteoblastic 
niche and in the G0 phase of the cell cycle, upon receiving the appropriate signal they 
will enter the cell cycle and divide, which result in differentiated, self-renewal and 
migration out of the niche into surrounding bone marrow and the general circulation 
33.  
1.1.5 Leukaemia 
Leukaemia is a malignant disease of the haematopoietic system characterized by the 
abnormal proliferation of either uncommitted or partially committed HSCs 34. 
Leukaemia is classified based on clinical aggressiveness and other features into two 
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broad groups:  acute and chronic leukaemia. Both of these groups are then sub-
classified, according to the origin of the leukemic cells, into myeloid or lymphoid 
leukaemia thus, leukaemia is classified into four main groups comprising acute 
lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), chronic 
lymphocytic leukaemia (CLL) and chronic myeloid leukaemia (CML). The individual 
types (except CML) can be categorised more extensively based on similarities to 
individual types of lymphoid (eg pre-B ALL and T-ALL) and other haematopoietic 
cells (eg erythro leukaemia and promyelocytic leukaemia).  
In many human leukaemias, the disease is caused by disruption in the regulation of 
normal haematopoiesis through altered or aberrant function of genes involved in 
regulation, self-renewal and apoptosis of HSCs. Different types of genetic alteration 
are responsible for development of leukaemia, including chromosomal translocation, 
epigenetic changes and mutations. Of these genetic lesions, alterations in genes 
responsible for proliferation and survival of the HSCs, and genes that regulate 
differentiation or self-renewal of the haematopoietic cells during development can 
give rise to leukaemia 35. A prime example of these genetic alterations is BCR-ABL 
in which chromosomal translocations occur between chromosomes 9 and 22 resulting 
in formation of abnormal fusion proteins where the BCR-ABL fuses the Bcr and Abl 
kinase genes resulting in formation of a unique Bcr-Abl protein in which the Abl 
kinase is constitutively active, the end result is hyper-proliferation and altered 
maturation which manifest as CML 36. Similarly, balanced translocation in the mixed-
lineage leukaemia gene (MLL) result in expression of fusion proteins and the 
consequent altered gene regulatory disruptions leads to either ALL or AML 
leukaemia depending on the type of the translocation. For example the MLL-AF4 
translocation is most frequently found in ALL, while the MLL-AF9 fusions is more 
common in AML 37.  
1.2 Eph-ephrin  
1.2.1 Classification, structure and binding of Eph/ephrin 
The Eph receptors and their membrane bound ephrin ligands represent the largest 
family of receptor tyrosine kinases (RTK’s). The first member was originally termed 
Eph, as it was first identified in an Erythropoietin-Producing Hepatocellular (Eph 
Nomenclature committee, 1997) carcinoma cell line 38. In mammals there are fourteen 
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members of the Eph family of RTKs these are divided into two groups, the EphA and 
EphB family. This classification is based on their sequence homology, ligand 
specificity and structural features. In mammals there are nine members of the EphA 
subgroup (EphA1-8 and EphA10) and five EphB receptors (EphB1-4 and EphB6) 
39,40. 
Eph receptors are type I transmembrane proteins composed of an extracellular region 
with four distinct domains. An N terminal ligand-binding domain with two distinct 
ligand-binding interfaces (N terminal β jelly roll domain) determining the ephrin 
binding. This is followed by a cysteine-rich region, which contains an epidermal 
growth factor (EGF)-like motif involved in receptor dimerisation. The main domain is 
followed by two fibronectin type-III domains 41,42.  The intracellular region comprised 
of a conserved juxtamembrane domain, a tyrosine kinase domain and a sterile alpha 
motif (SAM) domain, the latter have a potential role in receptor clustering 43,44. Most 
of the Eph receptors possess a C-terminal PDZ binding motif (Postsynaptic density 
protein, Disc large, Zona occludens tight junction protein) that is involved in 
signalling at a sub-cellular level and in the assembly of large molecular complexes 
40,42,45 (Figure 1.3A).  
The ephrin ligands of Eph receptors are membrane bound proteins and like the Ephs 
they are divided into two groups based on their structural features and preferential 
binding to either EphA or EphB receptors. The two classes of ephrin ligands are the 
A-class (ephrinA1-5) and B-class (ephrinB1-3) 40. These two classes of the ephrin 
ligands have homology at their N-terminus region while their C-terminal amino acid 
sequence differs. The ephrinA ligands are bound to the plasma membrane by a 
glycosylphosphatidylinositol (GPI)-linker and the ephrinB ligands possess a 
transmembrane–spanning region and a highly conserved cytoplasmic tail with a 
number of highly conserved tyrosine residues and a PDZ-binding motif. The 
conserved tyrosine residues have been shown to serve as a docking site for proteins, 
which mediate downstream ephrin signalling (Figure 1.3B) 39,46. 
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Figure 1.3.	  	  Schematic representation of Eph receptors and ephrin ligand structure.  (A) The 
structure of the Eph receptor. (B) The structure of the ephrinA and ephrinB ligand.	  
Generally, the EphA receptors will preferentially bind to members of the ephrinA 
ligands (ephrinA1-5) while the EphB receptors will preferentially bind to the ephrinB 
ligands (ephrinB1-3) 40,47. There is a high level of binding promiscuity between the 
Eph receptors and the ephrin ligands, however for an individual Eph receptor there is 
a distinct order of affinity of ephrin interactions with affinity constants ranging from 
5-500 nM 48. For instance, the EphA1 receptor binds with a high affinity to ephrinA1 
and a lower affinity to other members of the ephrinA family, including ephrinA3 and 
ephrinA4, and shows essentially no binding to ephrinA5 49. Similarly EphA3 and 
EphB4 have a higher affinity for ephrinA5 and ephrinB2 respectively than for other 
members of the ephrin family 48,50. High affinity interaction is also possible between 
the classes, for example EphA4 binds to both ephrinB and ephrinA ligands and some 
of its most important functions depend on interaction with ephrinB3. Another 
example is EphB2, which binds to ephrinA5 as well as ephrinB ligands (Figure 1.4) 
51,52.  
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Figure 1.4. Schematic of Eph receptor and ephrin binding preference. 
1.2.2 Eph/ephrin activation and signalling  
Eph/ephrin interactions have the capacity to initiate bidirectional signalling. In other 
words both Ephs and ephrins can act as a ligand as well as a receptor and they both 
have the ability to initiate signalling. Signalling initiated by the Eph receptor is 
referred to as forward signalling whereas signalling initiated by the ephrin ligand is 
termed reverse signalling. 
Eph receptor activation occurs following the physical association of the receptor and 
an ephrin ligand on adjacent cell surfaces mediated by the high affinity binding site 
(dimerization), this is followed by interaction with a second Eph/ephrin complex, 
mediated by separate low affinity (tetramerization) binding site to create a hetero-
tetrameric complex 53. The tetramers are then assembled into higher order clusters, 
which appear to be required for effective forward signalling 54,55. The clustering of 
Eph receptors results in ligand-dependent auto-phosphorylation of several tyrosine 
residues within the cytoplasmic kinase domain and juxtamembrane region of the 
receptor, which serve as docking sites for downstream signalling proteins including 
the small GTPases of the Rho and Ras family, focal adhesion kinase (FAK), the janus 
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kinase/signal transducers and activators of transcription (Jak/Stat) and 
phosphatidylinositol 3-kinase (P13K) pathways 56.  
Eph receptor activation influence cell shape and motility through the regulation of the 
Rho GTPases: including RhoA, Cdc42, Rac and Ras, via interactions with specific 
Rho GTPase activating (Rho GAP) and exchange (Rho GEF) factors. The interaction 
with individual Rho GTPases, mediated via direct binding to the cytoplasmic domain 
of Eph proteins of Rho GAP and Rho GEF or their recruitment via adaptor proteins, 
thereby mediating different effects on actin dynamics and cell process formation thus 
regulating cell shape and movement. For example, activation of EphA4 receptor 
results in ephexin (Rho GEF)-mediated activation of RhoA and α-chimaerin (Rho 
GAP)-mediated inactivation of Rac, resulting in actin depolymerization and retraction 
of cell processes 52. Activation through EphB plays a role in actin filament extension, 
morphogenesis and maturation of dendritic spines. Ras family of GTPases (H- and R- 
Ras) are also activated through Eph receptors, however unlike the Rho GTPases, the 
majority of Eph receptors negatively regulate the Ras/Mitogen-activated protein 
kinase (Ras/MAPK) pathway, with activation normally resulting in regulation of 
proliferation and migration 52. 
Eph receptors are also important in mediating a number of other molecules involved 
in cell migration and adhesion due to their ability to regulate signal transduction   
molecules including integrin signalling pathway elements paxillin, FAK, P130 (Cas) 
and integrins themselves. The effect of Eph signalling on integrins is complex as they 
can mediate either promoting or suppressing effects. FAK is important in mediating 
integrin signalling and Eph receptors can down-regulate this pathway 57.  
The Jak/Stat pathway, involved in cell growth and viability, is regulated by EphA 
receptor activation 58. EphB receptors mediate cell migration and proliferation 
through P13K pathway and the protein kinase B/phosphatidylinositol 3-kinase (Akt/ 
PI3K) pathway is involved in the regulation of cell proliferation and viability. 
Eph/ephrin also regulates other signalling pathways including Abl/Arg and p53-
family of tumour suppressor proteins 56. A recent study in glioblastoma multiforme 
(GBM) shows that loss of EphA3 results in elevated MAPK signalling thereby 
inducing differentiation and reducing proliferation and self-renewal. This study 
showed that regulation of extracellular signal-regulated kinases/mitogen-activated 
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protein kinases (ERK/MAPK) signalling by EphA3 is kinase independent of the 
upstream activators of MAPK signalling 59. A similar finding has been made for 
GBM, which express EphA2 at high levels 60.  
In the ephrin-expressing cells, reverse signalling can be induced after Eph/ephrin 
interaction 56,61. EphrinB reverse signalling partly depends on the tyrosine 
phosphorylation of conserved residues in the cytoplasmic region, where 
phosphorylation is mediated by associated tyrosine kinases, most notably members of 
the Src family (Src, Fyn, Lyn, Yes) of tyrosine kinases. When the ephrinB ligand is 
phosphorylated, it can bind to cytosolic adaptor molecules via (Src Homology-2) SH-
2 and SH-3 domains or PDZ domains 45. The protein tyrosine phosphatase basophil-
like (PTP-BL) has been identified as a negative regulator of ephrinB signalling and it 
binds to ephrinB through its C-terminal PDZ binding motif. De-phosphorylation of 
the ephrinB cytoplasmic domain can inactivate the Src family of kinase and therefore 
cause termination of reverse signalling 62.  In the activated ephrinB ligand, the PDZ 
motif plays an important role in assembly of other signalling molecules. EphrinB 
binds to cytoplasmic protein PDZ-RGS3, which contains a PDZ domain and a 
regulator of G-protein signalling (RGS) domain. Activation of the ephrinB ligand by 
EphB receptor via the PDZ-RGS interferes with signalling of the stromal derived 
factor (SDF)-1 via its G-protein coupled receptor and the chemokine receptor-4 
(CXCR4). EphrinB reverse signalling has thus been implicated with regulation of 
migration in cerebellar development 63. 
The ephrinA reverse signalling mechanism is not well understood, however it is likely 
that the signalling response is initiated by activity of the Src family of RTKs in which 
transmembrane adaptor molecules, associating with the lipid anchor of the ephrinA 
proteins, transmit the signal across the membrane. For example, ephrinA5 induces 
signalling within the ephrinA expressing cell when bound to its cognate Eph receptor 
64-66.  
1.2.3 Expression and function of the Eph and ephrin genes 
Eph signalling controls cell adhesion, migration, invasion and morphology by 
influencing integrin and intercellular adhesion molecule activity and by modification 
of actin cytoskeleton organization as described above. Through these mechanisms 
Eph function effects not only the processes of embryogenesis but also specialised 
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cellular function in adult tissues, including bone remodelling, immune function and 
synaptic plasticity as well as cell proliferation and survival of specific tissue stem 
cells as described further below 64,67. 
Both Eph and ephrin proteins are important in regulating cell-cell interactions and 
their interaction can initiate either cell adhesion or repulsion. Cell repulsion occurs 
when bidirectional signalling triggers cytoskeletal contraction, loss of focal adhesions, 
cell rounding and cell detachment, whereas cell attachment occurs when signals are in 
favour of cell adhesion and migration 68. This interaction influences many different 
cell behaviours during embryogenesis and in adult life 64. Eph/ephrin interactions 
mediate formation of tissue boundaries (e.g. hindbrain rhombomeres) 69, control axon 
guidance during development and also tissue morphogenesis and patterning 70,71. 
Eph/ephrin interactions are also involved in development of vascular system 72, stem 
cell biology 73, haematopoiesis, erythropoiesis, immune function and in tumour 
invasion and metastasis 64,67,74-76’.  
Many members of the Eph/ephrin family are expressed at high levels in some cancer 
cells and also elements of the tumour microenvironment, where they influence tumour 
growth and spread. Specific examples include lung, breast and prostate cancer, as well 
as melanoma, sarcomas and leukaemias 77,78. There is evidence that the Eph receptors 
can have either tumour suppressing or tumour promoting activity, depending on the 
tissue and their expression pattern 64. Thus, the role and function of Eph/ephrins in 
cancer is not yet fully elucidated as some tumours show an elevated level of Eph 
expression while others show a decrease in Eph expression and as yet no single model 
of their function encompasses all cancers. For example, EphA2 is up-regulated in 
many cancers including breast and prostate and its expression is linked to an increase 
in malignancy 79,80, however it’s is down-regulated in colon cancer 81. Similarly, 
EphA1 expression is up-regulated in ovarian cancer 77 but down-regulated in 
advanced skin and colorectal cancers 82,83. Studies have also shown the role of EphA7 
as a tumour suppressor in follicular lymphoma 84, tumour suppressor function has also 
been reported for EphB receptors, including EphB2 and EphB3 in colorectal cancer 
67,85. EphB4 is another important example as this gene can act as either a tumour 
suppressor or an oncogene in different facets of breast cancer progression 86,87.  Table 
1.1 represents the expression of Eph receptor in normal and malignant tissues. 
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Table 1.1. Eph expression in normal and malignant tissues. 
Eph Tissue expression Expression in cancer References 
EphA1 Widely express in 
mouse epithelial 
tissues evidence of 
expression in 
hematopoietic 
progenitors 
Over expressed in many different cancers 
including hepatocellular, colon, prostate, lung, 
gastric, colon cancer  
Down regulated in non-melanoma skin cancer, 
colorectal cancer 
 
38,61,82,83,88-93 
EphA2 Expressed highly in 
adult human epithelial 
cells and endothelium 
Over expressed in prostate, breast, melanoma, lung 
and ovarian cancers 
Up regulated in glioblastoma 
Down-regulated in colon cancer 
 
60,61,79,80,92-99 
EphA3 Expressed in various 
stages of embryonic 
development and in 
adult central nervous 
system 
Expressed in neural cancers, leukaemia, 
lymphomas and sarcomas 
Up-regulated in lung, brain, liver and kidney and 
over expressed in melanoma 
 
61,92,93,100-104 
EphA4 Expressed in 
development, final 
stages of 
embryogenesis and 
central nervous system 
Expressed in prostate, pancreatic cancer 
Up regulated in lung cancer  
Down-regulated kidney 
Over expressed in gastric cancer 
 
61,92,93,100,105-108 
EphA5 Expressed in nervous 
system 
Expressed in neuroblastomas and neural cancer  
Down-regulated in breast cancer 
 
61,92,93,108-110 
EphA6  Expressed more 
prominent in adult 
tissues than in 
embryonic tissues 
Down-regulated in colon cancer and renal 
carcinoma 
Up-regulated in lung and liver cancer 
 
61,92,93 
EphA7 Expressed in 
developing neural 
tubes, thymus, 
lymphoid tissues and 
foetal bone marrow 
Expressed in colorectal cancer, lung, suppressed 
on follicular lymphoma 
Up-regulated in ALL1 leukaemia 
 
 
61,81,84,92,93,111-
113 
EphA8 Expressed in spinal 
cord and neuronal cells 
Expressed in colon cancer 
Down regulated in glioblastoma  
 
61,92,93 
EphA10 Expressed in testis   114 
EphB1 Expressed in Brain and 
colon  
Expressed in lung cancer 
Down-regulated in colon carcinoma and in kidney 
cancer 
 
61,83,92 
EphB2 Expressed in epithelial 
cells, thymus, 
lymphoid, osteoblastic 
and osteoclastic cells  
Over expressed in gastrointestinal  
Expressed in colon, ovarian and lung cancer 
Up-regulated in colorectal, kidney and 
hepatocellular cancer 
 
61,92,115 
EphB3 Expressed in various 
tissues 
Expressed in prostate cancer, lung cancer and 
melanoma 
 
61,92 
EphB4 Expressed in placenta 
and in range of 
primary tissues 
including brain, 
endothelium, 
hematopoietic cells 
Expressed in colon cancer, endometrial, breast, 
neuroblastoma, glioblastoma and leukaemia and 
lymphoma cancer 
 
61,92,116-118 
EphB6 Expressed in various 
tissues including brain, 
pancreas, thymus and 
T-cells 
Expressed in thymus and leukaemia  
Up regulated in colon cancer 
Down-regulated in breast, lung and kidney cancer  
 
61,92,119 
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1.3 The Eph/ephrin in HSC and leukaemia  
1.3.1 Eph/ephrin expression in HSCs and progenitors 
The expression of Eph/ephrin has been detected on purified population of 
haematopoietic stem cells (HSCs) in both human and mouse. Gene expression 
analysis of HSCs showed expression of ephrinB2, indicating that it may be involved 
in signalling between HSCs and their microenvironment. Other array based studies on 
primary human HSCs (CD34+ hematopoietic cells) showed expression of the EphA1 
protein and its ligands ephrinA3 and ephrinA4 suggesting that their interaction may 
play a role in haematopoietic stem and progenitor cell positioning and function 120,121. 
Further analysis of CD133+ and CD34+ hematopoietic stem cells in peripheral blood 
showed expression of EphA2 in all CD34+ cells and the majority of CD133+ cells 
however EphB2 was expressed in all CD133+ cells and fifty percent of CD34+ cells, 
these data suggest that a number of elements of the Eph/ephrin system may have a 
role in HSC function through regulatory effects on cell adhesion, migration and 
differentiation but also that there may be a degree of functional redundancy 122.  
Real-time quantitative PCR of mouse Lin-ckit+sca1+ (LKS) cells showed detectable 
expression of all EphA receptors except EphA6 and EphA8, along with ephrinA 
ligands, with the ephrinA4 and ephrinA5 being the most highly expressed ligands on 
purified HSCs in the mouse bone marrow 123. Flow cytometric analysis of EphA2, 
A3, A4 and A5 along with ephrinA1-5 showed that EphA2 and EphA3 were the 
highest expressing EphA receptors. Expression of EphA2, A3, A4 and A5 was also 
detected in the mouse stromal cell lines however human stromal cell line expressed 
only EphA2 at moderate levels 123. Whilst the function of Eph/ephrin has not been 
fully investigated, a role in HSC trafficking was demonstrated by treatment of mice 
with an Eph/ephrin inhibitor, EphA3-Fc, which resulted in mobilisation of bone 
marrow progenitor cells into peripheral blood 123.  
Some of the members of the Eph/ephrin family are also involved in development and 
regulation of mature haematopoietic cells. For example, EphA4 and EphB1 along 
with ephrinB1 ligand are expressed on human platelets 124, these studies shows that 
EphA4 is involved in regulation of platelet aggregation and adhesion to fibrinogen, a 
process dependent on integrin αIIbβ3 engagement 76.  
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EphB4 was originally identified on human bone marrow CD34+ cells and its 
expression has been reported on erythroid progenitor cells in early stages of red blood 
cell development.  Significantly, the EphB4 ligand, ephrinB2, is expressed on bone 
marrow stromal cells 125 where it has been reported to be involved with regulating 
erythropoiesis via interaction with EphB4 126. Studies by Suenobu et al 126 showed co-
culturing haematopoietic progenitor cells expressing EphB4 with stromal cells 
expressing ephrinB2 results in haematopoietic progenitor cells detachment from 
stromal layer and differentiation into a mature erythroid cells accompanied by EphB4 
down regulation, however co-culturing these cell with ephrinB2-negative stromal 
cells resulted in less maturation of erythroid cells and no change to EphB4 expression 
126. EphrinB2 ectopic expression in stromal cells increased adhesion of 
haematopoietic cells to stromal cells and decreased transmigration of haematopoietic 
cells beneath a stromal cell monolayer.  These findings strongly support a role for the 
EphB4/ephrinB2 interaction in migration and colonisation of stem/progenitors cells in 
the bone marrow microenvironment 127. 
Some of the Eph/ephrin molecules are also involved in lymphoid development. The 
expression of Eph/ephrin has been studied extensively in T-lymphocytes and 
expression of some of the members of this family including EphA1, EphA2, EphA3, 
EphA4, EphA7, EphB2, EphB6, ephrinA1 ephrinA3, ephrinA5 and ephrinB1 has 
been reported in the thymus, both on thymic stroma and lymphoid cells suggesting a 
role in T-cell development 128-130. Interestingly, there are no reports of defective T-
lineage development in knockout mice, perhaps a result of there being multiple Eph 
receptors with over-lapping functions in the T-cell compartment.  
As well as T-lymphocytes the expression of Eph/ephrin gene has been also reported in 
B-lymphocytes 75,131,132. EphA7 and EphA4 transcripts were found in human foetal 
bone marrow pre-B and pro-B cells (pre/pro B-cells). EphA4 expression is found in 
both adult and foetal pro-B and pre-B lineage cells with high levels of expression in 
peripheral blood. The full length EphA7 transcript, however, was not found in mature 
foetal B-lineage and adult B-lineage cells. This suggests that EphA7 may be involved 
in expansion and /or differentiation of pre/pro B-cell but is lost on mature B-cells 132. 
Further studies show that there are different types of EphA7 mRNA, one of which 
encodes the full length EphA7 and another splice variant encodes a truncated, soluble 
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protein that lacks the cytoplasmic domain.  Studies by Dawson et al 112 showed that 
normal lymphocytes express and secrete the truncated form of EphA7 112, which has 
been shown to have tumour suppressive effects in lymphoma 84. 
1.3.2 Eph/ephrin in vascular development 
In the context of haematopoiesis, the vascular system is crucial in development of 
blood cells within the bone marrow and also in the function and migration of mature 
haematopoietic cells.  The vascular system arises from two distinct processes known 
as vasculogenesis and angiogenesis. Vasculogenesis is an early event in embryonic 
development involving mesodermal cells differentiation to form a vascular plexus in 
embryonic tissues and angiogenesis is a process in which new blood vessels are 
formed from existing blood vessels. Angiogenesis has a role both in early 
development and in the adult haematopoietic system, it also promotes sprouting of 
new blood vessels in embryonic and postnatal vasculature and it has been shown to be 
important in development and metastasis of solid tumours 133. Some members of 
Eph/ephrin family have established roles in vasculogenesis and angiogenesis. The 
expression analysis of Eph/ephrin using real-time polymerase chain reaction (RT-
PCR) has shown expression of EphB2, EphB3, EphB4, ephrinB1 and ephrinB2 in the 
yolk sac 134. EphrinB1 expression has been detected on both arteries and veins while 
the high affinity ligand for EphB4, ephrinB2, is only detected on arteries and EphB4 
expression is only detected on veins. Knockout ephrinB2 mice and some of the 
EphB2 and EphB3 double mutants mice have defects in embryonic vasculature and 
therefore these mice are embryonically lethal. EphB2 and ephrinB2 expression in 
mesenchyme adjacent to vessels and the vascular defects in EphB2/EphB3 double 
mutants indicate a requirement for Eph/ephrin signalling between endothelial cells 
and surrounding mesenchymal cells 134. EphA2 has also been reported to have a role 
in angiogenesis and the expression of EphA2 and its ligand ephrinA1 has been 
reported in both human and mouse tumour vasculature 99.  
1.3.3 Eph/ephrin in bone remodelling and formation 
The bone marrow is the principal site of haematopoiesis in adult animals and requires 
both vascular and other stromal cell types to create the haematopoietic niche. 
Important amongst these are the osteoblasts and osteoclasts, which mediate bone 
formation and remodelling. Bone is constantly remodelled through resorption of 
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mineralized bone by osteoclast and formation of new bone by osteoblast. Coupling of 
bone resorption and formation is critical during normal bone remodelling and it is 
necessary for bone growth, any deregulation in this process will result in pathological 
bone disease 56,115.  
Eph receptors and ephrin ligands are important in bone remodelling and homeostasis 
during this process. Eph/ephrin bidirectional signalling regulates differentiation and 
function of the bone cells. Real time PCR (RT-PCR) analysis of the Eph/ephrin 
showed mRNA expression of ephrin ligands, ephrinB1, ephrinB2 and ephrinA1, A2, 
A4 and A5, as well as Eph receptors including EphB2, B3, B4, B6, EphA2, EphA3, 
EphA4 and EphA7 receptors on osteoblastic and osteoclastic cells 135-137. Expression 
of EphB4 is observed on the osteoblasts and forward signalling through EphB4 results 
in bone formation and reverse signalling through ephrinB2 inhibit bone resorption 
therefore ephrinB2/EphB4 act as coupling stimulator 135. Expression of ephrinA2 was 
observed during early osteoclastogenesis and unlike the ephrinB2 it acts as coupling 
inhibitor as reverse signalling through ephrinA2 result osteoclastogenesis and EphA2 
forward signalling into osteoblast inhibit osteoblastic bone formation and 
mineralization 136. EphrinA2/EphA2 bidirectional signalling facilitates bone 
remodelling at initiation phase, forward signalling through EphA2 receptor on 
osteoblast inhibit osteoblastic differentiation and bone formation and reverse 
signalling into osteoclast through ephrinA2 promote osteoclast differentiation 115,136. 
EphrinB1 full knockout mice are prenatally lethal and they have skeletal defects. 
Studies on disruption of ephrinB1 on collagen I producing cells result in reduce bone 
formation and skull defect and studies on ephrinB1 conditional knockout mice shows 
defect in osteoblastic mediated bone formation with no increase in osteoclastic bone 
resorption and this condition results in reduction in bone size and density 138,139.   
The importance of Eph/ephrin has also been shown in various stem cell niches, 
including: neural, dental and intestinal stem cell compartments 140,141. More recent 
studies show their involvement in bone homeostasis and mesenchymal stem cell 
(MSC) regulation. Arthur et al 141 showed increase in osteogenic differentiation upon 
ephrinB1 and/or ephrinB2 expression by MSC. They also showed that ephrinB1 
activation promoted chondrogenic differentiation. Therefore, EphB/ephrinB 
interactions may be involved in recruitment, migration and differentiation of MSC 
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during bone repair 141. Studies by Ting et al 123 showed that ephrinA signalling 
interact with stem/progenitor cells in the bone marrow niche as its signalling mediates 
the release of progenitor cells from haematopoietic niche 123.  
Interestingly, Eph/ephrin interaction is also involved in bone malignancies and 
tumours. Osteocarcinoma is a malignant bone tumour in adolescence and microarray 
analysis studies show increased expression of EphA2, EphA4, ephrinB1 and 
ephrinA1 in osteosarcoma cells 142,143.  
1.3.4 Eph/ephrin expression in leukaemia and other haematopoietic 
tumours 
Both chronic and acute myeloid leukaemias are malignant diseases of the 
haematopoietic system, which in most cases are believed to arise through the 
abnormal proliferation of either uncommitted or partially committed HSCs 34. The 
origin of other types of leukaemia such as promyelocytic leukaemia, pre-B acute 
lymphoblastic leukaemia (Pre-B ALL), T-ALL and CLL are more likely due to 
malignant transformation of more mature progenitor cells. Expressions of elements of 
the Eph/ephrin system have been detected on many types of human leukaemias. One 
of the best studied is EphA3, which was originally identified in the LK63 pre-B ALL 
cell line and further investigations revealed its expression in T-cell leukaemia cell 
lines such as Jurkat, JM and HSB-2 103,144. It has been shown that EphA3 can induce 
both adhesive and cell repulsive responses in different cell types 145. In analysing 
ephrin induced cell adhesion in LK63 cells, a critical role was identified for protein 
phosphatase activity, which prevented EphA3 phosphorylation and hence maintained 
the Eph/ephrin adhesive bond and prevented initiation of the signalling mechanisms 
leading to cell repulsion 145. In leukaemia, EphA3 is expressed at significantly higher 
levels compared to normal blood cells, elevated expression of EphA3 has been 
detected in a proportion of clinical samples including cases of lymphoid and myeloid 
leukaemias 103. Elevated EphA3 expression has also been detected on other cancers 
such as lung cancer, melanoma and brain tumours 59,102,103,145, where expression was 
found to be absent or low in corresponding normal tissues 92,103,146. Recent array based 
studies showed EphA3 as one of the genes with loss in copy number alteration (CNA) 
in the genome of acute myeloid leukaemia (AML) patients 147. Further studies by 
Guan et al 148 showed copy number variation (CNV) of EphA3 to be associated with 
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various types haematological malignancies and therefore CNV of EphA3 could be 
used as a diagnostic indicator for different types of leukaemia 148. Many cancers 
including leukaemia require multiple cooperative oncogene mutations for malignant 
cell transformation. Specific sets of genes synergically dis-regulated by cooperative 
oncogenes are known as cooperative response genes (CRGs), which regulate 
leukaemia stem cell (LSC) growth and survival.  Studies by Ashton et al 149 where 
stem cells were retrovirally-transduced with two fusion genes found in human 
myeloid leukaemias, NUP98-HoxA9 and Bcr-Abl, have identified EphA3 as a 
common CRG.  They showed that shRNA knockdown of EphA3 in leukemic stem 
cells reduce leukemic cell engraftment, that this gene may be responsible for 
leukaemia stem cell growth and survival in bone marrow microenvironment 149. With 
the involvement of EphA3 in many different types of leukaemia a high affinity 
monoclonal antibody to EphA3 (cIIIA4) 103 has been fully humaneered by Kalabios 
and the resulting antibody, KB004, is now in phase I clinical trial in leukaemia and 
other haematological cancers 150.  
As mentioned previously EphB4 was originally identified in human bone marrow 
CD34+ cells and its expression has been reported in erythroid progenitor cells, 
however its ligand ephrinB2 is expressed in bone marrow stromal cells 125.  Co-
expression of EphB4 and ephrinB2 is found in the yolk sac, which is the first site of 
haematopoiesis and vascular development during embryogenesis. EphB4/ephrinB2 
expression has been shown in the majority of leukaemia and lymphoma cell lines 
although expression in clinical samples appears less prominent 118. Antibodies to 
EphB4 have undergone extensive pre-clinical evaluation and shown good anti-tumour 
effects in solid tumours which over-express EphB4 by inhibition of angiogenesis, 
however no efficacy has been shown for their effect in haematopoietic tumours to 
date 151. Nevertheless, these antibodies may have the potential to be developed to 
target EphB4 in leukaemia and related blood cancers. 
Studies by Nakanishi et al 113 shows EphA7 up regulation in the ALL1 associated 
leukaemia (ALL1/AF4 and ALL1/AF9). They also showed that EphA7 up-regulation 
was associated with phosphorylation of ERK and treatment with a phosphorylated 
ERK blocking drug resulted in apoptotic cell death in ALL1/AF4 leukemic blast cells 
113.  Thus, anti-EphA7 antibodies or other inhibitors may well have a role in 
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leukaemia associated with this translocation. In contra-distinction to this positive role 
in leukaemia, EphA7 is lost in lymphomas, where the gene is hypermethylated and 
repressed in germinal center B-cell non-Hodgkins lymphomas and this has a potential 
to influence tumour progression and spread 112. Further studies show EphA7 as 
targeted tumour suppressor gene in T-cell lymphoblastic lymphoma (T-LBL) and 
follicular B-cell lymphoma 84,152.  
EphB6 expression has been observed in normal human tissue and over-expression of 
EphB6 has also been reported in both myeloid 153 and lymphoid leukaemias 119,154. 
The expression level of EphB6 decreases with maturation of the cells in T-cell 
derived leukaemia-cells, therefore suggesting that EphB6 expression regulates T-cell 
development but has less significant role in mature T cells 119.  To date, there are no 
reports of experimental therapies targeting EphB6. Table 1.2 represent the summary 
of Eph receptors used as therapy target in various malignancies.  
Table 1.2. Eph receptors as a therapy target for cancer. 
Eph Targeted therapy References 
EphA1 Tumour suppressor in colorectal cancer 81 
EphA2 EphA2 targeting reagents in ovarian cancer therapy 155 
EphA3 Therapeutic target in leukaemia and glioblastoma 59,146 
EphA7 Tumour suppressor in T-LBL and follicular lymphoma 84,156 
EphB4 EphB4 antibody to inhibit solid tumour growth  151 
In summary, the aberrant expression of Eph receptors in haematopoietic tumours 
reflects the spectrum of functions of these receptors in all cancers. In some cancers 
these genes act as tumour suppressor, examples being EphA1 in colorectal cancer and 
EphA7 in follicular lymphomas. On the other hand, these proteins can also have 
oncogenic effects, examples being the expression of EphA2 and EphA3 in glioma and 
the over-expression of EphA3 in leukaemia. In terms of therapy, the over-expression 
in certain tumours, taken together with the surface expression of these proteins, makes 
a strong case for targeted therapies. This is particularly the case when expression on 
normal tissues is minimal. This is exemplified by EphA3 and EphB4 where no 
toxicity was evident in pre-clinical testing of potential therapeutic antibodies. These 
studies reveal the therapeutic potential of targeting components of the Eph/ephrin 
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system in leukaemia and other cancers. These results should prompt further research 
into the specific roles of these proteins in different cancers as a prelude to designing 
and optimizing the therapeutic targeting of these proteins. 
1.4 Hypothesis and Aims 
1.4.1 Hypothesis 
The available literature indicates that many leukaemias express high levels of Eph 
receptors but that any individual receptor is only expressed in a proportion of cases. 
The expression of the Eph/ephrin gene has been found in HSCs and leukaemia, 
however the function of this family of RTKs is not yet fully understood. Based on 
these preliminary data, I have hypothesized that the Eph genes have a role in the 
pathogenesis of leukaemia and in regulation of normal and leukemic haematopoietic 
stem cells and progenitor cells. It is envisaged that Eph proteins may provide novel 
therapeutic targets in leukaemia. To explore these hypotheses I have proposed the 
following aims: 
Aim 1 – To explore the expression and role of EphA receptors particularly EphA1, 
EphA2 and EphA7 in normal haematopoiesis. 
Aim 2 – To use animal models of acute leukaemia to explore the role of EphA2 genes 
by utilising EphA2 knockout mice and test for modification of leukaemogenesis and 
to test EphA2 targeted therapy. 
Aim 3 – To use EphA3 targeting agents (monoclonal antibodies and soluble 
inhibitors) as possible therapeutics in the murine xenograft and leukaemia models. 
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2.1 Introduction 
Eph/ephrins belong to the largest family of receptor tyrosine kinases (RTKs). Eph 
signalling controls many cellular responses including cell adhesion, migration and 
invasion during development and homeostasis. Many members of this family of 
RTKs are strongly expressed at different stages of embryonic development and later 
in adult tissues. Severe embryonic defects in cardiovascular, skeletal or neural 
systems are observed upon deletion of some members of Eph/ephrin family 157. 
Eph/ephrin together with fibronectin and integrin are involved in mesenchymal 
development and the signalling controls formation of tissue boundaries and neuronal 
growth. They also have a role in vasculogenesis and angiogenesis early in 
development. EphA2 expression has been reported in angiogenesis 99 and RT-PCR 
analysis showed expression of EphB2, EphB3, EphB4, ephrinB1 and ephrinB2 in the 
yolk sac 134. Eph/ephrin signalling regulates cell movement and positioning in many 
developmental processes through control of cell adhesion and de-adhesion. These 
processes are present throughout life in the haematopoietic system. Thus, Eph/ephrin 
regulation, via cell-cell signalling, could provide a highly localised mechanism of 
regulation in the temporal-spatial development of haematopoietic cells.  
Expressions of members of the Eph/ephrin family have been reported on mouse 
thymus and the expression is involved with T-cell development 64. In situ 
hybridisation and RT-PCR analysis of thymus showed expression of Eph receptors on 
different thymocytes compartments, expression of EphA1 and EphA2 is detected on 
medullary stromal cells, EphA4 on thymic medulla and EphA7 on thymic cortex and 
subcapsule 111. EphA1 expression has been detected on thymic medulla. Studies by 
Aasheim et al. showed expression of EphA1 and EphA4 on CD4+ T-lymphocytes and 
suggested that activation of EphA1 through ephrinA1 ligand causes intracellular 
tyrosine phosphorylation, and actin polymerization, which result in an increased 
chemotactic response 158. EphB6 is also expressed on CD4+/CD8+ T-cells, however 
it was shown that T-cell population in the EphB6 null mice is normal and these mice 
have no defect in T-cell development 130.  
The expression of Eph/ephrin has been described on both malignant and normal B-
cells. EphA3 was originally described on malignant pre B-cells 103 and EphA4 
transcript is expressed on all B-cell populations obtained from foetal and adult bone 
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marrow 132. Expression of full length EphA7 is detected on pre/pro B-cells but is lost 
on mature B-cells however expression of truncated form of EphA7 is found on both 
embryonic and mature B-cells, which suggests that EphA7 might be involved in 
expansion and differentiation of B-cells 112,132,159. RT-PCR analysis showed mRNA 
expression of EphA2, EphA4, EphA7, EphB1 and EphB3 on dendritic cells obtained 
from CD34+ progenitors 160. EphB4 and ephrinB2 expression has been reported on 
erythroid precursors and the expression of EphA4, EphB1 and ephrinB1 has been 
detected on platelets 124,161. 
To fully understand the effect of Eph genes on haematopoiesis, I will analyse the 
differentiated lineage+ cells, progenitor cells and haematopoietic stem cells in EphA1, 
EphA2 and EphA7 knockout mice and their wild type littermates as these EphA 
receptors are widely expressed on many haematopoietic cells. Steidl et al. (2004) 
showed expression EphA1 along with its ligands ephrinA3 and ephrinA4 on human 
CD34+ჼhaematopoietic cells.  Other studies showed expression of EphA1 on mouse 
HSCs, thymocytes and B-lymphocytes, which suggest a possible role for EphA1 in 
haematopoietic stem and progenitor cell positioning and function 121,123. Expression of 
EphA2 has been reported on LKS+ cells, thymocytes and dendritic cells and EphA2 
has been reported to be involved with angiogenesis 123. EphA7 is expressed on 
thymocytes and dendritic cells and is developmentally regulated during human B-
lymphopoiesis, EphA7 expression has also been detected on mixed lineage leukaemia 
(MLL) 113,162. Therefore, EphA1, EphA2 and EphA7 could be interesting targets for 
analysis in haematopoiesis.  
EphA1 was the first member of Eph/ephrin family to be discovered and it was 
originally cloned from erythropoietin producing hepatocarcinoma cell line 38.  The 
highest affinity ligands for EphA1 are ephrinA1 followed by ephrinA3 and ephrinA4 
with lower affinities, the expression of EphA1 along with its ligands is found during 
the early stages of development 163. EphA1 expression is found on mouse epithelial 
tissues including skin, lung, liver, kidney, thymus uterus and vagina 88,164. Like most 
other Ephs, over expression of EphA1 has been found on variety of cancers including 
skin, lung, liver, pancreas, breast, stomach and colon carcinomas 92. EphA1 mutant 
mice were generated in our laboratory by insertion of an internal ribosome entry site 
(IRES)-human placental alkaline phosphatase (ALPP) reporter cassette into EphA1 
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exon-II gene to develop a genetic knockout. EphA1 is important in tissue pattering 
and the EphA1 knockout mice have two distinct phenotypes, the more common 
phenotype is development of kinky tail and the other one is imperforate uterovaginal 
development with hydrometrocolp, which is caused by resistance of cells to hormone-
induced apoptosis 165.  
EphA2 was first discovered in human epithelial carcinoma HeLa cells and was 
originally named epithelial cell kinase (Eck) for its expression in the majority of 
epithelial cells 166. EphA2 has the ability to bind to all members of ephrinA ligands, 
however it could also function in a ligand independent manner 167,168. EphA2 
expression has been detected on embryonic tissues and is mainly found in the 
embryonic nervous system, embryonic spinal cord, in lens development and 
developing retina. EphA2 signalling is involved with regulation of cell growth, 
migration, and invasion and is strongly expressed in embryonic stem cells and during 
organogenesis. EphA2 is also found in adult tissues with low levels of expression on 
the surface of variety of proliferating epithelial cells including mammary glands, 
ovary, colon, kidney, and lung epithelial cells 167,168. EphA2 is expressed in a range of 
different cancers including melanoma, breast, prostate and glioblastoma. EphA2 null 
mice were generated using the gene trap method, where most common phenotype of 
these mice is kinky short tail on a 129/Svj and C57BL/6 mixed background although 
this phenotype was lost when the mice where backcrossed with C57BL/6 mice 169.  
Murine EphA7 was first discovered in central nervous system and human EphA7 was 
isolated from cDNA clones of human foetal brain library and was found to be 
expressed widely in human tissues 170,171. Expression of EphA7 is found on various 
embryonic tissues including central nervous system and kidney vasculature 92,172. 
Three forms of EphA7 have been discovered in human and mouse including one full-
length EphA7 and two truncated forms of EphA7, where they lack an intracellular 
tyrosin kinase domain 173,159. The expression is involved with different types of 
cancers including up-regulation in hepatocellular carcinomas and lung cancer and 
down-regulation in colon carcinomas 92. The EphA7 knockout mice were generated 
using homologous recombination in the gene encoding EphA7 and by excising the 
first exon, which contained the start codon and signal peptide for the EphA7. EphA7 
null mice were fertile and showed no morphological or behavioural defects 174.  
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As mentioned previously, expression of members of Eph/ephrin family of RTKs is 
found on many haematopoietic cells however currently there is a lack of knowledge in 
understanding the functional significances of the individual Eph/ephrins in 
haematopoiesis. Therefore, I have utilised EphA1, EphA2 and EphA7 knockout mice 
to investigate the effect of genetic deficiency of these Eph receptors on 
haematopoiesis. In this chapter the EphA1, EphA2 and EphA7 knockout mice were 
phenotyped and mature differentiated cells, progenitors and haematopoietic stem cells 
were analysed for haematopoietic abnormalities. This analysis will determine if 
individual Eph receptors have a significant role in normal haematopoiesis or 
alternatively if redundancy means loss of individual receptors will not be functionally 
significant. 
2.2  Methods 
2.2.1 Animals 
Female mice of the congenic strains C57BL/6 (Ly 5.2) and PTPRC (Ly 5.1) were 
purchased from Animal Resource Centre (Perth, Australia) at the age of 5-6 weeks. 
C57BL/6 (Ly 5.2) and PTPRC (Ly 5.1) were crossed to produce double positive 
CD45.1/45.2 congenic mice. EphA1 knockout mice were developed in our laboratory 
and backcrossed to C57BL/6 for more than 10 generations 165. EphA2 knockout mice 
were kindly supplied by Dr Naruse-nakajima (University of Tokyo)169, these mice 
were similarly backcrossed with C57BL/6 (Jackson Labs) mice for 12 generations and 
subsequently maintained as homozygous knockouts on the C57BL/6 background. The 
EphA7 heterozygous mice were purchased from Jackson Laboratory, these mice were 
on a mixed background (129/C57BL/6) and were crossed with each other to develop 
homozygous mutant EphA7 mice and homozygous wild type EphA7 mice 175. All of 
these mice were kept in QIMR Berghofer Medical Research Institute pathogen free 
animal facility according to institute protocols.  
2.2.2 Immunophenotyping analysis 
Peripheral blood was collected using submandibular blood sampling and analysed on 
a Hemavet analyser (Drew Scientific) to obtain the number of following blood 
parameters, hematocrit (HCT), white blood cell (WBC), red blood cell (RBC) 
neutrophil, lymphocyte, monocyte and platelet. For immunophenotyping analysis, 
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bone marrow and spleen tissues were collected from mice euthanized according to 
approved institute guidelines. To isolate bone marrow and spleen cells from these 
mice, bone marrow was flushed with a 26G needle and syringe containing 2% foetal 
bovine serum/phosphate-buffered saline (FBS/PBS) and filtered through 100 µm 
filters, spleen were dissociated, the cell suspension were washed through a 70 µm 
filter and red blood cells were lysed using red cell lysis buffer (Pharm Lyse™, BD 
Biosciences). All antibodies were obtained from eBioscience unless otherwise stated, 
and used at concentrations according to the manufacturer’s instruction. For 
phenotyping of mature cells peripheral blood, bone marrow and spleen cells were 
stained with CD3 (12-0031-82) for T-cells, Gr1 (Biolegend, 108412) for 
Granulocytes and B220 (Biolegend 103204) for B-cells.  
Bone marrow and spleen cells from EphA7 knockout mice were labelled for B-cell 
development and maturation analysis with the fluorescently conjugated antibody 
master mixes (B220, IgD and IgM) and (CD19, CD21 and CD23) provided by 
Professor Lynn Corcoran (Walter and Eliza Hall Institute of Medical Research) and 
SYTOX-Blue (Life Technologies) was used for separation of live cells. CD71 (12-
0711-82) and Ter-119 (17-5921-82) antibodies were used for erythroid maturation 
analysis of bone marrow and spleen.  
Total bone marrow cells from 6-8 week old EphA1, EphA2 and EphA7 knockout and 
wild type mice were counted on a Coulter Counter (BD Biosciences) machine.  For 
analysis of haematopoietic stem and progenitor cells (HSPC) by flow cytometry, bone 
marrow cells from knockout and wild type mice were stained with a cocktail of 
biotinylated anti–mouse antibodies against antigens expressed on mature 
haematopoietic cells. Terminally differentiated cells (lineage) were labelled with a 
panel of biotinylated monoclonal antibodies to Ter119 (553672, BD Biosciences), 
CD3 (553060, BD Biosciences), CD5 (553019, BD Biosciences), B220 (553086, BD 
Biosciences), Mac-1 (553308, BD Biosciences) and Gr-1 (553125, BD Biosciences). 
The lineage+ cells were detected with streptavidin (Biolegend, 405208) for 
phenotyping and were depleted with Dynabeads (Life Technologies) for sorting the 
HSCs.  The lineage- cells were stained with a combination of C-kit (clone 2B8, 17-
1171-82) and Sca-1 (clone D7, 25-5981-82). This population of cells contain two 
subpopulations known as Lineage-c-Kit+Sca-1+ (LKS+) cells and Lineage-c-Kit+Sca-1- 
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progenitor cells. Progenitor cells were stained with CD34 (clone RAM34, 11-0341-
82), FcγRII/III (clone 93, 12-0161-82) to further fractionate this population to GMP, 
CMP and MPP. LKS+ cells were stained with either CD34 (clone RAM34, 11-0341-
82) and Flk2 (clone A2F10.1, 12-1351-82) or CD150 (clone TC15-12F12.2, 
Biolegend 115912), and CD48 (clone HM48-1, Biolegend 103418) antibodies to 
further fractionate these cells into LT-HSCs, ST-HSCs and MPP cells. All flow 
cytometry data were analysed with FlowJo software (TreeStar). 
2.2.3 Histological analysis  
Whole spleen was dissected from EphA1, EphA2, EphA7 knockout mice and the 
corresponding wild type littermates and fixed in 10% formaldehyde followed by 
embedding in paraffin blocks and serial sectioning. The sections were stained with 
hematoxylin and eosin (H&E) and examined to determine pathology using Aperio XT 
(Leica Biosystems). 
2.2.4 Competitive repopulation and transplantation assays  
Bone marrow obtained from 6-8 week old EphA2 knockout or wild type control mice 
expressing the CD45.2 allotype antigen were flushed with 2% FBS/PBS and 
subjected to red blood cell lysis (Pharm Lyse™, BD Biosciences). For the 
competitive transplant experiment 1×106 viable, nucleated EphA2 knockout or wild 
type CD45.2 bone marrow cells were injected together with equal numbers of double 
positive CD45.1/45.2 congenic competitor bone marrow cells into the tail vein of 
lethally irradiated (11 Gy in 2 separate fractions at least 3 hours apart) CD45.1 
recipient mice. Blood chimerism was analysed every 4 weeks for 16 weeks and on 
week 16 the bone marrow and spleen chimerism were determined. For secondary 
transplantation experiments, viable nucleated CD45.2 bone marrow cells from 
primary transplant were sorted on FACSAria (BD Biosciences) and injected, together 
with equal numbers of double positive CD45.1/45.2 congenic competitor bone 
marrow cells, into the lateral tail vein of lethally irradiated CD45.1 congenic 
secondary recipient mice and blood chimerism were analysed every 4 weeks for 24 
weeks and on week 24 the bone marrow and spleen chimerism were determined. For 
determination of chimerism in transplantation assays, CD45.1 (clone A20, Biolegend 
110708) and CD45.2 (clone 104, Biolegend 109814) antibodies were used in flow 
cytometric analysis and data were analysed with FlowJo software (TreeStar). 
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2.2.5 Statistical analysis 
Statistical analyses were performed using GraphPad Prism Version 6.01 software. 
Data are shown as mean ± SEM of at least three replicates, unless stated otherwise. 
Statistical significance was determined using an unpaired t test and a p-value <0.05 
was considered significant.   
2.3 Results 
2.3.1 Analysis of full blood parameters, spleen weight, bone marrow 
and spleen nucleated cell numbers in EphA1, EphA2 and EphA7 
knockout mice 
To characterize haematopoietic function in EphA1, EphA2 and EphA7 knockout 
mice, I performed submandibular blood sampling on mice at 6-8 weeks of age. There 
were no statistically significant differences in baseline blood parameters, including 
hematocrit (HCT), white blood cell (WBC), red blood cell (RBC), neutrophil, 
lymphocyte, monocyte or platelet counts in any of the Eph knockout mice compared 
to wild type controls (Figure 2.1). 
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Figure 2.1. Full blood count examination of EphA1, EphA2 and EphA7 knockout mice compared 
to wild type littermates. (A) No significant differences in full blood differentiation of EphA1 
knockout mice in comparison to EphA1 wild type mice were observed (n=10, 2 experiments). (B) No 
significant differences in full blood differentiation of EphA2 knockout mice in comparison to EphA2 
wild type mice were observed (n=15, 3 experiments). (C) No significant differences in full blood 
differentiation of EphA7 knockout mice in comparison to EphA7 wild type mice were observed (n=10, 
2 experiments). The data represent mean ± SEM. (n) represent the number mice used in each 
experiment. Unpaired t test was performed for statistical analyses. Each parameter is represented as 
HCT (HCT%), WBC (x103/µL), RBC (x106/µL), Neutrophils (x103/µL), Lymphocytes (x103/µL), 
Monocytes (x103/µL) and platelets (x103/µL).  
The weight of spleen and liver in EphA1, EphA2 and EphA7 knockout mice was 
measured and compared to the wild type control. There were no significant changes 
observed in the size and weight of spleen and liver in any of the knockout mice 
compared to the wild type littermates. Number of nucleated bone marrow and spleen 
cells in EphA1, EphA2 and EphA7 knockout mice were compared to the wild type 
mice. The spleen and bone marrow showed no significant difference in number of 
nucleated cells (Figure 2.2). 
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Figure 2.2. EphA1, EphA2 and EphA7 knockout spleen weight and nucleated cell count 
compared to the wild type control.  (A) Spleen weight of EphA1, EphA2 and EphA7 knockout mice 
compared to the wild type littermates did not show any significant differences. (B) Number of 
nucleated spleen cells in EphA1, EphA2 and EphA7 knockout mice compared to the wild type 
littermates did not show any significant differences. (C) Number of nucleated bone marrow cells in 
EphA1, EphA2 and EphA7 knockout mice compared to the wild type littermates did not show any 
significant differences.  Each dot corresponds to one individual mouse. The data represent the mean ± 
SEM. Unpaired t test was performed for statistical analyses.  
2.3.2 EphA1, EphA2 and EphA7 bone marrow, spleen and blood 
immunophenotyping 
Bone marrow, spleen and blood immunophenotyping analysis were used to identify 
the effect of lack of specific Eph expression on particular cell lineages. These analysis 
were used to identify differences between Eph knockout and wild type mice in mature 
blood cell populations including granulocyte (GR-1), B-lymphocyte (B220), or T-
lymphocyte (CD-3) cell populations  (Figure 2.3A).   
Analysis of the lineage positive cells in EphA1 knockout mice showed significant 
reduction in bone marrow and spleen B-lymphocytes compared to the wild type 
control. There were also an elevated number of T-lymphocytes in both bone marrow 
and spleen of the knockout mice compared to the wild type control and a significant 
reduction in T-cell population in the blood of the EphA1 knockout mice. There were 
no differences between EphA1 knockout and wild type granulocyte populations 
(Figure 2.3B). Analyses of the granulocyte, B-lymphocyte and T-lymphocyte cell 
populations showed no significant differences in frequency of these cells in the 
EphA2 knockout mice compared to the wild type control mice (Figure 2.3C). In 
EphA7 knockout mice there were no differences in granulocytes population however 
a significant reduction in bone marrow T-lymphocytes and an increase in blood B-
lymphocytes were observed (Figure 2.3D).  
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Figure 2.3. B-lymphocytes, T-lymphocytes and granulocytes population in EphA1, EphA2 and 
EphA7 knockout mice. (A) B-lymphocytes (B220), T-lymphocytes (CD3) and Granulocytes (Gr-1) 
gating strategy. (B) EphA1 knockout mice had significantly less B-lymphocytes in bone marrow (P 
value. 0.0475) and spleen (P value. <0.0001) compared to wild type littermates. EphA1 knockout mice 
have significantly more T-lymphocytes in bone marrow (P value. <0.0001) and spleen (P value. 
<0.0001) and significantly less T-lymphocytes in blood (P value. 0.0072) compared to wild type 
control mice. There were no significant differences in bone marrow, spleen and blood granulocytes 
population (n=10, 2 experiments). (C) There were no difference in B-lymphocytes, T-lymphocytes or 
granulocytes population in bone marrow, spleen and blood of the EphA2 knockout mice compared to 
the wild type control mice (n=15, 3 experiments). (D) EphA7 knockout mice have significantly less T-
lymphocytes in bone marrow (P value: 0.0084) with no significant differences in spleen or blood T-
lymphocytes population. EphA7 knockout mice had significantly more B-lymphocytes in blood (P 
value: 0.009) compared to wild type EphA7 mice and no difference in bone marrow or spleen B-
lymphocytes population. There were no significant differences in EphA7 knockout bone marrow, 
spleen and blood granulocytes population compared to wild type mice (n=10, 2 experiments). Data are 
presented as percentage of viable bone marrow, spleen and blood cells. The data represent the mean ± 
SEM. (n) represent the number mice used in each experiment.  An unpaired t test was performed for 
statistical analyses.  
For evaluation of morphological changes in the EphA1, EphA2 and EphA7 knockout 
spleen, histological analysis of the knockout and wild type littermates were performed 
with documentation of any changes observed in the H&E sections. Spleen sections 
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from the knockout mice compared to wild type littermates displayed no changes in 
morphology and size of the spleen (Figure 2.4).  
 
Figure 2.4.  Representative spleen sections from EphA1, EphA2, EphA7 and wild type 
littermates. Spleen sections stained with H&E from EphA1, EphA2 and EphA7 knockout mice were 
phenotypically normal with no difference in morphology when compared to wild type littermates. 
2.3.3 B-cell analysis in bone marrow and spleen of the EphA7 knockout 
mice 
I sought to examine B lymphopoieis in EphA7 knockout mice based on the following 
factors: firstly, I have noted an elevated number of B-cells in blood of the EphA7 
knockout mice and secondly, EphA7 has been shown to be a tumour suppressor in the 
context of B-cell lymphoma particularly in follicular lymphoma. This suggested that 
EphA7 mice might have an abnormality in B-cell lymphopoiesis due to a failure of 
selection mechanism in B-cell follicles. Therefore, I have analysed the successive 
stages of B-cell development in bone marrow and spleen cells from EphA7 mutant 
and wild type mice. In the bone marrow I have found that EphA7 knockout mice have 
no defect in pre/pro B-cells (B220lowIgM−), transitional B-cells (B220lowIgM+), and 
mature B-cells (B220highIgM+) (Figure 2.5A). Statistical analysis of the spleen B220+ 
B-cells showed no significant difference in immature B-cells (B220+IgM+IgD−) 
however there was a statistically significant increase in transitional B-cells 
(B220+IgM+ IgDlow) and a statistically significant decrease in mature B-cells 
(B220+IgMhigh IgDlow) (Figure 2.5B). I further analysed the B-cell development in the 
spleen of the EphA7 knockout mice compared to the wild type littermates using 
CD19, CD21 and CD23 antibodies to discriminate between follicular B-cells 
(CD19+CD21intCD23hi) and marginal zone B-cells (CD19+CD21hiCD23lo). Total 
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splenic CD19+ B-cells in the EphA7 knockout mice showed no significant differences 
in any of the marginal zone and follicular B-cell subpopulations (Figure 2.5C). 
Overall, there was no significant disruption in B lymphopoiesis despite some 
evidence for delayed maturation in the spleen.  
 
Figure 2.5. Analysis of B-cell development in EphA7 knockout spleen and bone marrow cells.  
(A) There were no significant differences between bone marrow population-1 pro–B/pre–B cells 
(B220lowIgM−), population-2 transitional B-cells (B220lowIgM+) and population-3 mature B-cells 
(B220highIgM+) obtained from EphA7 knockout mice compared to wild type mice (n=4). (B) In the 
spleen there were no significant differences in the B220+ B-cell population. Total splenic B220+ B-cells 
were gated and analysed for IgM and IgD expression. In the spleen B220+ cells, there were no 
significant differences observed in population-1 immature B-cells (IgMhighIgDlow), there was a 
significant increase (P value. 0.0195) in population-2 transitional B-cells (IgMhighIgDhigh) and a 
significant decrease (P value. 0.0406) in population-3 mature B-cells (IgMlow IgDhigh) in the EphA7 
knockout mice compared to wild type mice (n=4). (C) In the spleen there was no significant difference 
in the CD19+ B-cell population. Total splenic CD19+ B-cells were gated and analysed for CD21 and 
CD23 expression. In the spleen CD19+ cells there were no significant differences in population-1 
marginal zone B-cells (CD21hiCD23lo) and population-2 follicular B-cells (CD21highCD23high) within 
the EphA7 knockout mice compared to wild type mice.  Data are presented as percentage of viable 
bone marrow, spleen and blood cells. The data represent the mean ± SEM. (n) represent the number 
mice used in each experiment. An unpaired t test was performed for statistical analyses. 
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2.3.4 EphA1, EphA2 and EphA7 knockout bone marrow and spleen 
erythroid maturation  
The stages of erythroid maturation were defined as erythoid-1 (Ery-1) corresponding 
to pro-erythroblasts (CD71high, Ter119mid), erythoid-2 (Ery2) corresponding to 
basophilic erythroblasts (CD71high, Ter119high), erythoid-3 (Ery3) corresponding to 
late basophilic and polychromatophilic erythroblasts (CD71mid, Ter119high), and 
erythoid-4 (Ery4) corresponding to orthochromatophilic erythroblasts (CD71low, 
Ter119high) (Figure 2.6A). Analysis of EphA1 and EphA7 knockout bone marrow and 
spleen cells for erythroid maturation showed no perturbation of erythropoiesis in 
comparison to wild type mice (Figure 2.6B, D). In the EphA2 knockout mice there 
was no perturbation of erythropoiesis in bone marrow, however spleen showed an 
increase in pro-erythroblast population with no changes in other stages of erythroid 
maturation (Figure 2.6C).  
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Figure 2.6. Erythroid maturation analysis of EphA1, EphA2 and EphA7 knockout mice 
compared to wild type control mice. (A) Ery-1 (CD71high, Ter119mid), Ery-2 (CD71high, Ter119high), 
Ery-3 (CD71mid, Ter119high) and Ery-4 (CD71low, Ter119high) gating strategy. (B) There were no 
differences in erythroid maturation in EphA1 knockout bone marrow or spleen cells compared to 
EphA1 wild type control cells (n=10, 2 experiments). (C) There were no differences in erythroid 
maturation of EphA2 knockout bone marrow cells compared to the wild type control cells. There was a 
significant increase (P value. 0.0429) in spleen Ery-2 population of the EphA2 knockout mice 
compared to the wild type control mice. There were no other significant differences at any stages of 
erythroid maturation in spleen cells compared to wild type control cells (n=15, 3 experiments). (D) 
There were no significant differences in erythroid maturation in EphA7 knockout bone marrow or 
spleen cells compared to EphA7 wild type cells (n=10, 2 experiments). The data is presented as 
percentage of bone marrow or spleen cells. The data represent the mean ± SEM. (n) represent the 
number mice used in each experiment. Unpaired t test was performed for statistical analyses. 
2.3.5 Stem/progenitor cell populations in EphA1, EphA2 and EphA7 
knockout mice 
In this section the EphA1, EphA2 and EphA7 knockout haematopoietic stem and 
progenitor populations were compared to wild type littermates. I analysed the 
percentage of immunophenotypically defined haematopoietic stem and progenitor 
cells. This analysis showed no significant differences in the percentage of LKS+ 
(lineage-Sca-1+cKithighSca-1+), progenitors (lineage-Sca-1-cKithigh) and mature 
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myeloid progenitor cells, including granulocyte-monocyte progenitors (GMPs), 
common myeloid progenitors (CMPs), and megakaryocyte-erythrocyte progenitors 
(MEPs) (Figure 2.7).  
	  
Figure 2.7. LKS+ and progenitor cell population in bone marrow of the EphA1, EphA2 and 
EphA7 knockout mice compared to wild type control. (A) Gating strategy for LKS+ cells 
(lineagelowcKithighSca-1+) this population is enriched for haematopoietic stem cells, Progenitors 
(lineagelowcKithighSca-1-), GMP (lineagelowcKithighSca-1-CD34+FCGRII/IIIhigh), CMP 
(lineagelowcKithighSca-1-CD34+FCGRII/IIIlow) and MEP (lineagelowcKithighSca-1-CD34-FCGRII/III-). 
(B) There were no differences in LKS+, progenitors, CMP, MEP or GMP populations in EphA1 
knockout mice compared to the wild type control mice (n=10, 2 experiments).  (C) There were no 
significant differences in LKS+, progenitors, CMP, MEP or GMP population in the EphA2 knockout 
mice compared to wild type control mice (n=15, 3 experiments). (D) There were no differences in 
LKS+, progenitors, CMP, MEP and GMP population in EphA7 knockout mice compared to the wild 
type control mice (n=10, 2 experiments). Each dot corresponds to one individual mouse. The data 
presented as percentage of Lineage- bone marrow cells for progenitors and LKS+ analysis. The data 
presented as frequency of progenitors for analysis of CMP, MEP and GMP population. The data 
represent mean ± SEM. Unpaired t test was performed for statistical analyses. 
To further analyse HSCs, CD34 and FLK2 (CD135) markers were utilised to isolate 
LT-HSC (LKS+CD34-Flk2-), ST-HSC (LKS+CD34+Flk2) or MPP (LKS+CD34+Flk2+) 
populations (Figure 2.8A). No significant differences were observed in LT-HSC, ST-
HSC or MPP populations in EphA1 or EphA7 knockout mice compared to the wild 
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type control (Figure 2.8B, D). EphA2 knockout mice showed a significant increase in 
the frequency of ST-HSC with no differences observed in the frequency of MPP or 
LT-HSC population (Figure 2.8C). CD150 and CD48 markers were also used as 
another method to fractionate the HSC, with (LKS+CD150+CD48-) cell population 
representing LT-HSC and (LKS+CD150-CD48+) representing MPP cells. Similar to 
the previous results, there were no significant differences in the frequency of LT-HSC 
or MPP cells in EphA1, EphA2 and EphA7 knockout mice compared to wild type 
control mice (Figure 2.8). 
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Figure 2.8. Long term HSC (LT-HSC), short term HSC (ST-HSC) and multipotent progenitor 
population (MPP) in EphA1, EphA2 and EphA7 knockout mice compared to the wild type 
control mice. (A) CD34/CD135 gating strategy, MPP (LKS+CD34+CD135+), ST-HSC 
(LKS+CD34+CD135-) and LT-HSC (LKS+CD34-CD135-). CD48/CD150 gating strategy, LT-HSC 
(LKS+CD150+CD48-) and MPP (LKS+CD150-CD48+). (B) There were no significant differences in 
LT-HSC, ST-HSC and MPP population gated by CD34/CD135 antigens in the EphA1 knockout mice 
compared to wild type controls. There were also no significant differences in LT-HSC and MPP 
population gated by CD48/CD150 antigens in the EphA1 knockout mice compared to wild type control 
(n= 4, 1 experiment). (C) There were no significant differences in LT-HSC and MPP population gated 
by CD34/CD135 antigens in the EphA2 knockout mice compared to wild type control however there 
were significantly more (P value. 0.0012) ST-HSCs in EphA2 knockout bone marrow compared to 
wild type control. There were no significant differences in LT-HSC and MPP population gated by 
CD48/CD150 antigens in EphA2 knockout mice compared to wild type control (n=15, 3 experiments). 
(D) There were no significant differences in LT-HSC, ST-HSC and MPP population gated by 
CD34/CD135 antigens in the EphA7 knockout mice compared to wild type control. There were also no 
significant differences in LT-HSC and MPP population gated by CD48/CD150 antigens in the EphA7 
knockout mice compared to wild type control (n=10, 2 experiments). Each dot corresponds to one 
individual mouse. The data presented as frequency of LKS+. The data represent mean ± SEM. 
Unpaired t test was performed for statistical analyses.  
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2.3.6 EphA2 knockout bone marrow repopulating potential in primary 
and secondary transplant 
EphA2 knockout mice showed an increase in the frequency of ST-HSCs which could 
indicate an altered stem cell dynamics, I aimed to explore whether there was 
functional difference in HSCs. Competitive bone marrow transplantation experiments 
were performed to assess the EphA2 knockout and wild type HSC self-renewal 
properties. No significant differences were observed in chimerism of EphA2 knockout 
at 4, 8, 12 and 16 weeks after transplantation (Figure 2.9A). Bone marrow and spleen 
chimerism analysis also didn’t show any statistical difference between EphA2 
knockout and wild type mice (Figure 2.9B). To assess whether there might be a more 
subtle effects of EphA2 knockout on long-term stem cell self-renewal in the murine 
haematopoietic compartment, a secondary competitive transplantation was performed. 
In the secondary transplant there were some mice with low percentage of chimerism, 
perhaps due to limiting numbers of LT-HSCs in the transplanted cell population. 
Importantly there were no significant differences between EphA2 knockout mice 
compared to the wild type control group (Figure 2.9C, D). This experiment was 
repeated with the same sized group of mice, and no significant differences were 
observed in either of these experiments indicating that lack of EphA2 does not have a 
significant functional effect on HSCs. 
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Figure 2.9. EphA2 knockout bone marrow has normal repopulating potential in primary and 
secondary recipients. (A) Whole-blood chimerism at 0, 4, 8, 12 and 16 weeks after transplantation of 
EphA2 knockout or wild type bone marrow cells into lethally irradiated CD45.1 recipients (n=5). (B) 
Analysis of bone marrow and spleen chimerism 16 weeks after primary transplantation. (C) Whole-
blood chimerism of secondary transplant at 0, 4, 8, 12, 16, 20 and 24 weeks after transplantation of 
EphA2 knockout or wild type primary bone marrow cells into lethally irradiated CD45.1 recipient 
(n=5). (D) Bone marrow and spleen chimerism analysis 24 weeks after secondary transplantation. Each 
dot on panel A and C corresponds to mean and error from all wild type or knockout blood chimerism. 
Each dot on panel B and D corresponds to one individual mouse. The data presented as percentage of 
blood, bone marrow and spleen chimerism. The data represent mean ± SEM. An unpaired t test was 
performed for statistical analyses. 
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2.4 Discussion 
Normal haematopoiesis requires complex bidirectional interactions between the bone 
marrow microenvironment (or niche) and haematopoietic stem cells (HSCs). These 
interactions are critical for the maintenance of normal HSCs quiescence and 
perturbations can influence HSCs self-renewal and differentiation. All lineages of 
blood are produced during the process of haematopoiesis and any disruption in this 
process can lead to different blood disorders. As mentioned previously, expression of 
members of Eph/ephrin family have been associated with different stages of blood 
development.  
In this chapter, I have focused on analysis of haematopoiesis in EphA1, EphA2 and 
EphA7 knockout mice as the expression of these three receptors have been reported 
on many different haematopoietic cells and analysis of these knockout mice will 
facilitate understanding of the novel function of these receptors in haematopoiesis. 
Given the data that EphA3 is highly expressed on mouse HSCs and is found to be 
expressed in leukaemias 103,123, studies were planned for analysis of haematopoiesis in 
EphA3 knockout mice but profound delays in obtaining these mice precluded their 
use in my experiments.  
Whole blood analysis showed no significant differences in blood parameters in any of 
the EphA1, EphA2 and EphA7 knockout mice compared to the wild type littermates.  
I have also analysed the effect of these Eph receptors on differentiated lineage+ cells 
in the knockout mice compared to the wild type littermates. EphA1 and EphA7 
knockout mice had altered B-lymphocytes and T-lymphocytes populations compared 
to the wild type littermates. Unlike EphA1 and EphA7 knockout mice, EphA2 
knockout mice did not exhibit any changes in T-lymphocytes and B-lymphocytes 
frequency. In addition, there was no disruption in bone marrow and spleen 
granulocyte frequencies in any of the EphA1, EphA2 or EphA7 knockout mice 
compared to wild type control.  
My results showed a significant reduction in frequencies of B-lymphocytes in bone 
marrow and spleen of EphA1 knockout mice compared to the wild type littermates. 
Previous studies have shown expression of EphA1 on normal human B-cells isolated 
from peripheral blood or lymph node 154. These data together with my results confirm 
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the possible effect of EphA1 on B-cell regulation.  EphA1 is also expressed on 
peripheral blood T-lymphocytes and thymocytes and it has been suggested to have a 
role in regulation of CD4+ T-cell entry into secondary lymphoid organs 158,176 thus 
suggesting a possible role of EphA1 in T-cell development and migration. My 
analysis of EphA1 knockout T-lymphocytes showed elevated number of T-cells in the 
bone marrow and spleen and a reduction in frequency of T-lymphocytes in blood of 
the EphA1 knockout mice. These results suggest that in the absence of EphA1, 
regulation of T-cells is disrupted hence an increase in spleen and bone marrow T-
lymphocytes, and possibly the release of T-cells to the blood is blocked and as a result 
a decrease in frequency of blood T-lymphocytes was observed.  
Expression of EphA7 has been documented on thymic cortex and subcapsule and the 
expression is involved with T-lymphocytes. EphA7 is also suggested as a tumour 
suppressor in T-cell lymphoblastic leukaemia/lymphoma due to its mutation in this 
type of cancer 177. My results showed reduction in bone marrow T-cells in EphA7 
knockout mice, which could be another indicator of the role of EphA7 in regulation of 
T-lymphocytes. I have also observed an elevated number of B-lymphocytes in blood 
of the EphA7 knockout mice, which could be an indication of a possible disruption in 
regulation of B-lymphocyte development and migration. Previous studies have shown 
possible involvement of EphA7 in B-cell regulation. It has been shown that mature B 
cells only express a splice variant encoding a soluble form of EphA7 112,159,173. A 
more recent study confirmed this finding and showed that EphA7 expression is lost in 
follicular lymphoma 84. They went on to show that soluble EphA7 could bind to other 
Eph receptors, notably EphA2 and EphA3, thus preventing pro-oncogenic signalling 
by inhibiting clustering of membrane bound Eph receptors. The lack of soluble form 
EphA7 in the knockout mice may explain the increase in B-cell population, since the 
lack of inhibition of Eph signalling would lead to increased Erk and Src activity and 
hence may lead to increased proliferation. In this regard a study of B-cell subsets may 
reveal altered B-cell differentiation in the knockout mice. The studies performed by 
Orricchio 84 showing that EphA7 is a tumour suppressor suggests that crossing the 
EphA7 knockout mice with transgenic mice, such as the VavP-Bcl2 mice used in their 
study, might lead to more rapid lymphomagenesis.  
Based on my finding and the previous studies on involvement of EphA7 in B-cell 
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lymphomas, I decided to look more closely at the stages of B-cell development in 
bone marrow and spleen of the EphA7 knockout mice compared to wild type 
littermates. B-cell development has been described in a linear process in which 
immature B-cells from bone marrow migrate to the spleen and give rise to transitional 
B-cells. These cells will then mature into marginal zone and follicular B-cells. The 
stages of B-cell maturation and development in the bone marrow of the knockout 
mice was not affected however the spleen showed an increase in transitional B-cells 
and reduction in the mature B-cells, indicating a delay in spleen B-cells maturation. 
Further analysis of B-cell development in the spleen did not show any significant 
disruption in marginal zone and follicular B-cells despite some evidence for delayed 
maturation in the spleen. This finding indicates that EphA7 is not functionally 
necessary for B-cell development in adult mice, although the functional redundancy 
between members of the Eph family of RTKs means that a role for Eph signalling 
cannot be excluded. 
Erythroid maturation was also unaffected in EphA7 and EphA1 knockout spleen and 
bone marrow and EphA2 knockout bone marrow. There was an elevated number of 
spleen basophilic erythroblasts observed in EphA2 knockout spleen compared to wild 
type control however there were no significant difference in spleen late basophilic and 
polychromatophilic erythroblasts. Therefore, it can be concluded that lack of EphA2 
may delay maturation but has no overall effect on erythropoiesis. 
Previously Ting et al. (2011) 123 showed expression of many members of Eph/ephrin 
family on the haematopoietic stem and progenitor cells however my analysis of 
EphA1, EphA2 and EphA7 knockout mice showed no changes in the frequency of 
CMP, MEP or GMP progenitor cells suggesting that the differences seen in the 
differentiated B-lymphocytes and T-lymphocytes in EphA1 and EphA7 knockout 
mice are not caused by altered progenitor cells. There were also no differences in the 
frequency of LT-HSCs, ST-HSCs or MPPs in the EphA1 and EphA7 knockout mice, 
which suggest that these members of Eph family are not essential for haematopoietic 
stem cell function. 
EphA2 knockout mice exhibited a significant increase in the number of ST-HSCs but 
no differences in the LT-HSCs and MPP populations, perhaps suggesting altered stem 
cell maturation. I therefore analysed the effect of EphA2 on haematopoietic stem cell 
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function. To determine overall stem cell self-renewal and maturation, I performed 
primary and secondary competitive transplantation assays. This was used to determine 
the repopulating ability of EphA2 knockout HSCs compared with congenic normal 
HSCs. The results indicate that EphA2-deficient and wild type bone marrow HSCs 
have the same contribution to haematopoiesis and the same capacity for self-renewal. 
Thus, despite the evidence that EphA2 is expressed on HSCs I have shown that loss 
of EphA2 does not alter HSC function.  
Taken together, in this chapter I have shown that, although the expression of 
Eph/ephrin has been reported on many haematopoietic cells, loss of individual Eph 
genes results in, at most, only mild phenotypic aberrations of haematopoietic cells and 
that the EphA1, EphA2 and EphA7 knockout mice have essentially normal steady 
haematopoiesis. This does not exclude a role for the Eph family of RTKs overall, as 
there is considerable redundancy of function between related members of this family 
such that other Eph proteins might compensate for the absence of one member. 
Indeed, expression of multiple members of Eph family of RTKs has been reported on 
haematopoietic cells 75,121,123. Therefore in haematopoiesis deletion of more than one 
Eph might reveal significant defects. For example, deletion of both EphA2 and 
EphA3, which are the highest expressing Ephs on mouse HSCs might have a more 
pronounced haematological defect 123. Deletion of both EphA2 and EphA7 might be 
another interesting target for analysis of haematopoiesis as interaction of EphA2 and 
EphA7 in follicular lymphoma has been reported in which truncated form of EphA7 
can bind to EphA2 receptor and act as inhibitor of EphA2 activation and block Erk 
and Src oncogenic signals 84. Although beyond the scope of this thesis, another 
interesting avenue to explore would be to see if the haematopoietic system in these 
knockout models would show defects in the presence of acute stresses such as 
systemic infection or severe anaemia.  
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3.1 Introduction 
Leukaemia is blood cancer, caused by disruption in normal function of the 
haematopoietic system. This chapter will focus on analysis of specific Eph receptor in 
acute myeloid leukaemia (AML). AML is characterised by clonal proliferation of 
myeloid precursors and accumulation of immature haematopoietic cells in the bone 
marrow, blood and other tissues. This results in reduction in production of 
granulocytes, platelets and normal red blood cells (granulocytopenia, 
thrombocytopenia, and/or anaemia). Leukemic cells also cause direct pathology 
through hyperleukocytosis and organ infiltration 34,178.  
The World Health Organization (WHO) classifies AML into four groups based on 
discrete biological entities and molecular pathways. The classification is based on a 
combination of morphology, immunophenotype, genetics, and clinical features and 
includes: AML with recurrent and characteristic genetic abnormalities which account 
for 11% of AML cases, AML with myelodysplasia related features which accounts 
for 6% AML cases, therapy related AML and MDS that accounts for 2% of AMLs 
and AML not otherwise specified which accounts for 81% of AML cases and includes 
AMLs that do not fall into the previous three groups 179.  
AML is heterogeneous disease and has different responses to treatment based on 
factors including patient age, blast-cell morphology and cytogenetic abnormalities 180. 
There are different types of treatments available for AML however depending on the 
sub-type of AML, these treatments, whilst often initially effective, do not prevent 
ultimate therapy-resistant relapse and death. Therefore, developments of new 
therapies, which target specific molecular mechanisms involved in the genesis of 
AML, have the potential to improve treatment outcomes 180.  
AML with specific genetic abnormalities frequently have favourable prognoses with 
high rates of remission. Different genetic factors have been linked to this type of 
leukaemia with the most common targets being the genes that encode DNA-binding 
transcription factors or the genes involved in regulation of transcriptional complexes 
181. The most frequent mutations involve genes that regulate proliferation and survival 
of haematopoietic cells and those that control differentiation. The genetic 
abnormalities in this type of leukaemia includes: AML with t(8; 21)(q22; q22) 
showing the molecular abnormality in AML/ETO, AML with t(16; 16)(p13; q22) or 
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inv(16) showing the molecular abnormality in CBFβ/MYH11, acute promyelocytic 
leukaemia with t(15; 17)(q22; q12) leading to PML-RARalpha and AML with 11q23 
alteration leading to mixed lineage leukaemia (MLL). MLL is associated with AML 
and ALL leukaemias and is a result of chromosomal translocations involving the 
MLL locus on chromosome 11. Some examples include: MLL-AF9 and MLL-AF6, 
which are consequence of chromosomal rearrangement in t(9;11) and t(6;11) 
respectively 162. 
Many pathways and genes have been linked to MLL type leukaemias, including the 
glycogen synthase kinase 3 (GSK-3), heat shock protein 90 (HSP-90) and RAS 
pathways. Expression of many downstream mediators including clustered homeobox 
(HOX) proteins, myeloid ecotropic viral integration site 1 (MEIS1) and EphA7 have 
also been studied in MLL leukaemias 162. Nakanishi et al 113 showed up regulation of 
EphA7 in MLL type leukaemias. They also showed that knocking-down EphA7 
decreased ERK phosphorylation and treatment with an ERK inhibitor results in 
apoptotic cell death. Therefore, they suggested that EphA7 may have a role in 
leukaemia cell survival and it may be a potential therapy target for MLL type 
leukaemias. They have also detected expression of other EphA transcripts including 
EphA1, EphA2, EphA3, EphA4 and EphA6 in the MLL-AF9 and MLL-AF4 
transfected K562 cells 113,162.   
EphA2 is one of the most significantly expressed genes detected on MLL-AF9 
transfected K562 cells. Expression of EphA2 has been detected in embryonic tissues, 
including embryonic nervous system and spinal cord. Low level of EphA2 expression 
is observed on adult epithelial tissues 168. EphA2 is expressed on many different 
malignancies including breast, melanoma, ovarian, lung, glioma, prostate, cervical, 
colon and gastric cancers. EphA2 expression is involved in angiogenesis and tumour 
neovasculation and in some cancer the expression correlates with disease progression, 
the degree of malignancy and metastasis 67. Studies by Brantley-Sieders on the 
implanted mammary adenocarcinoma in EphA2 deficient mice compared to the wild 
type mice showed decreased in the tumour volume, microvascular density and lung 
metastases. They also showed that EphA2 deficient endothelial cells have altered 
tumour vasculature and growth 182. EphA2 expression is associated with poor 
prognosis and decrease survival; therefore EphA2 can be an inhibitor of tumour 
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progression and a very attractive therapeutic target in different types of cancers with 
EphA2 over-expression. Various therapeutic strategies targeting EphA2 expression in 
solid tumours have been developed including monoclonal antibody treatment, RNAi 
EphA2 suppression and EphA2 antibody combinational therapy with 
chemotherapeutic agents, radiotherapy and molecular therapies 183,184.  
I have already shown that mice lacking EphA1, EphA2 and EphA7 have no 
significant defects in normal haematopoiesis. However, expression of EphA1, EphA2 
and EphA7 was previously observed on MLL transfected K562 leukemic cells 113. 
Therefore, the expression and functional effect of these Eph receptors in mixed-
lineage leukaemia (MLL) will be analysed in this chapter utilising the MLL-AF9 
mouse model of human AML leukaemia.  
Given the role of Eph tyrosine kinases in signal transduction, and indeed reports of 
their interaction with the Abl/Arg tyrosine kinases 185. I also chose to examine a 
model of leukaemia in which the kinome is disrupted through expression of the BCR-
ABL fusion gene. In BCR-ABL chromosomal translocation occurs between 
chromosomes 9 and 22 resulting in formation of abnormal fusion proteins. The BCR-
ABL fuses the Bcr and Abl kinase genes resulting in the formation of a unique Bcr-
Abl protein in which the Abl kinase is constitutively active and is the causative 
molecular lesion of CML 36. To develop this model of CML a construct containing the 
BCR-ABL transgene was used, which resulted in Abl kinase activation and 
development of leukaemia. Therefore this model of CML leukaemia was developed to 
determine if Eph expression might be present and having a part to play in 
pathogenesis of this type of leukaemia.  
Firstly the expression of EphA1, EphA2 and EphA7 was examined in BCR-ABL and 
MLL-AF9 mouse models of human CML and AML leukaemias. In examination of 
Eph expression in these leukemic models I observed an elevated level of EphA2 and 
EphA7 transcript in MLL-AF9 leukaemia but no significant expression was observed 
in BCR-ABL leukemic cells and thus I focused on the MLL-AF9 model. Since 
reagents for EphA7 are still being developed, I analysed the effect of EphA2 in MLL-
AF9 leukemic mice. EphA2 has a wide role in many different cancers and due to the 
existence of well-characterised antibodies I had the tools to assess whether it is a 
potential therapeutic agent in EphA2-positive MLL-AF9 leukaemias.  
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3.2 Methods 
3.2.1 Animals 
Female mice of the congenic strains C57BL/6 (Ly 5.2) were purchased from the 
Animal Resource Centre (Perth, Australia) at the age of 5-6 weeks. EphA2 knockout 
mice were kindly supplied by Dr Naruse-nakajima (University of Tokyo)169. EphA2 
knockout mice were backcrossed with C57BL/6 (Jackson Labs) mice for 12 
generations and maintained in the homozygous state. All of these mice were kept in 
QIMR Berghofer Medical Research Institute pathogen free animal facility according 
to institute protocols.  
3.2.2 Mouse model of leukaemia 
Retroviral supernatants were produced by transfection of 293T cells using FuGENE 6 
reagent (Roche Diagnostics), retroviral vectors for packaging (Ecopac) and the 
retroviral constructs encoding GFP-control (pMSCV-IRES-GFP) for the control mice 
and either MLL-AF9 or BCR-ABL (pMSCV-MLL-AF9-IRES-GFP or pMSCV-
BCR-ABL-IRES-GFP) for leukemic mice. Supernatants were collected 36–48 hours 
after transfection, passed through a 0.4 µm filter and concentrated to obtain 
supernatant with high titres of infectious retroviral particles. To generate the leukemic 
mice, wild type or EphA2 knockout cells from the femoral and tibial bone marrow of 
the donor mice were sorted on FACSAria (BD Biosciences) for HSC and cultured 
overnight on fibronectin in stem cell medium comprising of StemSpan (Stem Cell 
Technologies) serum-free medium supplemented with 100 ng/mL of Stem Cell Factor 
(SCF, PeproTech.), Thrombopoietin (TPO, PeproTech.), Granulocyte colony-
stimulating factor (G-CSF) and Penicillin-Streptomycin (Life Technologies).  The 
cultured cells were infected by incubation with retroviral supernatant (pMSCV-IRES-
GFP, pMSCV-MLL-AF9-IRES-GFP, pMSCV-BCR-ABL-IRES-GFP) and 48 hours 
after infection viable, green fluorescent protein-positive (GFP+) cells were sorted on 
FACSAria (BD Biosciences) for injection into sublethally irradiated (5.5 Gy) 
recipient mice. The mice were monitored for signs of leukaemia by analyses of whole 
blood including increase in WBC counts, GFP+ cells, reduction in platelet and RBC 
count and for clinical evidence of disease including loss of weight, paucity of 
movement and hunching of the back. These mice were given a clinical score based on 
the symptoms including WBC count (0-2), percentage of GFP+ cells (0-2), platelet 
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count (0-2), mouse weight (0-2) and movement (0-2) and culled once the clinical 
score reached 7 or more. Blood, spleen and bone marrow were harvested and 
processed into single cell suspensions for analysis and transplantation experiments. 
Bone marrow and spleen cells from the primary leukemic mice were sorted for viable 
GFP+ cells on FACSAria (BD Biosciences). The secondary recipient mice (C57BL/6) 
were sublethally irradiated (5.5 Gy) and 2×104 EphA2 knockout or wild type MLL-
AF9 leukemic cells from primary transplant were delivered via tail vein injection.  
For assessment of the potential therapeutic effect of anti-EphA2 antibody on MLL-
AF9 leukemic mice, the mice were treated intravenously with 0.1 mg of anti-mouse 
EphA2 monoclonal antibody (IF7 mAb) or vehicle only (PBS) control on alternate 
dates until the mice were euthanized due to progression of the disease. 
3.2.3 Flow cytometric analysis 
To examine cell surface expression of Eph proteins, 2×106 cells were washed in 2% 
foetal bovine serum/phosphate buffered saline  (FBS/PBS). The cells were stained 
with 10 µg of anti-EphA1, -EphA2, -EphA3 and -EphA7 monoclonal antibodies or 
ephrinA5-Fc fusion protein directly conjugated to Alexa Fluor 647 or Alexa Fluor 
488, and kept on ice for 30 minutes in the dark. Cells were washed twice with 2% 
FBS/PBS and stained with SYTOX-Blue (Life Technologies) dead cell marker and 
analysed on LSRFortessa (BD Biosciences). 	  
3.2.4 Real-time quantitative polymerase chain reaction analysis 
RNA was isolated from bone marrow of GFP-control, BCR-ABL and MLL-AF9 mice 
using RNeasy Mini Kit (QIAGEN) and complementary DNA (cDNA) was 
synthesized using SuperScript III (Life Technologies) with respect to the 
manufacturer's instructions. Relative transcript quantification was performed with 
SYBR Green QPCR Mastermix (Applied Biosystems) using RotorGene 3000 Real-
Time PCR system gene expression was calculated relative to 18S rRNA or β-actin 
housekeeping gene. 
3.2.5 Apoptosis analysis 
Apoptosis was assessed using the Apoptosis Detection Kit (BD Biosciences) 
according to the manufacturer’s instructions. Annexin V:Sytox Blue (Life 
Technologies) staining was assessed by flow cytometric analysis using LSRFortessa 
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(BD Biosciences). 
3.2.6 Cell cycle analysis 
Cell cycle was analysed on LSRFortessa (BD Biosciences), bone marrow and spleen 
cells were fixed and permeabilized using FIX & PERM® cell fixation and cell 
permeabilization kit (Life Technologies) and then stained with Hoechst 33342 (Life 
Technologies).  
3.2.7 Radiolabelling and immunoreactivity 
The EphA2 monoclonal antibody (IF7 mAb) and EphA3 monoclonal antibody (IIIA4 
mAb) were conjugated to 1,4,7,10- tetraazacyclododecane-N,N',N'',N'''-tetraacetic 
acid mono-(N-hydroxysuccinimidyl) (DOTA- NHS) ester as described previously 186. 
Briefly, 2 mg/mL of IF7 or IIIA4 antibody solutions in 0.1 M sodium bicarbonate and 
0.1 M sodium phosphate buffer (pH 8.5) were mixed with 50-fold molar excess of 
DOTA-NHS-Ester (Macrocyclics) dissolved in DMSO (Sigma Aldrich). The 
antibodies were conjugated for 1 hour at room temperature followed by fractionation 
to remove un-conjugated DOTA. The conjugate was buffer-exchanged into 0.2 M 
ammonium acetate (pH 5.5) using 100 kDa-cut-off microconcentrators as per the 
manufacturer’s instructions (Millipore). For radiolabelling, purified DOTA-IF7 or 
DOTA-IIIA4 antibodies (4 mg/mL in ammonium acetate, pH 5.5) were mixed with 
Lutetium-177 (177 LuCl3, PerkinElmer) at final concentration of 10-12 mCi/mL for 1 
hour at 37oC. Radiolabelled immunoconjugate was purified using 100-kDa cut off 
microconcentrators according to the manufacturer’s instructions. Specific 
radioactivity was determined using the ratio of Lutetium-177 radioactivity measured 
with AtomLab100 dose calibrator and the protein concentration measured using 
absorbance at 280 nm with NanoDrop 1000 spectrophotometer. The specific 
radioactivities were 8.1 and 8.5 mCi/mg (i.e. 300 and 316 MBq/mg) for 177Lu- IF7 
and 177Lu-IIIA4 respectively. Treatments with PBS, unlabelled IF7, 177Lu-IF7 and 
177Lu-IIIA4 antibodies were initiated 21 days after transplantation when the average 
percentage of GFP+ cells in mouse blood reached 25% or more of viable blood cells. 
The treatments were administered intravenously via tail vein injection with two-dose 
administration of 10 µg with 3 MBq dose three days apart. 
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3.2.8 Statistical analysis 
Statistical analyses were performed using GraphPad Prism Version 6.01 software. 
Data are shown as mean ± SEM of at least three replicates, unless stated otherwise. 
Statistical significance was determined using an unpaired t test. The survival of the 
control and the treatment groups were compared using Kaplan–Meier analysis and 
statistical differences analysed using the log rank test.  All flow cytometry data were 
analysed with FlowJo software (TreeStar). 
3.3 Results 
3.3.1 Expression of EphA1, EphA2 and EphA7 on leukemic xenograft 
models 
Whilst I had shown that the expression of EphA1, EphA2 and EphA7 is not required 
for normal haematopoiesis, the increased expression of these genes in MLL 
transfected K562 cells raised the possibility that they may be functionally important 
in MLL type leukaemias 113. I first examined the mRNA expression of these Ephs 
relative to 18S rRNA in bone marrow of GFP-control, BCR-ABL and MLL-AF9 
leukemic mice using RT-PCR. Analysis of MLL-AF9 bone marrow from leukemic 
mice showed no significant increase in expression of EphA1 compared to GFP-
control and BCR-ABL. However, the expression of EphA2 and EphA7 was 
significantly higher in bone marrow of MLL-AF9 leukemic mice compared to GFP-
control (Figure 3.1A, C). Further analysis of EphA2 expression on MLL-AF9 mice 
using flow cytometry showed significantly higher EphA2 expression in bone marrow 
and spleen of MLL-AF9 compared to BCR-ABL and GFP-control mice (Figure 3.1D-
F). Due to the lack of Eph expression in the BCR-ABL model this was not pursued 
further. However, elevated level of EphA2 expression in MLL-AF9 bone marrow and 
spleen raised the possibility that this protein may have a role in MLL-AF9 
leukaemogenesis. 
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Figure 3.1. EphA1, EphA2 and EphA7 expression on GFP-control, MLL-AF9 and BCR-ABL 
leukemic xenograft. (A) The level of EphA1 mRNA expression relative to 18S rRNA from bone 
marrow of MLL-AF9 mice compared to GFP-control and BCR-ABL mice was not significantly 
different (n= 7 GFP-control, n=10 MLL-AF9, n=4 BCR-ABL). (B) The level of EphA2 mRNA 
expression relative to 18S rRNA showed significantly higher EphA2 transcript in bone marrow of 
MLL-AF9 mice compared to GFP-control (P value. 0.0267) and higher EphA2 transcript compared to 
BCR-ABL (n= 7 GFP-control, n=10 MLL-AF9, n=4 BCR-ABL). (C) The level of EphA7 mRNA 
expression relative to 18S rRNA showed significantly higher EphA7 transcript in bone marrow of 
MLL-AF9 mice compared to GFP-control (P value. 0.0177) and higher EphA7 transcript compared to 
BCR-ABL (n= 7 GFP-control, n=10 MLL-AF9, n=4 BCR-ABL). (D) Representative flow cytometric 
overlay of the EphA2 expression in GFP-control, MLL-AF9 and BCR-ABL bone marrow. (E) Flow 
cytometric analysis of the EphA2 expression on spleen of GFP-control, MLL-AF9 and BCR-ABL mice 
measured as mean fluorescent intensity, showed significantly higher EphA2 expression on spleen of 
the MLL-AF9 mice compared to GFP-control mice (P value. 0.0143) and higher EphA2 expression on 
MLL-AF9 compared to BCR-ABL leukemic spleen (n= 5 GFP-control, n=4 MLL-AF9, n=3 BCR-
ABL). (F) Flow cytometric analysis of the EphA2 expression in bone marrow of GFP-control, MLL-
AF9 and BCR-ABL mice is measured as mean fluorescent intensity, showed significantly higher 
EphA2 expression on MLL-AF9 bone marrow compared to GFP-control bone marrow (P value 
<0.0001) and higher expression of EphA2 on MLL-AF9 compared to BCR-ABL leukemic bone 
marrow (P value. 0.0019) (n= 5 GFP-control, n=4 MLL-AF9, n=3 BCR-ABL). Each dot corresponds 
to one individual mouse. The data represent the mean ± SEM. Unpaired t test was performed for 
statistical analyses. 
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3.3.2 The effect of EphA2 loss in MLL-AF9 induced mouse leukaemia 
To explore the possibility that EphA2 was functionally important in MLL-AF9-driven 
leukaemias a series of MLL-AF9 leukemic transplantation experiments were 
performed (Figure 3.2A). Both C57BL/6 wild type and EphA2 knockout bone 
marrow cells were infected with the MLL-AF9 oncogene, the transduced bone 
marrow cells were transplanted into C57BL/6 wild type mice. The results from this 
transplantation showed that lack of EphA2 expression in the donor mice had no 
significant effect on leukemic engraftment (Figure 3.2B, C).  
To test for a more subtle abnormality of leukemic stem cell (LSC) function in the 
absence of EphA2 in MLL-AF9 leukaemia, serial transplantations were set up to 
determine if LSC self-renewal in EphA2 knockout MLL-AF9 is different to the wild 
type MLL-AF9 LSCs. 2×104 GFP+ leukemic cells harvested from primary 
transplanted MLL-AF9 mice were sorted on FACSAria for viable GFP+ leukemic 
cells and injected into sublethally irradiated (5.5 Gy) C57BL/6 recipient (secondary 
transplant). The leukemic cells from both EphA2 knockout and wild type MLL-AF9 
mice induced leukaemia with comparable disease latencies (Figure 3.2D). There were 
no significant differences in bone marrow, spleen and blood engraftment and in 
spleen and liver weight in EphA2 knockout and wild type MLL-AF9 mice at the time 
of cull in the secondary transplantation experiment (Figure 3.2E). The primary MLL-
AF9 transplantation experiment was performed twice and the secondary MLL-AF9 
transplantation experiment was set up four times with different primary donors. This 
result indicates that absence of EphA2 does not affect self-renewal of MLL-AF9 LSC 
in vivo. 
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Figure 3.2. MLL-AF9 EphA2 knockout mice have similar leukaemogenic potential as the wild 
type MLL-AF9 mice in primary and secondary leukemic transplant models. (A) Serial MLL-AF9 
leukemic transplantation model. (B) Survival of leukemic mice transplanted with EphA2 knockout 
MLL-AF9–transduced haematopoietic stem cells (LKS+) compared to wild type MLL-AF9–transduced 
haematopoietic stem cells (LKS+) showed no significant differences between the two groups (n= 4 wild 
type, n=3 EphA2 knockout, 2 experiments).  (C) Percentage of GFP+ cells in bone marrow, spleen and 
blood of the EphA2 knockout and wild type MLL-AF9 bone marrow, spleen and blood at time of cull 
didn’t show any significant differences between the two groups. (D) Survival of secondary MLL-AF9 
mice transplanted with GFP+ EphA2 knockout or GFP+ wild type MLL-AF9 cells from the primary 
transplant showed no significant differences between the two groups (n=16 wild type, n=19 EphA2 
knockout, 4 experiments).  (E) Percentage of GFP+ cells in bone marrow, spleen and blood of the 
secondary transplanted wild type or EphA2 knockout MLL-AF9 mice didn’t show any significant 
differences between the two groups. Each dot corresponds to one individual mouse. The survival is 
presented as Kaplan-Meier survival curve. The data represent the mean ± SEM. Unpaired t test was 
performed for statistical analyses. 
To determine whether EphA2 loss had any effect on cell proliferation or survival in 
MLL-AF9 leukemic mice, cell cycle and apoptosis analysis were subsequently 
performed on GFP+ MLL-AF9 bone marrow and spleen cells obtained at the time of 
cull from EphA2 knockout and wild type mice. Analysis of the bone marrow cells 
from EphA2 knockout and wild type leukemic mice using Hoechst 33342 showed no 
significant changes in any of the G1/S/G2-M fractions of the cell cycle profile (Figure 
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3.3B). Flow cytometric analysis of apoptosis in the spleen and bone marrow cells 
from EphA2 knockout and wild type MLL-AF9 mice using annexin V and SYTOX-
Blue showed no significant difference in bone marrow apoptosis. However, the 
apoptosis analysis of the spleen cells obtained from the EphA2 knockout MLL-AF9 
mice showed a significant increase in necrotic cells compared to wild type spleen 
cells from MLL-AF9 mice (Figure 3.3C-F). In summary, lack of EphA2 does not 
significantly alter cell cycle and apoptosis of the MLL-AF9 leukemic cells except for 
an increased observed in the percentage of spleen necrotic cells.  
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Figure 3.3. Cell cycle and apoptosis analysis of the EphA2 knockout MLL-AF9 mice compared to 
wild type MLL-AF9 mice. (A) Gating strategy for cell cycle and apoptosis analysis respectively. (B) 
Cell cycle analysis of the EphA2 knockout MLL-AF9 mice compared to the wild type MLL-AF9 mice 
showed no significant differences in any of G1/S/G2-M cell cycle fractions (n= 7 wild type, n=9 
EphA2 Knockout, 2 experiments). (C) Percentage of necrotic cells in GFP+ MLL-AF9 bone marrow 
was not significantly different in leukemic mice compared to wild type MLL-AF9 mice, however there 
were a significant increase (P value. 0.0010) in the percentage of GFP+ necrotic spleen cells in EphA2 
knockout MLL-AF9 spleen compared to wild type spleen cells. (D) Percentage of late-apoptotic cells 
in GFP+ MLL-AF9 bone marrow and spleen cells was not significantly different between EphA2 
knockout mice compared to wild type control mice. (E) Percentage of apoptotic cells in GFP+ MLL-
AF9 bone marrow and spleen cells was not significantly different between EphA2 knockout mice 
compared to wild type control mice. (F) Percentage of live cells in GFP+ MLL-AF9 bone marrow and 
spleen cells was not significantly different between EphA2 knockout mice compared to wild type 
control mice (n=10 wild type, n=12 EphA2 Knockout, 2 experiments). Each dot corresponds to one 
individual mouse. The data represent the mean ± SEM. Unpaired t test was performed for statistical 
analyses.  
3.3.3 Analysis of EphA expression in MLL leukaemia 
A possible explanation for the lack of effect of EphA2 deletion in MLL-AF9 
leukaemia is that other Eph proteins with overlapping ephrin-binding affinities, such 
as EphA7, might show a compensatory increase in expression. To explore this 
possibility I analysed EphA7 expression and also total EphA expression on EphA2 
knockout and wild type MLL-AF9 leukemic cells using flow cytometric analysis. 
Total EphA expression was determined by binding of ephrinA5-Fc with high binding 
affinity for members of EphA subfamily. In EphA2 knockout MLL-AF9 leukemic 
cells, EphA7 expression was not significantly up-regulated compared to wild type 
MLL-AF9. However, the levels of ephrinA5-Fc binding in EphA2 knockout MLL-
AF9 was not significantly different to wild type MLL-AF9 cells suggesting that, 
despite loss of EphA2, the complement of Eph receptors was similar on MLL-AF9 
leukemic mice (Figure 3.4A). This supported the possibility that some compensatory 
increase in other Eph genes was present in the EphA2 knockout leukemic cells. Thus, 
I performed a RT-PCR analysis of the MLL-AF9 leukemic bone marrow cells from 
EphA2 knockout and wild type mice to determine the expression of other EphA 
genes. This again showed no significant change in EphA7, in support of the flow 
cytometric data. There was an increase in EphA5 expression in EphA2 knockout 
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MLL-A9 when compared to wild type MLL-AF9 leukemic cells but this did not reach 
statistical significance  (Figure 3.4B). 
	  
Figure 3.4. Expression analysis of EphA subfamily on EphA2 knockout and wild type MLL-AF9 
mice. (A) Flow cytometric analysis of EphA2, EphA7 and ephrinA5-Fc in EphA2 knockout and wild 
type bone marrow cells showed no EphA2 expression in the EphA2 knockout mice and significantly 
high expression of EphA2 in the wild type mice as expected (P value. 0.0165). Comparable levels of 
EphA7 (P value. 0.3099) and ephrinA5-Fc (P value. 0.8710) expression were observed in EphA2 
knockout and wild type mice. (B) RT-PCR analysis of EphA1, EphA2, EphA3, EphA4, EphA5 and 
EphA7 in EphA2 knockout and wild type bone marrow cells showed no EphA2 transcript in the EphA2 
knockout mice compared to wild type MLL-AF9 (P value. 0.0776) and comparable level of EphA1 (P 
value. 0.3458), EphA5 (P value. 0.7020) and EphA7 (P value.  0.6167) transcript in EphA2 knockout  
and wild type mice. There were no expression of EphA3 and EphA4 observed in any of the MLL-AF9 
mice (n=4). Each dot corresponds to one individual mouse. The data represent the mean ± SEM. 
Unpaired t test was performed for statistical analyses.  
To further evaluate the expression of Eph family of RTKs on MLL type leukaemias. I 
have analysed eight clinical samples from MLL-driven leukaemias and two human 
cell lines (THP-1 and MV4-11) bearing MLL fusion genes MLL-AF9 and MLL-AF4 
respectively. Expression of EphA1, EphA2, EphA3, EphA7 and total Eph, as 
determined by ephrinA5-Fc, was analysed using flow cytometry. The results showed 
significant but variable expression of EphA1 and EphA3, and moderate expression of 
EphA2 and EphA7. Importantly, expression of total Ephs as determined by ephrinA5-
Fc staining was significant on all samples (Figure 3.5). Together these data showed 
variable level of Eph expressions on patient samples and leukemic cell lines with 
MLL rearrangement.  In particular, EphA2 was expressed at different levels in 
individual leukemic samples but the significant expression in a proportion of clinical 
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samples bearing the 11q23 chromosomal (MLL) re-arrangement, suggested that 
EphA2 might be a therapeutic target in human MLL-driven leukaemias. 
	  
	  
Figure 3.5. Expression analysis of EphA1, EphA2, EphA3 and EphA7 subfamily and ephrinA5-
Fc on patient samples and human leukemic cell lines with MLL-rearrangement. (A) 
Representative overlay of flow cytometric analysis of EphA1, EphA2, EphA3, EphA7 and ephrinA5-
Fc on patient samples and human cell lines. (B) This table represents the expression level of Eph 
receptors on patient samples (patients 1-8) and human leukaemia cell lines (THP-1 and MV4-11). 
3.3.4 MLL-AF9 leukemic mice treated with EphA2 monoclonal antibody 
or radiolabelled conjugated EphA2 antibody 
Whilst EphA2 expression is not functionally important for the leukemic process, the 
expression has been detected on MLL-AF9 leukemic mice indicating that this protein 
might be a potential therapeutic agent in the treatment of MLL-AF9 leukaemias. To 
test this possibility I have used the EphA2 monoclonal antibody (IF7 mAb), which 
binds at nanomolar affinity to both mouse and human EphA2, in the treatment of high 
EphA2 expressing MLL-AF9 secondary transplanted leukemic mouse model. When 
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C57BL/6 mice were injected with different doses of IF7 every 48 hours, it had been 
shown previously that serum levels >1 mg/ml, a level predicted to give saturation 
binding of EphA2, were sustained for at least 48 hours when doses of 0.1 mg or 
greater were administered intraperitoneally. Thus, the MLL-AF9 mice were treated 
with 0.1 mg of IF7 mAb or vehicle only (PBS) control every second day until the 
mice were euthanized based on the severity of the disease. The results showed that 
there were no statistical difference in survival and engraftment of leukemic mice 
treated with IF7 mAb compared to vehicle only PBS control (Figure 3.6A, B). As the 
antibody had no significant effect, I next examined whether it could be used to deliver 
a radioactive "payload" to the leukemic cells. To verify this, the EphA2 mAb 
conjugated to radiolabelled Lutetium-177 (Lu-IF7) was utilised in the treatment of 
MLL-AF9 leukemic mice. The mice bearing GFP+ MLL-AF9 leukaemia were treated 
with two separate doses of 3 MBq/10 mg of Lu-IF7 mAb, unlabelled IF7 mAb or PBS 
only control, 21 and 23 days after transplantation with MLL-AF9 leukemic cells from 
primary transplant. A significant reduction in blood engraftment was observed in Lu-
IF7 treated mice compared to PBS treated control (Figure 3.6D). There were also 
significant improvement in the survival of Lu-IF7 treated mice compared to IF7 mAb 
and PBS treated control group (Figure 3.6E). More importantly, control mice with no 
leukemic cells exhibit no significant weight loss or clinical signs of toxicity when 
treated with Lu-IF7 mAb at the specific treatment dose. In a further experiment I also 
looked at the non-specific effect of Lutetium-177 on the MLL-AF9 leukaemia by 
treating the mice with radiolabelled EphA3 mAb (Lu-IIIA4), which shows no specific 
binding to the leukemic cells. Again, the Lu-IF7 mAb showed a prolonged survival 
but there were no significant differences between PBS, IF7 unlabelled and the Lu-
IIIA4 treatment groups (Figure 3.6F).  These data suggest that EphA2 may be a 
therapeutic target for some cases of MLL-driven leukaemia.  
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Figure 3.6. Survival and engraftment data from MLL-AF9 leukemic mice treated with PBS, IF7 
mAb, radiolabelled EphA2 (Lu-IF7) or radiolabelled EphA3 (Lu-IIIA4) antibody. (A) Survival of 
MLL-AF9 leukemic mice treated with IF7 mAb or PBS control showed no significant differences 
between the two groups. (B) Percentage of GFP+ cells in bone marrow, spleen and blood showed 
significantly higher GFP+ cells in bone marrow of IF7 mAb treated mice compared to PBS control (P 
value. 0.0055). There were no significant differences observed in spleen and blood of the IF7 treated 
MLL-AF9 mice compared to wild type control mice at time of cull (n= 5 PBS treated, n=6 IF7 treated). 
(C) Percentage of GFP+ cells in blood of MLL-AF9 leukemic mice 21 days post transplantation and 
prior to the antibody treatment. (D) Percentage of GFP+ leukemic cells in bone marrow and spleen of 
the MLL-AF9 mice treated with PBS, IF7 mAb and Lu-IF7 mAb didn’t show any significant 
differences in engraftment, however there were significantly less blood engraftment in the Lu-IF7 
treated group compared to PBS treated mice (P value. 0.0038). (E) Survival of MLL-AF9 leukemic 
mice treated with PBS, IF7 mAb and Lu-IF7 antibody showed no significant differences between PBS 
and IF7 mAb treated group. Significant increase in the survival of Lu-IF7 antibody treated group was 
observed compared to PBS (P value. 0.0404) and IF7 mAb treated group (P value. 0.0201) (n= 3 PBS 
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treated, n=4 IF7 mAb treated and n=5 Lu-IF7 treated). (F) Survival of MLL-AF9 leukemic mice 
treated with PBS, IF7 mAb, Lu-IIIA4 or Lu-IF7 antibody showed no significant differences between 
PBS, IF7 and Lu-IIIA4 antibody treated groups. Significant increase in the survival of Lu-IF7 mAb 
treated group was observed compared to PBS (P value. 0.0140), IF7 mAb (P value. 0.0100) and Lu-
IIIA4 mAb (P value. 0.0100) treated group (n= 3 PBS treated, n=3 IF7 mAb treated, n=3 Lu-3A4 
antibody and n=4 Lu-IF7 treated). The data represent mean ± SEM. (n) represent the number mice used 
in each experiment. Unpaired t test was performed for statistical analyses. 
3.4 Discussion 
In this chapter I initially analysed expression of EphA1, EphA2 and EphA7 in the 
bone marrow cells from GFP-control mice, BCR-ABL and MLL-AF9 leukemic mice. 
My results clearly showed detectable levels of both mRNA and protein expression of 
EphA2 and EphA7 in the MLL-AF9 leukemic cells compared to negligible expression 
of EphA2 and EphA7 in BCR-ABL leukaemia or GFP-control. Thus, I subsequently 
focused on the MLL-AF9 model only.  I investigated the possible functional effects of 
EphA2 expression on MLL-AF9 type leukaemia along with the capacity of EphA2 
mAb as a targeted antibody therapy or radio-immunotherapy. As previously 
mentioned, EphA2 is expressed on variety of different cancers and studies by 
Nakanishi et al. 113 showed expression of EphA2 mRNA along with other members of 
Eph family on MLL-AF9 transfected K562 cells.  
To test whether EphA2 was functionally important in the MLL-AF9 model, I looked 
at the effect of EphA2 deficiency on progression and severity of MLL-AF9 type 
leukaemias. When MLL-AF9 transduced haematopoietic stem cells derived from 
either wild type or EphA2 knockout mice were injected into wild type recipients they 
gave rise to leukaemias with comparable disease latency and severity. To explore any 
effect of EphA2 knockout on LSC self renewal, secondary transplantation 
experiments were performed in which the secondary recipient mice were transplanted 
with EphA2 knockout or wild type MLL-AF9 leukemic cells, and the results again 
showed no effect on survival, implying no functional effect of EphA2 in LSCs. Using 
specific markers, I have also checked cell cycle and apoptosis of the EphA2 knockout 
leukemic cells compared to wild type control. My results showed no significant 
differences in cell cycle between the two groups. However, the apoptotic assay 
showed an increase in the number of necrotic cells in the EphA2 knockout MLL-AF9 
spleen compared to wild type control. EphA2 expression has been associated with 
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angiogenesis in solid tumours 99 hence, whilst not affecting disease outcome, the 
increased number of necrotic cell could be the result of reduction in angiogenesis in 
the absence of EphA2 expression. Overall, my results showed that EphA2 is not 
essential for MLL-AF9 induced leukaemogenesis. 
Whilst these findings suggest that EphA2 itself has no direct functional role in MLL-
AF9 leukaemia, this does not exclude an Eph-mediated effect, as there may be 
compensation from other Eph proteins.  Based on the published literature, the most 
obvious candidate was EphA7 and as shown in Figure 3.4, expression of EphA7 was 
detected on both EphA2 knockout and wild type MLL-AF9 cells, although the 
expression level was not higher in the EphA2 knockout leukemic cells. On the other 
hand, ephrinA5-Fc staining was utilised as an indicator of total EphA expression in 
the MLL-AF9 leukaemia, it was notable that wild type control and EphA2-null 
leukemic cells had similar levels of ephrinA5-Fc expression. This suggests that in the 
absence of EphA2, there is a compensatory increase in expression of other members 
of EphA family such that the total capacity for Eph signalling is unchanged. Thus, a 
role for Eph receptors in MLL-AF9 leukaemia cannot be excluded. Therefore it would 
be of interest to examine this leukemic model in the mice with more than one Eph 
knockout, and in particular EphA2/EphA7 double knockout mice. However, at this 
stage these mice are not available for analysis and thus this is beyond the scope of this 
thesis. 
As a prelude to exploring the possibility of targeting EphA2 in MLL-driven 
leukaemia, I performed a limited analysis of AML and ALL leukaemias from human 
patient samples and human leukemic cell lines with MLL rearrangement. As in the 
mouse leukaemias, EphA2 expression was variable but some cases showed moderate 
levels of EphA2 expression along with expression of other EphA proteins including 
EphA1, EphA7 and EphA3. This analysis suggested that pre-clinical testing of anti-
EphA2 mAb therapy in the MLL-AF9 murine leukaemia model would potentially 
inform the possibility of clinical translation. EphA2 mAb treatment has been 
previously used in different types of cancers that express EphA2 and has recently 
been reviewed by Boyd et al. 157.  Therefore, I hypothesised that treatment with 
EphA2 mAb maybe effective in reducing the latency and the severity of MLL-AF9 
type leukaemia. My findings indicate that treatment with unmodified IF7 mAb had no 
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effect on tumourigenicity and latency of the MLL-AF9 leukaemia. This may not be 
surprising as IF7 is an IgG1 mAb and it is not expected to mount a significant Fc-
mediated cytotoxic response, therefore any effect would have to be a direct effect on 
EphA2 function. Given the expression of other Eph receptors to compensate for any 
effect on EphA2, as discussed in the context of the EphA2 knockout, even an 
inhibitory effect of IF7 on EphA2 might have no overall effect on the leukemic cells.  
Recently the use of monoclonal antibodies conjugated to target a radionuclide to the 
cancer cells but not other normal cells have been studied extensively. Previous studies 
in non-Hodgkin’s lymphoma using monoclonal antibodies conjugated to 131I-
tositumomab and 90Y-ibritumomab tiuxetan have shown promising effects as 
treatment option in this type of leukaemia 187. Therefore I examined the EphA2 
antibody as a target for delivering cytotoxic "payload" to the EphA2 expressing 
leukemic cells. To do this, I used the EphA2 mAb radiolabelled with lutetium-177 to 
directly target leukemic cells in MLL-AF9 mice. Reassuringly, there were no 
significant toxicity observed in these mice, despite concerns raised by trial of an 
EphA2 antibody conjugated to a drug which was halted due to bleeding complications 
188. My results showed a significant increase in the survival of the 177Lu-IF7 treated 
mice along with significant reduction in blood engraftment.  In this study the increase 
in survival, whilst relatively small, is significant in this highly malignant, treatment-
refractory, leukaemia model. The magnitude of the effect may also be compromised 
by the fact that these mice were treated in the late stages of the disease and with only 
two doses.  Therefore, in future studies I will be required to treat these mice when 
blasts first become detectable in the blood and also to study multiple dosing regimens 
and combination with anti-leukemic drugs. Notably, this result is consistent with 
recent studies by Day et al. (2013) where effective targeting of tumourigenic cells was 
achieved upon treatment with lutetium-177 conjugated-EphA3 mAb in glioblastoma 
59.  
In conclusion, I found that the presence of EphA2 expression is not essential for 
leukaemogenesis, perhaps due to functional redundancy between members of Eph 
family of receptor tyrosine kinases.  However, targeting MLL-AF9 leukaemia with 
radiolabelled EphA2 could be a successful approach in treatment of EphA2-positive 
leukaemias as EphA2 is not strongly expressed on normal haematopoietic cells. I also 
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showed that by using 177Lu-IF7 anti-EphA2 mAb it was possible to specifically target 
the leukemic cells with minimal toxicity. 
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4.1 Introduction 
Eph receptor tyrosine kinase proteins interact with cell-surface ephrin ligands to 
regulate cell growth, positioning and migration by modulating cell shape and 
adhesion. Both Eph and ephrin proteins are important in regulating cell-cell 
interactions and their engagement can initiate either cell adhesion or repulsion in 
different cellular contexts. Cell repulsion occurs when bidirectional signalling triggers 
cytoskeletal collapse and loss of focal adhesions, resulting in cell rounding and cell 
detachment while cell attachment occurs when signals are in favour of cell adhesion 
and migration 68. 
Eph and ephrin genes are strongly expressed on various embryonic tissues and they 
are involved in many developmental processes, particularly in formation of tissue 
boundaries, development and assembly of neuronal circuits and also in the 
development of vasculature 71. Eph/ephrin genes also have an important role in adult 
tissues and mainly in organ pathogenesis, regeneration and maintenance 157. High 
expression of Eph genes have been observed in many cancers and over-expression 
could have both tumour promoting and inhibiting effect depending on the tumour 
type, type of Eph receptor, kinase activity and the stage of disease 157. For instance, 
the expression of Eph and ephrin has been linked to invasiveness and metastatic 
spread of the tumour cells.  
EphA3 was originally identified in LK63 pre-B acute lymphoblastic leukemic (ALL) 
cells, which show high expression, and has been shown to be highly expressed on 
embryonic tissues and it is involved in different stages of embryonic developments 
including lung, kidney, brain, spinal cord and central nervous system 103,144,189,190. The 
most notable expression was observed in developing heart, a finding motivated by the 
observation that EphA3 knockout mice have cardiac defects and 75% of these mice 
die of cardiac failure 191. EphA3 is expressed at very low levels in adult tissues but 
this expression is high in many different malignancies including sarcomas, lung 
cancer, melanoma, glioblastoma and leukaemia 157. EphA3 expression has been 
identified in T-cell leukaemia cell lines including Jurkat, Molt-4, JM and HSB-2, 
while expression was absent in normal T-cells. Studies by Smith et al. (2004) 
suggested that EphA3 may have a role in malignant T-cells adhesion and motility, as 
they showed loss of cell adhesion to fibronectin upon ephrinA5 stimulation of Jurkat 
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cells and regulation of EphA3 expression via CD28 or insulin-like growth factor 1 
receptor (IGF-1R) signalling 192. As mentioned previously, significantly elevated 
EphA3 expression, compared with normal blood cells, was detected in a proportion of 
lymphoid and myeloid malignancies 103. Studies by Guan et al. (2011) showed 
presence of copy-number variations (CNVs) of EphA3 in various haematological 
malignancies and recent studies on primary leukemic mouse models and human 
leukaemias showed EphA3 as a cooperative response gene (CRG) responsible for 
leukaemia stem cell growth and survival 148,149. Previous studies have shown that 
EphA3 can induce both adhesive and cell repulsive responses in different cell types 
68,145. By analysing ephrin-induced cell adhesion in LK63 leukemic cells, a critical 
role was identified for protein phosphatase activity, which prevented EphA3 
phosphorylation and hence maintained the Eph/ephrin adhesive bond and prevented 
initiation of the signalling mechanisms leading to cell repulsion 68.  
The monoclonal antibody (IIIA4) used to isolate EphA3 protein was raised by 
immunising mice with LK63 pre-B ALL cells. This antibody was the key for 
identifying EphA3 (Hek) as a new member of the Eph family 103,144. The IIIA4 
antibody binds with high affinity to the EphA3 protein close to the ephrin-binding site 
55,193. Previous studies showed that treatment of EphA3 on HEK293 cells with pre-
clustered IIIA4 could induce activation of EphA3 thereby causing cytoskeleton 
contraction and cell rounding 146. EphA3-specific monoclonal antibody, IIIA4, binds 
and activates both human and mouse EphA3 with similar affinities and binding is 
followed by internalization of receptor-antibody complexes 146. Through these studies 
EphA3 was identified as a potential therapy target for leukaemia and KaloBios 
Pharmaceuticals Inc. developed a Humaneered® derivative of the original IIIA4 anti-
EphA3 monoclonal antibody. This antibody is known as KB004, and a clinical trial 
has commenced which targets EphA3 protein using this antibody in acute leukaemia.  
Recent studies by Day et al. (2013) investigated the tumourogenic and therapeutic 
role of EphA3 in glioblastoma. In this study EphA3 knockdown glioblastoma (GBM) 
cell lines showed reduced tumourigenicity. Consistent with this finding it was shown 
that treatment with radiolabelled IIIA4 antibody induced tumour regression in 
xenograft model of GBM 59.  
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In this chapter I looked at the role of EphA3 expression in the development and 
spread of leukaemia in leukemic NOD/SCID mice. In particular, I analyse the effect 
of the IIIA4 monoclonal antibody treatment in EphA3 positive and negative leukemic 
mouse models to explore the functional effect of this antibody and to examine if this 
direct effect can be amplified by antibody targeting of a cytotoxic payload.   
4.2 Methods 
4.2.1 Cell culture 
All the leukemic cell lines, including LK63, Reh, Jurkat, K562, Molt-4, NB-4, SKM-
1, THP-1, U937 and MM6, were maintained in RPMI, 10% foetal calf serum (FCS) 
medium. Stable firefly luciferase-transfected Reh (Reh/Luc) and LK63 (LK63/Luc), 
Reh EphA3-expressing (Reh/A3) and LK63 EphA3-knockdown (LK63/A3KD) cells 
were maintained in RPMI, 10% FCS and 0.5 µg/mL puromycin medium.  
4.2.2 Antibodies and Eph fusion proteins 
The following monoclonal antibodies generated in our laboratory were used in this 
study: 3E9 anti-EphA1, 1F7 anti-EphA2, IIIA4 anti-EphA3 and 1F9 anti-EphA4, all 
are IgG1k, antibodies. Anti-EphB4 monoclonal antibody clone 395810 was purchased 
from R&D Systems (FAB3038P). For therapeutic targeting of EphA3, a humanised 
chimeric version of IIIA4, in which the VH domain of the IIIA4 was inserted into a 
human IgG1 antibody backbone (provided by Prof. Andrew Scott, Ludwig Institute) 
was employed. 
EphA3-Fc and EphB4-Fc, fusion proteins, were used in which the coding regions for 
the Eph or ephrin extracellular domains were fused to the hinge and Fc regions of the 
heavy chain of human IgG1 as previously described 194. The resulting expression 
vectors were transfected into Chinese Hamster Ovary (CHO) cells to obtain stably 
expressing cell lines. Fusion proteins were purified from supernatants of CHO cell 
transfected lines by protein-A sepharose chromatography 195. EphA3-Fc and EphB4-
Fc were utilised for analysis of total ephrinA and ephrinB expression in leukemic 
cells. 
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4.2.3 Flow Cytometry 
To analyse cell surface expression of Eph proteins, 2×106 cells were washed in 2% 
foetal bovine serum/phosphate buffered saline (FBS/PBS). The cells were stained 
with 10 µg of anti-EphA1, -EphA2, -EphA3 and -EphA4 monoclonal antibodies 
directly conjugated to Alexa Fluor 647 or Phycoerythrin (PE)-conjugated anti-EphB4 
monoclonal antibody (R&D Systems, FAB3038P), and incubated on ice for 30 
minutes in the dark. Cells were washed twice with 2% FBS/PBS and stained with 
SYTOX-Blue (Life Technologies) dead cell marker and analysed on LSRFortessa 
(BD Biosciences).  
For analysis of the ephrin ligand expression aliquots of 2×106 LK63 or Reh cells were 
stained with EphA3-Fc or EphB4-Fc fusion proteins. The cells were washed twice 
with 2% FBS/PBS and stained with Alexa fluor 488 goat anti-human IgG (A-11013, 
Life Technologies) as a secondary antibody. The cells were washed twice with 2% 
FBS/PBS and analysed on LSRFortessa (BD Biosciences).  
To analyse the leukemic cell engraftment, blood, bone marrow and spleen tissues 
were collected from mice that were euthanized according to procedures approved by 
the QIMR Berghofer Medical Research Institute Animal Ethics Committee. Blood 
samples were obtained using submandibular blood sampling technique and lysed with 
red blood cell lysis buffer (Pharm Lyse™, BD Biosciences). In order to obtain bone 
marrow cells, both femurs from mice were flushed with a 26G needle and syringe 
containing 2% FBS/PBS and passed through 100 µm mesh filters. Spleens were 
dissociated into single cell suspensions and passed through a 70 µm mesh filters and 
red blood cells were lysed using red cell lysis buffer (Pharm Lyse™, BD 
Biosciences).  Blood, bone marrow and spleen cells were counted and stained with R-
phycoerythrin/Cyanine dye (PE/Cy7) anti-human CD45 (Biolegend) and 
Allophycocyanin (APC) anti-mouse CD45 (Biolegend) antibodies to enable separate 
enumeration of human and mouse haematopoietic cells. Then SYTOX-Blue (Life 
Technologies) was utilised to exclude dead cells. Data acquisition was performed 
using LSRFortessa flow cytometer (BD Bioscience) and the data were analysed using 
FlowJo software (Tree Star).  
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4.2.4 Reverse transcriptase polymerase chain reaction 
RNA was isolated from leukemic cell lines using the RNeasy Mini Kit (QIAGEN) 
and complementary DNA (cDNA) was synthesized using SuperScript III (Life 
Technologies) with respect to the manufacturer's instructions. Relative transcript 
quantification was performed with SYBR Green QPCR Mastermix (Applied 
Biosystems) using the RotorGene 3000 (QIAGEN). Real-Time PCR System and gene 
expression was calculated relative to β-actin as the housekeeping reference gene. 
4.2.5 The leukemic xenograft model 
The LK63, Reh, LK63/A3KD, Reh/A3, LK63/Luc and Reh/Luc cell lines were used 
to establish leukemic engraftment xenograft models in the NOD/SCID mice. The 
mice were injected intravenously into the tail vein with 5×106 cells for the leukemic 
engraftment model. A leukemic intrafemoral mouse model was established in which 
NOD/SCID mice were injected in the right femur with 2×105 leukemic cells. These 
xenograft models were treated intraperitoneally with humaneered anti-EphA3 
monoclonal antibody IIIA4 (IIIA4 mAb), control IgG antibody or vehicle (PBS), 
starting on the day of the cell transfer and then repeated on alternate dates until the 
mice were euthanized due to progression of the disease. These mice were monitored 
for disease progression and signs of illness and scored accordingly. All mice were 
scored individually based on weight loss (Score 0-2), body posture (Score 0-2), 
activity level (score 0-2), and grooming (score 0-2) and were subsequently euthanized 
once the total score was 7 or greater.  
4.2.6 In vivo bioluminescence imaging 
Anaesthetised mice were injected with 500 µg of firefly luciferin (PerkinElmer) 
subcutaneously. Mice were imaged 5 minutes later using the Xenogen imaging 
system IVIS 100 (PerkinElmer).  
4.2.7 Activation assay, western blot and microscopy 
Western blot analysis was used to evaluate phosphorylation states of Src (phospho-
Src-419, phospho-Src-527, 1:1000, Cell Signaling), Akt (phospho-Akt, 1:1000, Cell 
Signaling), Erk (phospho-Erk 1:1000, Cell Signaling) and total Src (1:1000, Cell 
Signaling) in LK63 and LK63/A3KD cells. Aliquots of 1.5 µg/ml of IIIA4, human 
IgG controls and ephrinA5-Fc were pre-clustered with 0.75 µg/ml of anti-human IgG 
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(huIgG) at 4°C for 1 hour. 1×106 LK63 and LK63/A3KD cells were incubated in 
serum free media for minimum of 4 hours. These cells were then incubated in PBS or 
PBS containing 1.5 µg/ml of IIIA4, pre-clustered human IgG controls, pre-clustered 
IIIA4 or pre-clustered ephrinA5-Fc and incubated at 37oC for 20 minutes after which 
they were pelleted and resuspended in 100 µl of ice cold lysis buffer (150 mM NaCl, 
1% Triton X-100, 5mM EDTA pH8, 10mM Tris-Cl pH7.4, 0.1 mM PMSF and 
cOmplete Protease Inhibitor Cocktail Tablets (Roche)). The lysates were centrifuged 
at 15,000 rpm to remove cell nuclei and debris and the protein concentration of the 
cleared lysate was determined by Bradford (Biorad) protein assay. Protein lysate at 
final concentration of (80 µg/sample) was mixed with appropriate volume of 5x 
sample buffer (130 mM Tris-Cl pH8.0, 20% (v/v) glycerol, 4.6% (w/v) SDS, 0.02% 
bromophenol blue, 2% DTT and 5% β-mercaptoethanol) and boiled for 5 minutes. 
Samples were run on denaturing SDS-PAGE gels (10% acrylamide) at 120 V for 1 
hour and transferred overnight at 30 V onto Immuno-Blot™ PVDF Membrane 
(BioRad). The membrane was blocked with 5% skim milk powder in TBST (137 mM 
NaCl, 10 mM Tris, pH7.4, 0.02% Tween 20) for 1 hour and incubated with primary 
antibody diluted in 5% skim milk powder in TBST for a minimum of 1 hour. The 
membrane was then washed three times with TBST for a total of at least 30 minutes 
before incubation for 1 hour in secondary detection antibody. Either anti-mouse or 
anti-rabbit IgG conjugated to horseradish peroxidase (HRP; 1:4000, Amersham 
Biosciences) was used as a secondary detection antibody. The membrane was then 
washed for 1 hour and the protein was detected using ECL™ Western Blotting 
Detection Reagents as per manufacturer’s instruction (Amersham Biosciences).  
For live cell imaging, 1×106 LK63 and LK63/A3KD cells were seeded onto 
fibronectin-coated plates for 24 hours prior to imaging. The cells were incubated in 
CO2-independent serum-free medium (Life Technologies) for a minimum of 4 hours 
and activated with IIIA4, pre-clustered human IgG control, pre-clustered IIIA4 or pre-
clustered ephrinA5-Fc. The cell were imaged every 10 seconds for 20 minutes using 
an Olympus IX81 Microscope (Olympus). 
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4.2.8 Radiolabelling and immunoreactivity 
Preparation and testing of the radiolabelled IIIA4 antibody was carried out in Prof. 
Andrew Scott's laboratory at the Ludwig Institute, Melbourne. 
Bismuth-213 (213Bi) was eluted from an Actinium-225 generator obtained from the 
Institute of Power Engineering and Physics, Obninsk, Russia. Radiolabelling of IIIA4 
and isotype control antibody with 213Bi was achieved using the bi-functional metal ion 
chelate C-functionalised trans-cyclohexyl-diethylenetriaminepentaacetic acid (CHX-
A″-DTPA) 196. The immunoreactivity of radiolablelled IIIA4 was determined by 
single point binding assays. The LK63 cells (10×106) were incubated with 20 ng 
radiolabelled 213Bi-IIIA4 for 30 minutes at room temperature. Cells were washed 
three times, and immunoreactivity was expressed as a percentage of activity in 
duplicate radioconjugate standards.  
4.2.9 213Bi-IIIA4 biodistribution study 
To assess the biodistribution of the radioconjugates in leukaemia, mice were injected 
with 213Bi-IIIA4 or 213Bi-isotype control in 0.1 ml saline 14 days after injection of 
LK63 cells. To assess the biodistribution of 213Bi-IIIA4, groups of 4 mice were culled 
at 5 minutes, 1 hour, 2 hours and 3 hours post radioconjugate injection. At each time 
point, the mice were euthanized according to institute guideline by isofluorane 
anaesthesia and then immediately bled via cardiac puncture. Blood and tissues (liver, 
spleen, kidney, muscle, skin, bone, lung, heart, stomach, brain, small bowel and 
colon) were resected, blotted dry for weighing and radioactive counting. For controls, 
213Bi-labeled isotype control was similarly injected into leukaemia-engrafted mice 
(n=4) and sacrificed 1 hour after injection for blood and tissue collection. The 
radioactivity of all samples was measured in a dual gamma scintillation counter 
(Cobra II Auto Gamma; Packard Instruments). The results of radiolabelled antibody 
biodistribution over time were calculated as the percentage injected dose per gram of 
blood or tissue (%ID/g) and were expressed as the mean ± standard deviation for each 
time point.   
4.2.10 213Bi-IIIA4 therapy study 
To assess the efficacy of 213Bi-IIIA4 α-emitter radioimmunotherapy in leukaemia, 
two therapeutic regimens were explored using mice injected with 13×106 LK63 cells. 
Chapter	  4	  
	  
	  
	  
	  
78	  
In the first study 6 days after injection of LK63 cells, mice were injected by tail vein 
injection with single doses of 213Bi-IIIA4 or controls. In the second study mice 
received multiple doses of 213Bi-IIIA4 or controls and the treatment injection were 
performed on day 2, 3, 5 and 6 after LK63 cells injection. In both studies treatment 
groups comprised individual 213Bi-IIIA4 doses of 12.5 µCi (115 mg protein) or 25 
µCi (180 µg protein) or 213Bi- isotype control at doses of 12.5 µCi (75 mg protein) or 
25 µCi (150 µg protein), delivered in 0.1-0.3 ml saline. Accordingly the multi-dose 
treatment groups received a total of 50 or 100 µCi radiolabel test or control antibody. 
Control groups received saline vehicle or 180 µg unlabelled IIIA4 per dose (total, 720 
mg protein) to match protein dose of monoclonal antibodies across all therapy groups, 
in equivalent volumes to the radiolabelled antibodies.  
4.2.11 Statistics 
Statistical analyses were performed using GraphPad Prism Version 6.01 software. 
Data are shown as mean ± SEM of at least three replicates, unless stated otherwise. 
Statistical significance was determined using an unpaired t test. The survival of the 
control and the treatment groups were compared using Kaplan–Meier analysis and 
statistical differences analysed using the log rank test.  
4.3 Results 
4.3.1 Expression of Eph receptors and their ephrin ligands in leukaemia 
Monoclonal antibodies generated in our laboratory were used to examine expression 
of EphA1, EphA2, EphA3 and EphA4 in 22 clinical samples of acute leukaemia and 
two refractory anaemia samples with excess blasts (RAEB) using flow cytometry. 
These results confirmed that majority of both myeloid and lymphoid leukaemias 
expressed significant levels of EphA3, but little or no expression of either EphA1 or 
EphA4 was detected even in EphA3-negative cases; however, a small number of 
samples did express EphA2, but at lower levels compared to EphA3 (Table 4.1).   
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Table 4.1. Analysis of EphA expression in patient samples. (- indicates no expression , ± indicates 
low level of expression, + refer to moderate level of expression and ++ indicates strong expression.) 
Tumour type Tissue EphA1 EphA2 EphA3 EphA4 
AML M0 (R24) BM - - ± - 
AML M0 (SM) BM - - ± - 
AML M1 (P4) Blood ± + ++ ± 
AML M1 (R22) Blood - +  ++ ± 
AML M1 (R32) BM - - ± - 
AML M1 (CC) BM - ± ++ - 
AML M2 (CH) BM - ± - - 
AML M2 (R7) Blood - ± + - 
AML M2 (R26) BM - - ± ± 
AML M2 (P23) BM ± + ++ + 
AML M2 (P10) BM - - ± - 
AML M2 (P22) BM - ± ++ + 
AML M4 Eo (P16) Blood - - ++ ± 
AML M4 (R19) BM - + ++ ± 
AML M6 (R12) Blood - - ± - 
AML M7 (P18) Blood - - ± - 
AML multi dys (P21) BM +(s) +(s) ++ +(s) 
AML multi dys (R14) BM - ± ++ - 
RAEB (P15) BM - - - - 
RAEB (R15) BM - ± + ± 
Pre B ALL (P20) BM - - + - 
Pre B ALL (R31) BM ± + ++ - 
Pre B ALL (R34) Apheresis - ± ± - 
Pre B ALL (KY) Apheresis - - ± - 
The expression of Eph and ephrin messenger RNA (mRNA) and protein levels were 
also assessed in a series of haematopoietic cell lines using RT-PCR and flow 
cytometric analysis. Similar to the results obtained from the clinical samples, EphA3 
mRNA was the most prominent transcript detected. In the analysis of the leukemic 
cell lines EphA3 was again the most prominent transcript detected and levels of 
mRNA for all other EphA genes were negligible with the exception of EphA1 where 
low levels of expression were detected in some cell lines.  Of all the EphB genes 
tested, EphB4 mRNA was detected in several lines, whereas EphB6 mRNA was only 
detected in T-cell lines, as previously reported (Figure 4.1A)118,119,130. Expression of 
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ephrin transcripts was generally low except for ephrinB2 and ephrinB1, which 
showed significant expression in Reh cells (Figure 4.1B).    
EphA3 and EphB4 were two of the most prominent Ephs expressed on leukemic cell 
lines. This was confirmed by analysis of cell surface expression of EphA3 and EphB4 
protein labelled with anti-EphA3 monoclonal antibody (IIIA4) or EphB4 monoclonal 
antibody and was performed using flow cytometric analysis. High expression of 
EphA3, which correlated with mRNA expression, was observed in LK63 and Jurkat, 
moderate EphA3 expression on Molt-4 and no expression on Reh cells, in keeping 
with previous data 101 (Figure 4.1C). EphB4 expression was assessed using anti-
EphB4 monoclonal antibody, which showed high expression of EphB4 in Reh, LK63, 
U937 and K562 (Figure 4.1D). EphA3-Fc and EphB4-Fc fusion proteins were used 
for analysis of the ephrinA and ephrinB expressionon on the LK63 and Reh cells. Reh 
cells stained weakly positive for both EphA3-Fc and EphB4-Fc, which correlates with 
the expression of ephrinA and ephrinB mRNA in these cells (Figure 4.1E).  
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Figure 4.1. Analysis of Eph and ephrin expression on leukemic cell lines.	   (A) Expression of 
EphA1, EphA3, EphB4 and EphB6 in LK63, Reh, Jurkat, K562, Molt-4, NB-4, SKM-1, THP-1, U937, 
MM6 analysed per 1000 β-actin using RT-PCR. (B) Expression of ephrinA1, ephrinA2, ephrinA4, 
ephrinB2 and ephrinB3 in LK63, Reh, Jurkat, K562, Molt-4, NB-4, SKM-1, THP-1, U937 and MM6 
analysed per 1000 β-actin using RT-PCR.  (C) Cell surface expression of EphA3 in LK63, Reh, Jurkat 
and Molt-4 cells analysed using the anti-EphA3 monoclonal antibody (IIIA4). LK63 showed highest 
expression of EphA3 followed by Jurkat, Molt-4 and Reh with no EphA3 expression. (D) Cell surface 
expression of EphB4 in LK63, Reh, K562 and U937 cells analysed using the anti-EphB4 monoclonal 
antibody. High expression of EphB4 was observed in all of the leukemic cells tested.  (E) Cell surface 
expression of ephrinA and ephrinB on LK63 and Reh cells using EphA3-Fc and EphB4-Fc fusion 
proteins. 
4.3.2 Establishing Leukemic mouse models to investigate the role of 
EphA3 in leukaemia 
To investigate the role of EphA3 in leukaemia, two pre-B ALL cell lines with similar 
characteristics and phenotype that differed in their EphA3 expression were chosen. 
Based on the expression analysis, LK63 cells showed the highest expression of 
EphA3, and Reh, did not express detectable level of EphA3, however both cell lines 
expressed comparable levels of EphB4. The LK63 cell line was derived from a child 
with pre-B ALL and its characteristics and phenotype (CD10+CD19+CD20±EphA3+) 
was described in detail previously 103. The Reh cell line is also from a childhood pre-
B ALL with similar characteristics and phenotype (CD10+CD19+CD20-EphA3-).  
When injected into mice both cell lines reliably gave rise to leukemic engraftment and 
were thus selected as xenograft models to analyse the function and potential targeting 
of EphA3 in leukaemia.  
The LK63 engraftment in bone marrow, spleen and blood was enumerated by flow 
cytometric analysis at different time points using human and mouse CD45 antigen to 
distinguish the relative number of LK63 cells and healthy mouse lymphocytes (Figure 
4.2A). It was evident that LK63 cells preferentially grew in the bone marrow before 
significant numbers were observed in the spleen and peripheral blood (Figure 4.2B). 
The LK63 xenograft had significantly higher spleen weight compare to normal spleen 
(Figure 4.2C). Histological analysis showed that growth in the bone marrow was 
relatively uniform whereas the spleen initially showed foci of proliferating LK63 
cells, which eventually became confluent and affected the normal splenic architecture 
(Figure 4.2D, E), consistent with the notion that the leukemic cells were seeded into 
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the spleen from the bone marrow. The Reh engraftment in bone marrow, spleen and 
blood was also analysed at different time points using flow cytometric analysis for 
human and mouse CD45 antigen. It was evident that Reh cells preferentially grew in 
the bone marrow followed by spread to the peripheral blood. Unlike LK63 xenograft, 
Reh xenografts showed minimal engraftment in the spleen with no significant 
differences in spleen weight at any time point after leukemic engraftment. Reh 
engraftment followed a somewhat slower time-course compared to LK63 xenografts 
(Figure 4.2F, G).  
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Figure 4.2. Leukemic progression in LK63 and Reh xenograft model. (A) Flow cytometry gating 
strategy for mCD45 and hCD45 in bone marrow, spleen and blood of leukemic mice. (B) Leukaemia 
progression in blood, spleen and bone marrow of LK63 leukemic mice was analysed by flow cytometry 
using hCD45 and mCD45 markers every 5 days for 30 days. (C) Spleen weight of LK63 leukemic mice 
compared to normal mice over 30 days in which the size of spleen became significantly enlarged in 
LK63 mice on day 25 and 30 post engraftment compared to normal control mice (n=3 LK63 mice, n=1 
normal mice per time point). (D) Histology of normal spleen. (E) Histology of leukemic spleen from 
LK63 xenograft.  (F) Leukaemia progression in blood, spleen and bone marrow of Reh-engrafted 
leukemic mice was analysed by flow cytometry using hCD45 and mCD45 markers for 35 days. (G) 
Spleen weight of Reh-engrafted leukemic mice compared to normal mice showed no changes in the 
spleen size over 35 days (n=3 LK63 mice, n=1 normal mice per time point).  
 
4.3.3 Treatment of leukemic mice with IIIA4 monoclonal antibody 
In this section I describe experiments in which the LK63 and Reh xenografted mice 
were treated with the humaneered anti-EphA3 monoclonal antibody IIIA4 (IIIA4 
mAb). Previous studies on IIIA4 tissue distribution showed effective targeting of 
EphA3-positive tumour cells with IIIA4 and negligible amounts of IIIA4 was 
observed in other tissues 146. A dose response experiment was performed on LK63 
xenograft model and the results showed optimum and maximum response in terms of 
reduction in spleen engraftment at a dose of 100 µg. Lower doses including, 10 µg 
and 30 µg were less effective compared to 100 µg. Higher concentrations at 250 µg 
and 1000 µg had similar therapeutic effect compared to 100 µg of IIIA4 treatment 
(Figure 4.3A).  Therefore, in all of the subsequent experiments 100 µg of IIIA4 
antibody was administered on alternate days starting immediately after LK63 
leukemic cells injection. 
Both LK63 and Reh xenografted mice were treated with 100 µg of IIIA4 mAb, 
vehicle only or control human IgG1 antibody (IgG control). In contrast to the IIIA4 
treated group, no effect on engraftment were observed in either of the control groups. 
As there were no significant differences between PBS and human IgG treated 
controls, PBS was used as the negative control in subsequent experiments (Figure 
4.3B, C).  
The LK63 mouse model of leukaemia showed significant leukemic engraftment in 
bone marrow and spleen of the mice. Treatment of LK63 xenografted mice with 
IIIA4, significantly reduced engraftment in the spleen, as it was evident from lower 
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numbers of human CD45-positive cells in the spleen and reduced spleen weight. 
Engraftment of the LK63 cells in the bone marrow was also reduced compared to the 
PBS-treated control group (Figure 4.3D, E). A lesser increase in spleen weight, and 
reduced engraftment of spleen and bone marrow are indicative of reduced tumour 
growth in the LK63 xenograft upon treatment with IIIA4.  In contrast, the Reh 
xenografted mice showed no therapeutic effect in response to treatment with IIIA4 
compared to PBS treated control group, which is consistent with the absence of 
EphA3 on Reh cells. As mentioned previously, the Reh leukemic model, unlike LK63 
xenografted mice, had minimal splenic engraftment. Treatment of Reh xenograft with 
IIIA4 showed no significant changes in splenic engraftment and in fact showed 
increased bone marrow engraftment compared to the PBS treated control group 
(Figure 4.3F, G). 
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Figure 4.3. LK63 and Reh leukemic mouse models treated with PBS or IIIA4 mAb. (A) Spleen 
engraftment in LK63 xenograft in response to PBS or IIIA4 treatment at 10 µg, 30 µg, 100 µg, 250 µg, 
and 1000 µg dosing. The engraftment was significantly reduced at 30, 100, 250 and 1000 µg of 
antibody treatment compared to the PBS-treated control group (***P value. 0.0007, ****P value. < 
0.0001). No significant difference in engraftment was observed between 100, 250 and 1000 µg of IIIA4 
dosing (n=4-9). (B) Percentage of bone marrow engraftment in the LK63 xenograft in response to PBS, 
IgG control and IIIA4 showed no significant differences between the three groups (n=8). (C) 
Percentage of spleen engraftment of the LK63 xenograft in response to PBS, IgG control and IIIA4 
showed no significant differences between PBS and IgG control groups. There was a significant 
reduction in the spleen engraftment of IIIA4 treated group compared to PBS (P value. 0.0001) and IgG 
control (P value. 0.0069) treated groups (n=8). (D) Spleen weight for IIIA4 and PBS treated LK63 
xenograft showed a significant reduction in spleen weight of IIIA4-treated mice compared to the PBS-
treated control group (P value. 0.0006) (n=16 PBS, n=17 IIIA4, 4 experiments). (E) Percentage of 
engraftment in spleen and bone marrow of LK63 mice treated with IIIA4 or PBS showed a significant 
reduction in spleen engraftment (P value. 0.0001) and a reduction in bone marrow engraftment (n=16 
PBS, n=17 IIIA4, 4 experiments). (F) Spleen weight for IIIA4 and PBS treated Reh mice showed no 
significant differences between the two groups (n=15, 3 experiments). (G) Percentage of leukemic 
engraftment in spleen and bone marrow of Reh mice treated with IIIA4 or PBS was not significantly 
different (n=15, 3 experiments). Each dot on the graph D and E corresponds to one individual mouse. 
The data are presented as mean percentage ± SEM of spleen or bone marrow engraftment. An unpaired 
t test was performed for statistical analyses.	  
The data from LK63 and Reh leukemic models are consistent with a significant, direct 
anti-leukemic effect of IIIA4 on EphA3-positive LK63 cells. The lack of any effect 
on the EphA3-negative Reh cells is consistent with there being no effect on the 
stromal elements, which form the tumour microenvironment. Interestingly, apart from 
the effect on LK63 tumour growth and spleen and bone marrow engraftment, there 
appears to be a secondary effect on spread of the leukemic cells from bone marrow to 
the spleen. Even when animals were terminally ill and had bone marrow engraftment 
of almost 100% in both treated and un-treated animals the degree of splenic 
infiltration as indicated by both % engraftment and total spleen weight was 
dramatically less in treated animals. This disparity suggested an effect on tumour 
mobilisation and/or homing. 
To further define the specificity of IIIA4 treatment, LK63 EphA3-knockdown 
(LK63/A3KD) and Reh EphA3-expressing (Reh/A3) cells were developed. The 
LK63/A3KD cells were developed by transducing LK63 cells with an EphA3 shRNA 
expressing lentivirus with a GFP-tag and selecting for low EphA3-expressing cells 
Chapter	  4	  
	  
	  
	  
	  
87	  
using puromycin, followed by, sorting the low EphA3 and high GFP expressing cells. 
The established LK63/A3KD line showed EphA3 levels of <10% of parental control 
LK63 cells. Reh/A3 cells were derived by infecting Reh cells with EphA3-encoding 
lentiviral particles (GeneCopeia). Reh/A3 cells were selected using puromycin 
selection and then sorted for EphA3-positive cells with level of EphA3 expression 
comparable to LK63 cells (Figure 4.4A, B).  
Engraftment of LK63/A3KD cells in NOD/SCID mice was somewhat slower when 
compared to control LK63 cells engraftment. Significantly smaller spleen size 
compared to normal LK63 xenograft spleen and significantly less bone marrow 
engraftment at the time of cull was observed in these mice. Comparable percentage of 
spleen engraftment was observed which could indicate significantly less engraftment 
in total spleen cells of LK63/A3KD considering that it has significantly smaller 
spleen compared to LK63 (Figure 4.4C, D).  
More importantly in the LK63/A3KD xenografts, treatment with IIIA4 mAb did not 
significantly affect the spleen and bone marrow engraftment when compared to the 
PBS treated control group (Figure 4.4E, F). In contrast, when xenografts of Reh/A3 
cells were treated with IIIA4 mAb there were a significant reduction in bone marrow 
engraftment compared to PBS treated control group. In Reh/A3 xenograft model 
similar to the Reh xenograft model there is a very low engraftment in the spleen 
however in this model a statistically significant reduction in spleen engraftment was 
observed. In the Reh/A3 xenograft model treatment with IIIA4 results in reduction in 
leukemic engraftment as opposed to Reh xenograft model where no therapeutic effect 
was observed in either spleen or bone marrow (Figure 4.4G, H).  
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Figure 4.4. LK63/A3KD and Reh/A3 leukemic mice treated with PBS or IIIA4 mAb. (A) Flow 
cytometric and analysis of LK63 and LK63/A3KD, Reh and Reh/A3 cells. (B) EphA3 and β-actin 
expression analysis determined using western blot analysis of LK63 and LK63/A3KD, Reh and 
Reh/A3 cells. (C) Comparison of spleen weight from LK63 and LK63/A3KD mice showed 
significantly smaller spleens in LK63/A3KD mice compared to EphA3 positive LK63 xenograft (P 
value. <0.0001) (n=4 PBS, n=5 IIIA4). (D) Percent engraftment in bone marrow of LK63 compared to 
LK63/A3KD mice showed significantly less engraftment in the bone marrow of LK63/A3KD 
xenograft (P value. 0.0060) (n=4 PBS, n=5 IIIA4) and comparable percent engraftment of spleen cells. 
(E) LK63/A3KD mice showed no significant differences in spleen weight between the IIIA4-treated 
and the PBS-treated control group (n=13 PBS, n=14 IIIA4, 3 experiments). (F) Percent engraftment in 
spleen and bone marrow of LK63/A3KD mice treated with IIIA4 or PBS showed no significant 
differences between the IIIA4 treated and PBS treated control group (n=4 PBS, n=5 IIIA4). (G) 
Reh/A3 mice showed no significant differences in spleen weight of the IIIA4-treated group compared 
to PBS-treated control mice. (H) Percent engraftment in spleen and bone marrow of Reh/A3 mice 
treated with IIIA4 or PBS showed a significant reduction in bone marrow (P value. 0072) and spleen (P 
value. 0.0464) engraftment in the IIIA4-treated group compared to PBS-treated control group. Each dot 
on the C, E and G plot corresponds to one individual mouse. The data are presented as mean 
percentage ± SEM of spleen or bone marrow engraftment. An unpaired t test was performed for 
statistical analyses. 
To further investigate differences in engraftment of Reh and LK63 xenograft models, 
I transduced Reh and LK63 cells with a firefly luciferase containing lentivirus to 
isolate Reh/Luc and LK63/Luc cell lines. I used this method to track and image 
migration of LK63 and Reh cells in mice intravenously injected with 5×106 Reh/Luc 
or LK63/Luc cells. The mice were subsequently monitored twice on a weekly basis 
with Xenogen imaging and, as before, culled when they exhibited significant signs of 
illness (Figure 4.5). These mice were treated with 100 µg of IIIA4 or PBS on alternate 
days. Consistent with the previous results, the LK63 mice treated with IIIA4 showed 
similar bone marrow engraftment to PBS-treated mice at early stages of leukaemia 
progression; however, in the later stages of leukaemia progression minimal splenic 
engraftment was observed in the IIIA4-treated group compared to high levels of 
engraftment in the PBS-treated controls (Figure 4.5A). An interesting observation was 
the apparent decrease in signal from bone in mice with massively enlarged spleens. 
This appears to be an artefact as the bone marrow analysis showed progressive 
infiltration. A possible explanation is that there is competition for luciferin substrate 
whereby the massive splenic involvement "starves" other tissues of substrate. In the 
Reh model of leukaemia the Xenogen image analysis was consistent with previous 
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engraftment results in which no splenic engraftment was observed in both PBS- and 
IIIA4-treated mice and the bone marrow engraftment was comparable or increased in 
IIIA4-treated mice compared to the PBS-treated group (Figure 4.5B).  
	  
Figure 4.5. Xenogen images of Reh and LK63 leukemic mice. (A) LK63 leukemic engraftment 
model treated with PBS or IIIA4 mAb on alternate days and representative images from day 9, 14, 18 
and 22. On day 9 there was minimal and similar engraftment in the bone marrow of PBS- and IIIA4-
treated mice. On day 14 PBS-treated mice have minimal engraftment in the spleen and IIIA4-treated 
group showed no spleen engraftment. On day 18 and 22 PBS-treated mice have significantly higher 
engraftment in the spleen compared to IIIA4-treated group. (B) Reh leukemic engraftment model 
treated with PBS or IIIA4 mAb on alternate days and representative images from day 14, 18, 25 and 
29.  The mice showed similar engraftment on day 14, 18 and 25; however, on day 29 the mice treated 
with IIIA4 showed higher bone marrow engraftment compared to PBS treated group. 
The previous results had suggested that initial engraftment only occurred in bone 
marrow and that spread to spleen and other sites was a secondary event. In an attempt 
to confirm this, I developed an intrafemoral model of leukaemia in which 2×105 
Reh/Luc or LK63/Luc cells were directly injected into the right femur and mice were 
monitored for pattern of leukemic spread, using Xenogen imaging, and signs of 
illness. Similar to previous models, these mice were also treated with 100 µg of IIIA4 
Day 14 
Day 18 
Day 25 
Day 29 
Reh cIIIA4 Reh PBS 
Day 9 
Day 14 
Day 18 
Day 22 
LK63 cIIIA4 LK63 PBS A B 
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mAb or PBS on alternate days until the mice were euthanized due to progression of 
disease (Figure 4.6). 
The LK63 intrafemoral mouse model showed that the LK63 cells initially engrafted at 
the injection site in the right femoral bone marrow and then engrafted to the other 
bones before the leukemic cells spread to the spleen. This was not observed in the 
Reh model of engraftment in which the cells grow in the injected bone marrow and 
then move to the other bones and, as with intravenously injected cells, did not 
significantly engraft in the spleen  (Figure 4.6). Thus, the pattern of spread observed 
in this model recapitulated the patterns observed in animals injected intravenously. 
For LK63, in particular, this confirmed that leukemic cells preferentially engraft and 
grow in the bone marrow and only once the disease is well-advanced spread to other 
sites, notably the spleen. The marked reduction in splenic engraftment in IIIA4-
treated animals again suggests that infiltration of the spleen may depend, at least in 
part, on EphA3. 
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Figure 4.6.	  Intrafemoral model of Reh and LK63 Leukemic mice. (A) LK63 intrafemoral model 
treated with PBS and IIIA4 representative images from day 18, 22 and 28 showed initial right bone 
marrow engraftment followed by left bone marrow engraftment and spleen engraftment in the PBS 
treated model and displayed a much slower disease progression in the IIIA4 treated group. (B) Reh 
intrafemoral model treated with PBS and IIIA4 imaged on days 30, 35 and 40 showed initial 
engraftment in the right femoral bone marrow followed by significant engraftment in the left femoral 
bone marrow with no splenic engraftment up to day 40. (C) Spleen weight for LK63 intrafemoral 
model showed significantly smaller spleen (P value. 0.019) in the IIIA4-treated group at the time of 
cull (n=7 PBS, n=9 IIIA4, 2 experiments) (D) Percent engraftment in the right bone and left bone 
Ri
gh
t B
M
Le
ft B
M 
Sp
lee
n
0.0
0.1
20
40
60
80
100
%
 E
ng
ra
ftm
en
t PBS
cIIIIA4
PB
S 
cII
IA
4
0.00
0.05
0.10
0.15
0.20
W
ei
gh
t (
gr
)
 PB
S
 cI
IIA
4
0.0
0.2
0.4
0.6
0.8
1.0
W
ei
gh
t (
gr
)
0.0109
*
Ri
gh
t B
M
Le
ft B
M 
Sp
lee
n
0
20
40
60
80
%
 E
ng
ra
ftm
en
t
PBS
cIIIA4
0.0006
***C D 
E F 
LK63 IIIA4 LK63 PBS 
Day 18 
Day 22 
Day 28 
Reh IIIA4 Reh PBS 
Day 30 
Day 35 
Day 40 
A B 
Chapter	  4	  
	  
	  
	  
	  
93	  
marrow of LK63 intrafemoral model treated with IIIA4 was less than PBS-treated mice. Percent 
engraftment in the spleen of LK63 intrafemoral model treated with IIIA4 was significantly less (P 
value: 0.0006) compared to the PBS-treated group (n=7 PBS, n=9 IIIA4, 2 experiments). (E) Spleen 
weight for Reh intrafemoral model showed no differences between PBS and IIIA4 treated mice (n=7 
PBS, n=9 IIIA4, 2 experiments). (F) Percent engraftment in the right bone marrow of the Reh 
intrafemoral model was similar between IIIA4- and PBS-treated groups. Percent engraftment in the left 
bone marrow was higher in the IIIA4-treated compared to the PBS-treated mice. Percent engraftment 
in the spleen of the Reh intrafemoral model treated with IIIA4 was minimal but less compared to PBS 
treated group (n=7 PBS, n=8 IIIA4, 2 experiments). Each dot on the plot corresponds to one individual 
mouse. The data are presented as mean percentage ± SEM of spleen or bone marrow engraftment. An 
unpaired t test was performed for statistical analyses.	  
4.3.4 The effect ephrinA5 or IIIA4 antibody induced stimulation on LK63 
and Reh cells 
In seeking to define how the antibody treatment may affect LK63 cell migration and 
homing, LK63 cells were incubated with either PBS, pre-clustered huIgG, IIIA4, pre-
clustered IIIA4 or pre-clustered ephrinA5-Fc, a form of the high affinity ligand which 
induces receptor clustering and activation. I examined the effect of these stimuli on 
several pathways downstream of Eph receptors including Akt, the MAP kinases 
Erk1/2 and Src. In LK63 cells, treatment with IIIA4, pre-clustered IIIA4 and pre-
clustered ephrinA5-Fc resulted in increased phosphorylation of the activation loop of 
Src on tyrosine 419 with no significant effect on tyrosine phosphorylation of the auto-
inhibitory 527 site (Figure 4.7A). No effect was observed on Akt or Erk 
phosphorylation. More importantly, no activation of any of the above pathways, 
including Src, was observed in LK63/A3KD cells. I also looked at the effect of 
EphA3 activation on cell morphology and shape in LK63 and LK63/A3KD using live 
cell imaging over 20 minutes with one frame per 10 seconds. This showed increased 
cell rounding and membrane blebbing in response to activation with IIIA4, pre-
clustered IIIA4 or pre-clustered ephrinA5-Fc; this effect was less pronounced in 
LK63/A3KD cells (Figure 4.7B-C).  
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Figure 4.7. The effect of EphA3 activation on downstream signalling and cell morphology in 
LK63 and LK63/A3KD cells. (A) Increase phosphorylation of Src on tyrosine 419 was observed in 
LK63 cells upon activation with IIIA4, pre-clustered IIIA4 or pre-clustered ephrinA5-Fc compared to 
the PBS control. Stimulation had no effect on phosphorylation of Src on tyrosine 527. In the 
LK63/A3KD phophorylation of Src on tyrosines 419 and 527 was unaffected by these stimuli. (B) 
Representative images from LK63 cells upon activation with IIIA4, pre-clustered IIIA4 or pre-
clustered ephrinA5-Fc. The images showed membrane blebbing and cytoskeleton contraction upon 
EphA3 activation. The arrows point to the cells with membrane blebbing or cytoskeleton contractions. 
(c) Representative images from LK63/A3KD cells upon activation with IIIA4 pre-clustered IIIA4 or 
pre-clustered ephrinA5-Fc showing minimal changes in cell shape and morphology.  
4.3.5 Radiolabelled IIIA4 Mab antibody treatment 
4.3.5.1 Immunoreactivity of radiolabelled IIIA4 
213Bi-IIIA4 and control 213Bi-labelled antibodies were prepared at respective specific 
activities of 109 mCi/mg and 167 mCi/mg for in vitro and in vivo characterisation. 
Assessment of radiochemical purity by Instant Thin Layer Chromatography (ITLC) 
consistently demonstrated >99% 213Bi- bound to IIIA4 and 97.7% for the isotype 
control. Immunoreactivity of 213Bi-IIIA4 for LK63 cells was determined by the single 
point cell binding assay and was 38.7%.  
4.3.5.2 Biodistribution 
The biodistribution results for 213Bi-radiolabeled IIIA4 and isotype control treatment 
in LK63 leukemic NOD/SCID mice are presented in Figure 4.8. The biodistribution 
studies indicate that 213Bi-IIIA4 localised to the expected areas of leukaemia 
involvement, including blood, spleen, lung and liver, within 15 minutes of injection 
and were maintained over the 3 hours of the experiment. Peak uptake of 20.8 ± 3.9 
%ID/g and 20.9 ± 3.8 %ID/g were observed at 2 hours in the liver and spleen, 
respectively (Fig 4.8A). Minimal uptake (0.2–6 %ID/g) was observed in other normal 
tissues at all time points (Fig 4.8A). The specificity of the 213Bi-IIIA4 for EphA3-
positive leukaemia was confirmed by the low levels of tissue localisation observed 
with the isotype control antibody (Figure 4.8B). 
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Figure 4.8. Biodistribution of 213Bi-labeled IIIA4 and isotype control antibodies. (A) 213Bi-IIIA4 
biodistribution in LK63 leukemic NOD/SCID mice at 5 minutes, 1 hour, 2 hours and 3 hours after 
treatment. (B) Distribution of 213Bi-isotype controls in NOD/SCID mice bearing LK63 cells at 1 hour 
after treatment. (n=4). Results of the biodistribution are presented for each tissue as mean percent of 
injected dose per gram of tissue (%ID/g) values ± SD. 
4.3.5.3 Efficacy of 213Bi-IIIA4 therapy 
The effect of a single dose of 213Bi-IIIA4 radioimmunotherapy in the LK63 xenograft 
at day 6 post LK63 leukemic cell injection showed no significant difference in the 
median survival between the saline-treated group, 213Bi-labeled isotype control and 
213Bi-IIIA4 at 12.5 or 25 mCi dose levels (Figure 4.9A).  
The effect of four doses of 213Bi-IIIA4 on animal survival of leukaemia engrafted 
NOD/SCID mice is presented in Figure 4.9. Following engraftment on Day 0, the 
median survival for the vehicle control group was 21 days. Multi-dose treatment with 
unlabelled IIIA4 or 12.5 mCi 213Bi-isotype control commencing on Day 2 caused a 
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slight increase in median survival to 24 days. Radioimmunotherapy with 213Bi-IIIA4 
significantly increased median survival in a dose dependant manner compared to 
IIIA4 protein alone, with a median survival of 26.5 days at the 12.5 mCi repeat dose 
and 41.5 days at the 25 mCi repeat dose. The specificity of the IIIA4 
radioimmunotherapy is indicated by the significantly shorter survival of the 
corresponding arms of 213Bi-isotype control antibody-treated groups at both the 12.5 
mCi and 25 mCi repeated dose levels (Figure 4.9B). 
 
Figure 4.9. Survival curve in response to treatment with 213Bi-IIIA4. (A) Single dose 213Bi-IIIA4 
radioimmunotherapy treatment following engraftment with LK63 leukemic cells on Day 0 showed no 
significant differences between the control groups (saline, 180 mg IIIA4, 213Bi-isotype control at 12.5 
and 25 mCi) and the 213Bi-IIIA4-treated (12.5 mCi and 25 mCi) groups. (B) Multi-dose 213Bi-IIIA4 
radioimmunotherapy following engraftment with LK63 leukaemia cells on Day 0 showed significant 
increase in survival of IIIA4 or 12.5 mCi 213Bi-isotype control  (P value. 0.001) compared to saline 
control. Significant increase in survival of 12.5 mCi 213Bi-IIIA4 (P Value. 0.01) and 25 mCi 213Bi-
IIIA4 (P value. <0.0001) was observed compared to IIIA4 control group.  Survival of the 12.5 mCi 
213Bi-IIIA4 compared to 12.5 mCi 213Bi-isotype was significantly improved (P value. 0.0011).  Survival 
of the 25 mCi 213Bi-IIIA4 compared to 25 mCi 213Bi-isotype was significantly improved (P value. 
0.0001). (n=8). Days of injection of with saline (!), 180 mg mAb IIIA4 (!), 213Bi-isotype controls at 
12.5 mCi ("), or 25 mCi (") or 213Bi-IIIA4 at 12.5 mCi (#), or 25 mCi ($) are indicated by arrow. 
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4.4 Discussion 
Given the expression of EphA3 in many different human cancers including 
leukaemia, I explored the expression and function of EphA3 and the possibility of 
using it as a therapeutic target in the treatment of leukaemia. Of the tested EphA 
antigens, I found EphA3 to be the most prominent Eph expressed on a panel of 
leukemic patient samples and cell lines. Therefore I have investigated therapeutic 
targeting of EphA3 in two pre-B ALL cell lines, the EphA3-positive LK63 and the 
EphA3-negative Reh cell lines.  
In these models, LK63 cells preferentially grow in the bone marrow followed by 
engraftment in the spleen and peripheral blood; however, Reh engraftment was 
observed to be largely confined to the bone narrow with minimal splenic engraftment. 
Administration of the IIIA4 anti-EphA3 mAb to LK63 xenograft resulted in inhibition 
of tumour growth and marked delay in spread from bone marrow to the spleen and 
other organs and increased in the latency of the disease. However, no therapeutic 
effect was observed in the Reh xenograft model suggesting that the effect of IIIA4 
mAb treatment is primarily directed against the leukemic cells expressing EphA3 with 
little or no effect on host cells.  
To further confirm that EphA3 bearing leukemic cells were the direct target of the 
IIIA4 treatment, LK63 EphA3-knockdown (LK63/A3KD) and Reh EphA3-
expressing (Reh/A3) cell lines were developed. Similar to the lack of antibody 
treatment effect on Reh xenograft group, treatment of LK63/A3KD xenograft with 
IIIA4 showed no significant changes in the spleen and bone marrow engraftment or 
spleen weight. However, treating Reh/A3 mouse with IIIA4 showed significant 
reduction in bone marrow and spleen engraftment similar to the therapeutic effect 
observed in LK63 xenograft. These results confirm that the effect of EphA3 mAb 
treatment is directed against the leukemic cells rather than the stromal and vascular 
elements.  
To understand the mechanism leading to therapeutic effect of IIIA4 on EphA3-
expressing leukemic cells, I looked at the effect of EphA3 activation on the LK63 and 
LK63/A3KD cells. My analysis showed elevated Src kinase activity upon stimulation 
with either IIIA4 or ephrinA5-Fc. Src kinases have been implicated in Eph-mediated 
signalling in other systems, and rather than a growth promoting effect, its activation 
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appears to target adhesive mechanisms, particularly integrins, and cell motility 
functions 197-199. There is abundant evidence in other cells that the latter functions of 
Eph proteins are mediated by activation of RhoA leading to actin depolymerisation 
and inactivation of Rac and Cdc42 leading to retraction of cell processes and decrease 
in cell migration 52,64,200. My preliminary analysis of cell behaviour in response to 
antibody binding shows an increase in cell rounding and membrane blebbing as it was 
previously demonstrated in LK63 cells in response to ephrin stimulation 68. Future 
studies are needed to fully elucidate the role of Src signalling in initiating the cell 
shape and movement changes induced by antibody binding which may underpin the 
observed anti-leukemic effect. 
The other aspect of these studies was to explore if EphA3 could be used as a targeting 
agent, particularly given its low level expression in normal tissues. In glioblastoma 
treatment with radiolabelled IIIA4 antibody showed a great anti-tumour effect in 
EphA3-positive glioblastoma tumours 59. In the LK63 model an alpha particle 
emitting isotope was used to minimise the off target effects on EphA3-negative cells. 
Consistent with the Day et al. (2013) finding, an impressive anti-tumour effect on 
EphA3 positive leukemic model was delivered by the alpha particle emitting bismuth-
213 isotope directly linked to the IIIA4 antibody. These results strongly suggest that 
the direct inhibitory effect of IIIA4 therapy on EphA3 positive leukaemias might be 
further enhanced by payloading with an isotope or with cytotoxic drugs, as has been 
demonstrated for the anti-HER2 antibody trastuzumab in breast cancer 201. 
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Chapter 5 . GENERAL DISCUSSIONS 
AND FUTURE DIRECTIONS 
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I started out with the knowledge that various members of Eph/ephrin family of 
proteins are expressed on haematopoietic cells and leukemic tumours 75.  However, 
there were limited data on the functional effect of Eph family of RTKs in normal 
haematopoiesis and leukaemia. In this thesis I aimed to explore the potential 
functional effects of several members of the EphA subfamily of Eph RTKs. In 
particular, I explored the roles of EphA1, EphA2 and EphA7 in haematopoiesis by 
utilising the available knockout mice. I have also investigated the role of EphA2 and 
EphA3 in leukaemogenesis. My lab had highly specific monoclonal antibodies to all 
of these Eph proteins, providing the essential tools for exploring the targeting of these 
proteins in the treatment of haematological malignancies.  
In Chapter 2, I examined the functional role of EphA1, EphA2 and EphA7 in normal 
haematopoiesis by using the EphA1, EphA2 and EphA7 null mice in comparison to 
congenic littermates. This study demonstrated that loss of EphA1, EphA2 or EphA7 
does not significantly disrupt normal haematopoiesis. In essence, these mice have a 
normal steady haematopoietic system. Expression of other members of Eph family 
have been reported on haematopoietic cells which could be an indication that other 
members of this family of RTKs can compensate for the function in the absence of 
one member. For example, Ting et al. (2011) reported expression of EphA3 and 
EphA5, both of which are functionally similar to EphA2 and EphA7, on 
haematopoietic progenitor cells 123.  The necessary experiments to explore 
redundancy were not feasible within the scope of this project. Therefore, in future it 
will be important to investigate the potential redundancy of Eph receptors in 
haematopoiesis by studying the functional effect of Eph blockade using broad 
spectrum inhibitors or examining mice with multiple Eph deletions on hematopoietic 
system. Another alternative approach would be to pathologically "stress" the 
haemopoietic system, for example with infection, and see whether the response to this 
challenge in knockout mice is normal.  
The study presented in chapter 3 initially examined expression of Eph genes in two 
models of the leukaemia, the MLL-AF9 model of acute myeloid leukaemia and the 
BCR-ABL model of chronic myeloid leukaemia. Aberrant expression of Eph genes 
specifically EphA2 and EphA7 were only significantly present in the MLL-AF9 
model, a finding foreshadowed by previous studies 113. Given the availability of well-
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characterised reagents for EphA2, I focused on the potential role of EphA2 in MLL-
AF9 leukaemia. These studies showed that lack of EphA2 expression did not 
significantly alter the leukaemogenic process initiated by the MLL-AF9 oncogene. 
However, as expression of other members of EphA subfamily was found on MLL-
AF9 leukemic cells, this may reflect again the redundancy of function such that other 
members of Eph family proteins compensate for loss of EphA2. This could be further 
explored once knockout animals with several EphA deletions are available. A small 
survey of human leukaemias suggested that EphA1, EphA2, EphA3 and EphA7 are 
variably expressed on MLL-driven leukaemias and thus combination knockouts of 
these genes could be prioritised.  
I then examined whether EphA2 could serve as a therapy target in MLL-AF9 
leukaemia using the IF7 monoclonal antibody, which specifically binds to human and 
mouse EphA2 protein. There was, however, no direct anti-tumour effect delivered 
upon treatment of MLL-AF9 mice with EphA2 monoclonal antibody (IF7 mAb). This 
monoclonal antibody is an IgG1 isotype antibody, thus it does not have any 
significant Fc effector function. Therefore a different isotypic form of EphA2 mAb 
might provide some functional effect in the treatment of the EphA2 positive MLL-
AF9 leukaemia. This could be verified through the development of new antibodies or 
by engineering the IF7 V regions into, for example, a mouse IgG2a backbone. 
Next, I investigated if the antibody could be used to specifically target a cytotoxic 
payload to MLL-AF9 leukemic cells. I showed that IF7 radiolabelled with lutetium 
was capable of significantly delaying the course of MLL-AF9 leukaemias. Given the 
highly aggressive nature and therapy refractoriness of this model of leukaemia, this 
was an exciting finding, which needs further exploration. The experiments presented 
were performed with mice in the late stages of disease and with only two doses of 
radiolabelled antibody treatment. Thus, further experiments are needed to determine if 
treating at an earlier stage when blasts first appear in the blood, with more 
sophisticated dosing regimens, perhaps combined with chemotherapy, could induce a 
more profound effect. The EphA2 targeting also provides proof of principle that other 
Eph monoclonal antibodies, including EphA3 or EphA7, could be used in a similar 
fashion. In adults MLL-driven leukaemias represent a minority of acute leukaemias 
but in childhood, particularly in infants, they commonly cause acute lymphoblastic 
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leukaemia with poor prognosis. Thus, antibodies that target these leukaemias may 
well have clinical usefulness, particularly in the paediatric setting 202.  
In chapter 4, the anti-leukemic effect of an antibody to EphA3, IIIA4 was examined. 
The EphA3 antibody was shown to exert a direct anti-leukemic effect in the LK63 
pre-B ALL model. By further testing of the EphA3-positive and the EphA3-negative 
xenograft models, I was able to show that this was a direct effect on the leukemic 
cells, with no evidence of an effect on normal host cells. In vitro studies had 
previously shown that this antibody had no effect on proliferation or cell survival but 
it clearly exerted an anti-tumour effect in vivo. Notably, treatment of the LK63 model 
with IIIA4 mAb had shown effects on tumour spread. This finding indicated that the 
antibody was able to directly alter spread from the bone marrow to other sites and 
suggested an effect on adhesion and migration. In an attempt to understand the effect 
of IIIA4 treatment on adhesion and migration of EphA3 positive leukemic cells, I 
showed that both ephrin ligand and IIIA4 could induce autophosphorylation of the Src 
kinase. Src kinase has been previously linked with a pathway that disrupts the 
cytoskeleton such that cells became less adhesive and motile 197. Consistent with 
effects on this pathway, I found that antibody treatment induced cells rounding and 
membrane blebbing, cellular changes, which had been reported previously in response 
to ephrin-stimulation 68. In future studies it will be important to analyse signalling 
pathways downstream and upstream of Src signalling pathway, including FAK, Rho 
family GTPases and paxillin. This will provide further insight into the mechanism 
involved in the anti-leukemic effect of the IIIA4 mAb treatment.  
The overall effect of IIIA4 mAb treatment in the LK63 model was a modest 
prolongation of survival suggesting that antibody alone might not be highly effective 
as a therapy. However, these models were depended on xenografts, which only 
formed in highly immunocompromised mice and thus there was no antibody-
mediated immune response that might synergise with the direct effect. In this regard, 
Kalobios has engineered a humaneered form of the antibody and shown that this 
elicits strong antibody-dependent cell cytotoxicity 203. This form of EphA3 antibody, 
KB004, is now in clinical trial. In the xenograft models, as with the studies of the 
EphA2 mAb in the MLL-AF9 model, a much more potent anti-tumour effect was 
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observed when IIIA4 was used to deliver a cytotoxic payload to the leukemic cells 
providing a further possible therapeutic approach for EphA3-positive leukaemias. 
Overall, in this thesis I showed that individual members of the Eph family are not 
essential for haematopoiesis and leukaemogenesis. However, I have shown that the 
Eph RTK family, in particular EphA2 and EphA3, represents a new group of potential 
therapy targets in haematological malignancies. Targeting of these proteins with 
monoclonal antibodies provides a highly specific means of delivering a cytotoxic 
payload to the tumour cells. I have thus far only explored delivery of radioactive 
isotopes but in principle this approach could also be used to deliver cytotoxic drugs, 
an approach already being used for other targets 157.   
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of highly conserved tyrosine residues and a PDZ-binding motif. The 
conserved tyrosine residues have been shown to serve as a docking site 
for proteins, which mediate downstream ephrin signaling [2,9] (Figure 
1b).
Keywords: Eph receptor; Ephrin; Receptor Tyrosine Kinase; 
Hematopoiesis; Hematopoietic Stem Cells; Leukemia
Classification, Structure and Binding of Eph/ephrin
The Eph receptors and their membrane bound ephrin ligands 
represent the largest family of receptor tyrosine kinases (RTK’s). The 
first member, EphA1, was originally termed Eph, as it was first identified 
in an Erythropoietin-Producing Hepatocellular (Eph Nomenclature 
committee, 1997) carcinoma cell line [1]. Fourteen members of the Eph 
family of RTK have been identified in mammals, which are divided into 
two groups, the EphA and EphB family. This is based on their sequence 
homology, ligand specificity and structural features. In mammals there 
are nine members of the EphA subgroup (EphA1-8 and EphA10) and 
five EphB receptors (EphB1-4 and EphB6) [2,3].
Eph receptors are type I transmembrane proteins composed of 
extracellular region including a ligand binding domain with two 
distinct ligand-binding interfaces (N terminal β jelly roll domain) 
determining the ephrin binding, and a cysteine-rich region containing 
an epidermal growth factor (EGF)-like motif that is involved in receptor 
dimerization followed by two fibronectin type-III domains [4,5]. The 
intracellular region comprised of a conserved juxtamembrane domain, 
a tyrosine kinase domain and a sterile alpha motif (SAM) domain, the 
latter having a potential role in receptor clustering [6,7]. Most of the 
Eph receptors, possess a C-terminal PDZ (Postsynaptic density protein, 
Disc large, Zona occludens tight junction protein) binding motif that is 
involved in signaling at a sub-cellular level and in the assembly of large 
molecular complexes [3,5,8] (Figure 1a). 
The ephrin ligands of Eph receptors are also membrane bound 
proteins and like the Ephs they are divided into two groups based 
on their structural features and preferential binding to either EphA 
or EphB receptors. The two classes of ephrin ligands are the A-class 
(ephrinA1-5) and B-class (ephrinB1-3) [3]. The two classes of the 
ephrin ligands have homology at their N-terminus region while their 
C-terminal amino acid sequence differs, the ephrin-A ligands that are 
bound to the plasma membrane by a glycosylphosphatidylinositol 
(GPI)-linker and the ephrin-B ligands, which possess a transmembrane–
spanning region and a highly conserved cytoplasmic tail with a number 
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Generally, the EphA receptors will preferentially bind to members 
of the ephrin-A ligands (ephrinA1-5) while the EphB receptors will 
preferentially bind to the ephrin-B ligands (ephrinB1-3) [3,10]. There 
is a high level of binding promiscuity between the Eph receptors and 
the ephrin ligands, however for an individual Eph receptor there is a 
distinct order of affinity of ephrin interactions with affinity constants 
ranging from 5-500 nM [11]. For instance the EphA1 receptor binds 
with a high affinity to ephrin-A1 and a lower affinity to other members 
of the ephrin-A family, including ephrin-A3 and ephrin-A4, and 
shows essentially no binding to ephrin-A5 [12]. Similarly EphA3 and 
EphB4 have a higher affinity for ephrin-A5 and ephrin-B2 respectively 
than for other members of the ephrin family [11,13]. High affinity 
interaction is also possible between the classes, for example EphA4 
binds to both ephrin-B and -A ligands and some of its most important 
functions depend on interaction with ephrin-B3. Another example is 
EphB2, which binds to ephrin-A5 as well as ephrin-B ligands [14,15] 
(Figure 2).
Eph/ephrin Activation and Signaling
Eph/ephrin interactions have the capacity to initiate bidirectional 
signaling. In other words both Ephs and ephrins can act as a ligand as 
well as a receptor and they both have the ability to initiate signaling. 
Signaling initiated by the Eph receptor is referred to as forward 
signaling whereas signaling initiated by the ephrin ligand is termed 
reverse signaling.
Eph receptor activation occurs following the physical association 
of the receptor and an ephrin ligand on adjacent cell surfaces mediated 
by the high affinity binding site (dimerization), this is followed by 
interaction with a second Eph/ephrin complex, mediated by separate 
low affinity (tetramerization) binding site to create a hetero-tetrameric 
complex [16]. The tetramers are then assembled into higher order 
clusters, which appear to be required for effective forward signaling 
[17,18]. The clustering of Eph receptors results in ligand-dependent 
auto-phosphorylation of several tyrosine residues within the 
cytoplasmic kinase domain and juxtamembrane region of the receptor, 
which serve as docking sites for downstream signaling proteins 
including the small GTPases of the Rho and Ras family, focal adhesion 
kinase (FAK), the Janus kinase/signal transducers and activators of 
transcription (Jak/Stat) and phosphatidylinositol 3-kinase (P13K) 
pathways [19]. 
Eph receptor activation influence cell shape and motility through 
the regulation of the Rho GTPases, including RhoA, Cdc42, Rac and 
Ras, via interactions with specific Rho GTPase activating (Rho GAP) 
and exchange (Rho GEF) factors. The interaction with individual 
Rho GTPases, mediated via direct binding to the cytoplasmic domain 
of Eph proteins of Rho GAP and Rho GEF or their recruitment via 
adaptor proteins, thereby mediating different effects on actin dynamics 
and cell process formation thus regulating cell shape and movement. 
For example, activation of EphA4 receptor results in recruitment of 
ephexin (Rho GEF), leading to activation of RhoA, and α-chimaerin 
(Rho GAP), leading to inactivation of Rac, jointly resulting in actin 
depolymerization and retraction of cell processes [15]. Activation 
through EphB plays a role in actin filament extension, morphogenesis 
and maturation of dendritic spines. Ras family of GTPases (H- and 
R- Ras) are also activated through Eph receptors however, unlike 
the Rho GTPases, the majority of Eph receptors negatively regulate 
the Ras/Mitogen-activated protein kinase (Ras/MAPK) pathway, 
with activation normally resulting in regulation of proliferation and 
migration [15].
Eph receptors are also important in mediating a number of other 
molecules involved in cell migration and adhesion due to their ability 
to regulate signal transduction   molecules including integrin signaling 
pathway elements paxillin, FAK, P130 (Cas) and integrins themselves. 
The effect of Eph signaling on integrins is complex as they can mediate 
either promoting or suppressing effects. FAK is important in mediating 
integrin signaling and Eph receptors can down-regulate this pathway 
[20]. 
The Jak/Stat pathway, involved in cell growth and viability, is 
regulated by EphA receptor activation [21]. EphB receptors mediate 
cell migration and proliferation through P13K pathway and the protein 
kinase B/phosphatidylinositol 3-kinase (Akt/ PI3K) pathway is involved 
in the regulation of cell proliferation and viability. Eph/ephrin also 
regulates other signaling pathways including Abl/Arg and p53-family 
of tumor suppressor proteins [19]. A recent study in glioblastoma 
multiforme (GBM) shows that loss of EphA3 results in elevated MAPK 
signaling thereby inducing differentiation and reducing proliferation 
and self-renewal. This study showed that regulation of extracellular 
signal-regulated kinases/mitogen-activated protein kinases (ERK/
MAPK) signaling by EphA3 is kinase independent of the upstream 
activators of MAPK signaling [22]. A similar finding has been made for 
GBM which express EphA2 at high levels [23]. 
In the ephrin-expressing cells reverse signaling can be induced 
after Eph/ephrin interaction [19,24]. Ephrin-B reverse signaling partly 
depends on the tyrosine phosphorylation of conserved residues in the 
cytoplasmic region, where phosphorylation is mediated by associated 
tyrosine kinases, most notably members of the Src family (Src, Fyn, Lyn, 
Yes) of tyrosine kinases. When the ephrin-B ligand is phosphorylated it 
can bind to cytosolic adaptor molecules via (Src Homology-2) SH-2 and 
SH-3 domains or PDZ domains [8]. The protein tyrosine phosphatase 
basophil-like (PTP-BL) has been identified as a negative regulator of 
ephrin-B signaling and it binds to ephrin-B through its C-terminal 
PDZ binding motif. De-phosphorylation of the ephrin-B cytoplasmic 
domain can inactivate the Src family of kinase and therefore cause 
termination of reverse signaling [25]. In the activated ephrin-B ligand, 
the PDZ motif plays an important role in assembly of other signaling 
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molecules. Ephrin-B binds to cytoplasmic protein PDZ-RGS3, which 
contains a PDZ domain and a regulator of G-protein signaling (RGS) 
domain. Activation of the ephrin-B ligand by EphB receptor via the 
PDZ-RGS interferes with signaling of the stromal derived factor (SDF)-
1 via its G-protein coupled receptor and the chemokine receptor-4 
(CXCR4). Ephrin-B reverse signaling has thus been implicated with 
regulation of migration in cerebellar development [26].
The ephrin-A reverse signaling mechanism is not well understood, 
however it is likely that the signaling response is initiated by activity 
of the Src family of RTK in which transmembrane adaptor molecules, 
associating with the lipid anchor of the ephrin-A proteins, transmit the 
signal across the membrane. For example ephrin-A5 induces signaling 
within the ephrin-A expressing cell when bound to its cognate Eph 
receptor [27-29]. 
Expression and Function of the Eph and Ephrin Genes
Eph signaling controls cell adhesion, migration, invasion and 
morphology by influencing integrin and intercellular adhesion 
molecule activity and by modification of actin cytoskeleton organization 
as described above. Through these mechanisms Eph function effects 
not only the processes of embryogenesis but also specialized cellular 
function in adult tissues, including bone remodeling, immune function 
and synaptic plasticity as well as cell proliferation and survival specific 
tissue stem cells as described further below [27,30].
Both Eph and ephrin proteins are important in regulating cell-cell 
interactions and their interaction can initiate either cell adhesion or 
repulsion. Cell repulsion occurs when bidirectional signaling triggers 
cytoskeletal contraction, loss of focal adhesions, cell rounding and 
cell detachment, whereas cell attachment occurs when signals are in 
favor of cell adhesion and migration [31]. This interaction influence 
many different cell behaviors during embryogenesis and in adult life 
[27]. Eph/ephrin interactions mediate formation of tissue boundaries 
(e.g. hindbrain rhombomeres) [32], control axon guidance during 
development and also tissue morphogenesis and patterning [33,34]. 
Eph/ephrin interactions are also involved in development of vascular 
system [35], stem cell biology [36], hematopoiesis, erythropoiesis, 
immune function and in tumor invasion and metastasis [27,30,37-39]. 
Many members of the Eph/ephrin family are expressed at high levels 
in some cancer cells and also elements of the tumor microenvironment, 
where they influence tumor growth and spread. Specific examples 
include lung, breast and prostate cancer, as well as melanoma, sarcomas 
and leukemias [40,41]. There is evidence that the Eph receptors can 
have either tumor suppressing or tumor promoting activity, depending 
on the tissue and their expression pattern [27]. Thus, the role and 
function of Eph/ephrins in cancer is not yet fully elucidated as some 
tumors show an elevated level of Eph expression while others show a 
decrease in Eph expression and as yet no single model of their function 
encompasses all cancers. For example EphA2 is up regulated in many 
cancers including breast and prostate and its expression is linked to an 
increase in malignancy [42,43] but it is down regulated in colon cancer 
[44]. Similarly, EphA1 expression is up-regulated in ovarian cancer [40] 
but down-regulated in advanced skin and colorectal cancers [45,46]. 
Studies have also shown the role of EphA7 as a tumor suppressor in 
follicular lymphoma [47], tumor suppressor function has also been 
reported for EphB receptors, including EphB2 and EphB3 in colorectal 
cancer [30,48]. EphB4 is another important example as this gene can 
act as either a tumor suppressor or an oncogene in different facets of 
breast cancer progression [49,50].  Table 1 represents the expression of 
Eph receptors in normal and malignant tissues [51-82].
The Eph/ephrin in HSC and Leukemia
Eph/ephrin expression in HSC and progenitors
The expression of Eph/ephrin has been detected on purified 
population of hematopoietic stem cells (HSCs) in both human and 
mouse. Gene expression analysis of HSC showed expression of 
ephrin-B2, indicating that it may be involved in signaling between HSC 
and their microenvironment. Other array based studies on primary 
human HSC (CD34+ hematopoietic cells) shows expression of the 
EphA1 protein and its ligands ephrin-A3 and ephrin-A4 suggesting that 
their interaction may play a role in hematopoietic stem and progenitor 
cell positioning and function [83,84]. Further analysis of CD133+ and 
CD34+ hematopoietic stem cells in peripheral blood showed expression 
of EphA2 in all CD34+ cells and the majority of CD133+ cells however 
EphB2 was expressed in all CD133+ cells and fifty percent of CD34+ 
cells, these data suggest that a number of elements of the Eph/ephrin 
system may have a role in HSC function through regulatory effects on 
cell adhesion, migration and differentiation but also that there may be 
a degree of functional redundancy between several Eph proteins [85]. 
Real-time quantitative PCR of mouse Lin-ckit+sca1+ (KLS) showed 
detectable expression of all EphA receptors except EphA6 and EphA8, 
along with ephrin-A ligands, with ephrin-A4 and ephrin-A5 being the 
most highly expressed ligands on purified HSCs in the mouse bone 
marrow [86]. Flow cytometric analysis of EphA2, A3, A4 and A5 along 
with ephrinA1-5 showed that EphA2 and EphA3 were the highest 
expressing EphA receptors. Expression of EphA2, A3, A4 and A5 was 
also detected in the mouse stromal cell lines however human stromal 
cell line showed only EphA2 expression at moderate levels [86]. Whilst 
the function has not been fully investigated, a role in HSC trafficking 
was demonstrated by treatment of mice with an Eph/ephrin inhibitor, 
EphA3-Fc, which resulted in mobilization of bone marrow progenitor 
cells into peripheral blood [86]. 
Some of the members of the Eph/ephrin family are also involved 
in development and regulation of mature hematopoietic cells. For 
example, EphA4 and EphB1 receptors along with ephrin-B1 ligand 
are expressed on human platelets [87], these studies also shows that 
EphA4 is involved in regulation of platelet aggregation and adhesion to 
fibrinogen, a process dependent on integrin αIIbβ3 engagement [39]. 
EphB4 was originally identified on human bone marrow CD34+ 
cells and its expression has been reported on erythroid progenitor cells 
in early stages of red blood cell development.  Significantly, the EphB4 
ligand, ephrin-B2, is expressed on bone marrow stromal cells [88] 
where it has been reported to be involved with regulating erythropoiesis 
via interaction with EphB4 [89]. Studies by Suenobu et al. [89] showed 
co-culturing hematopoietic progenitor cells expressing EphB4 with 
stromal cells expressing ephrin-B2 results in hematopoietic progenitor 
cells detachment from stromal layer and differentiation into a mature 
erythroid cells accompanied by EphB4 down regulation, however co-
culturing these cell with ephrin-B2-negative stromal cells resulted in 
less maturation of erythroid cells and no change to EphB4 expression 
[89]. Ephrin-B2 ectopic expression in stromal cells increased adhesion 
of hematopoietic cells to stromal calls and decreased transmigration 
of hematopoietic cells beneath a stromal cell monolayer.  These 
findings strongly support a role for the EphB4/ephrin-B2 interaction 
in migration and colonization of stem/progenitors cells in the bone 
marrow microenvironment [90].
 Some of the Eph/ephrin molecules are also involved in lymphoid 
development. The expression of Eph/ephrin has been studied 
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extensively in T-lymphocytes and expression of some of the members 
of this family including EphA1, EphA2, EphA3, EphA4, EphA7, 
EphB2, EphB6, ephrin-A1 ephrin-A3, ephrin-A5 and ephrin-B1 has 
been reported in the thymus, both on thymic stroma and lymphoid 
cells suggesting a role in T-cell development [91-93]. Interestingly, 
there are no reports of defective T lineage development in knockout 
mice, perhaps a result of there being multiple Eph receptors with over-
lapping functions in the T cell compartment. 
As well as T-lymphocytes the expression of Eph/ephrin gene has 
been also reported in B-lymphocytes [38,94,95]. EphA7 and EphA4 
transcripts were found in human fetal bone marrow pro-B and pre-B 
cells. EphA4 expression is found in both adult and fetal pro-B and 
pre-B lineage cells with high levels of expression in peripheral blood. 
The full length EphA7 transcript, however, was not found in mature 
fetal B-lineage and adult B-lineage cells. This suggests that EphA7 may 
be involved in expansion and /or differentiation of pre/pro B-cell but is 
lost on mature B cells [95]. Further studies show that there are different 
types of EphA7 mRNA, one of which encodes the full length EphA7 
and another splice variant encodes a truncated, soluble protein that 
lacks the cytoplasmic domain.  Studies by Dawson et al. [74] showed 
that normal lymphocytes express and secrete the truncated form of 
EphA7 [74], which have been shown to have tumor suppressive effects 
in lymphoma [47].
Eph/Ephrin in vascular development
In the context of hematopoiesis, the vascular system is crucial in 
development of blood cells within the bone marrow and also in the 
function and migration of mature hematopoietic cells.  The vascular 
system arises from two distinct processes known as vasculogenesis 
and angiogenesis. Vasculogenesis is an early event in embryonic 
development involving mesodermal cells differentiation to form a 
vascular plexus in embryonic tissues and angiogenesis is a process 
in which new blood vessels are formed from existing blood vessels. 
Angiogenesis has a role both in early development and in the adult 
hematopoietic system, it also promotes sprouting of new blood vessels 
in embryonic and postnatal vasculature and it has been shown to be 
important in development and metastasis of solid tumors [96]. Some 
members of Eph/ephrin family have established roles in vasculogenesis 
and angiogenesis. The expression analysis of Eph/ephrin using real-
time polymerase chain reaction (RT-PCR) has shown expression of 
EphB2, EphB3, EphB4, ephrin-B1 and ephrin-B2 in the yolk sac [97]. 
Ephrin-B1 expression has been detected on both arteries and veins 
while the high affinity ligand for EphB4, ephrin-B2, is only detected 
on arteries and EphB4 expression is only detected on veins. Knock out 
ephrin-B2 mice and some of the EphB2 and EphB3 double mutants 
mice have defects in embryonic vasculature and therefore these mice are 
embryonically lethal. EphB2 and ephrin-B2 expression in mesenchyme 
adjacent to vessels and the vascular defects in EphB2/EphB3 double 
mutants indicate a requirement for Eph/ephrin signaling between 
endothelial cells and surrounding mesenchymal cells [97]. EphA2 has 
also been reported to have a role in angiogenesis and the expression of 
EphA2 and its ligand ephrin-A1 has been reported in both human and 
mouse tumor vasculature [61]. 
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Eph/Ephrin on bone remodeling and formation
The bone marrow is the principal site of hematopoiesis in adult 
animals and requires both vascular and other stromal cell types to create 
the hematopoietic niche. Important amongst these are the osteoblasts 
and osteoclasts, which mediate bone formation and remodeling. Bone 
is constantly remodeled through resorption of mineralized bone by 
osteoclast and formation of new bone by osteoblast. Coupling of bone 
resorption and formation is critical during normal bone remodeling 
and it is necessary for bone growth, any deregulation in this process 
will result in pathological bone disease [19,78]. 
Eph receptors and ephrin ligands are important in bone remodeling 
and homeostasis during this process Eph/ephrin bidirectional signaling 
regulates differentiation and function of the bone cells. Real time PCR 
(RT-PCR) analysis of the Eph/ephrin showed mRNA expression of 
ephrin ligands, ephrin-B1, ephrin-B2 and ephrin-A1, A2, A4 and A5, as 
well as Eph receptors including EphB2-4, EphB6, EphA2-4 and EphA7 
receptors on osteoblastic and osteoclastic cells [98-100]. Expression of 
EphB4 is observed on the osteoblasts and forward signaling through 
EphB4 results in bone formation and reverse signaling through 
ephrin-B2 inhibit bone resorption therefore ephrin-B2/EphB4 act 
as coupling stimulator [98]. Expression of ephrin-A2 was observed 
during early osteoclastogenesis and unlike the ephrin-B2 it acts as 
coupling inhibitor as reverse signaling through ephrin-A2 result 
osteoclastogenesis and EphA2 forward signaling into osteoblast inhibit 
osteoblastic bone formation and mineralization [99]. Ephrin-A2/
EphA2 bidirectional signaling facilitates bone remodeling at initiation 
phase, forward signaling through EphA2 receptor on osteoblast inhibit 
osteoblastic differentiation and bone formation and reverse signaling 
into osteoclast through ephrin-A2 promote osteoclast differentiation 
[78,99]. Ephrin-B1 full knockout mice are prenatally lethal and they 
have skeletal defects. Studies on disruption of ephrin-B1 on collagen 
I producing cells result in reduced bone formation and skull defect 
and studies on ephrin-B1 conditional knockout mice shows defects in 
osteoblastic mediated bone formation with no increase in osteoclastic 
bone resorption and this condition results in reduction in bone size 
and density [101,102].  
The importance of Eph/ephrin interactions has also been shown in 
various stem cell niches, including neural, dental and intestinal stem cell 
compartments [103,104]. More recent studies show their involvement 
in bone homeostasis and mesenchymal stem cell (MSC) regulation. 
Arthur et al. [104] showed increase in osteogenic differentiation upon 
ephrin-B1 and/or ephrin-B2 expression by MSC. They also showed that 
ephrin-B1 activation promoted chondrogenic differentiation; therefore 
EphB/ephrin-B interactions may be involved in recruitment, migration 
and differentiation of MSC during bone repair [104]. Studies by Ting 
et al. [86]  shows that ephrin-A signaling interact with stem/progenitor 
cells in the bone marrow niche as it’s signaling mediates the release of 
progenitor cells from hematopoietic niche [86]. 
Interestingly, Eph/ephrin interactions are also involved in bone 
malignancies and tumors, osteocarcinoma is a malignant bone tumor in 
adolescence and microarray analysis studies show increased expression 
of EphA2, EphA4, ephrin-B1 and ephrin-A1 in osteosarcoma cells 
[105,106]. 
Eph/Ephrin expression in leukemia and other hematopoietic 
tumors 
Both chronic and acute myeloid leukemia are malignant diseases 
of the hematopoietic system which in most cases are believed to arise 
through the abnormal proliferation of either uncommitted or partially 
committed HSC [107]. The origin of other types of leukemia such as 
promyelocytic leukemia, pre-B acute lymphoblastic leukemia (ALL) 
and T-ALL and chronic lymphoblastic leukemia (CLL) are more likely 
due to malignant transformation of more mature progenitor cells. 
Expression of elements of the Eph/ephrin system has been detected on 
many types of human leukemia. One of the best studied is EphA3, which 
was originally identified in the LK63 pre-B ALL cell line and further 
investigations revealed its expression in T-cell leukemia cell lines such 
as Jurkat, JM and HSB-2 [65,108]. It has been shown that EphA3 can 
induce both adhesive and cell repulsive responses in different cell types 
[109]. In analyzing ephrin induced cell adhesion in LK63 cells, a critical 
role was identified for protein phosphatase activity, which prevented 
EphA3 phosphorylation and hence maintained the Eph/ephrin 
adhesive bond and prevented initiation of the signaling mechanisms 
leading to cell repulsion [31]. In leukemia, EphA3 is expressed at 
significantly higher levels compared to normal blood cells, elevated 
expression of EphA3 being detected in a proportion of clinical samples 
from cases of lymphoid and myeloid leukemias 111. Elevated EphA3 
expression has also been detected on other cancers such as lung cancer, 
melanoma and brain tumors [22,64,65,109], whereas expression was 
found to be absent or low in corresponding normal tissues [54,65,110]. 
Recent array based studies also showed EphA3 as one of the genes 
with copy number alteration (CNA) in the genome of acute myeloid 
leukemia (AML) patients [111]. Further studies by Guan et al. [112] 
showed copy number variation (CNV) of EphA3 to be associated with 
various types hematological malignancies and therefore CNV of EphA3 
could be used as a diagnostic indicator for different types of leukemia 
[112]. Many cancers, including leukemia, require multiple cooperative 
oncogene mutations for malignant cell transformation. Specific sets of 
synergistically dysregulated by cooperative oncogenes are known as 
cooperative response gene (CRGs), which regulate leukemia stem cell 
(LSC) growth and survival.  Studies by Ashton et al. [113], where stem 
cells were retrovirally transduced with two fusion genes found in human 
myeloid leukemias. NUP98-HOXA9 and BCR-ABL, have identified 
EphA3 as a common CRG.  They showed that shRNA knock down 
of EphA3 in leukemic stem cells reduced leukemic cell engraftment, 
concluding that this gene may be responsible for leukemia stem cell 
growth and survival in bone marrow microenvironment [113]. With 
the involvement of EphA3 in many different types of leukemia a high 
affinity monoclonal antibody to EphA3 (IIIA4) [65] has been fully 
humaneered by Kalabios and the resulting antibody, KB004, is now in 
phase I clinical trial in leukemia and other hematological cancers [114].
As mentioned previously EphB4 was originally identified in human 
bone marrow CD34+ cells and its expression been reported in erythroid 
progenitor cells, however it’s ligand ephrin-B2 is expressed in bone 
marrow stromal cells [88].  Co-expression of EphB4 and ephrin-B2 is 
found in the yolk sac, which is the first site of hematopoiesis and vascular 
development during embryogenesis. EphB4/ephrin-B2 expression 
has been shown in the majority of leukemia and lymphoma cell lines 
although expression in clinical samples appears less prominent [81]. 
Antibodies to EphB4 have undergone extensive pre-clinical evaluation 
and shown good anti-tumor effects in solid tumors, which over-express 
EphB4 and by inhibition of angiogenesis, although no efficacy has been 
shown in hematopoietic tumors to date [115]. Nevertheless, these 
antibodies may have the potential to be developed to target EphB4 in 
leukemia and related blood cancers.
Studies by Nakanishi et al. [75] shows EphA7 up regulation in 
the ALL1 associated leukemia (ALL1/AF4 and ALL1/AF9). They also 
showed that EphA7 up-regulation was associated with phosphorylation 
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of ERK and treatment with a phosphorylated ERK blocking drug 
resulted in apoptotic cell death in ALL1/AF4 leukemic blast cells [75]. 
Thus, anti-EphA7 antibodies or other inhibitors may well have a role 
in leukemia associated with this translocation. In contra-distinction 
to this positive role in leukemia, EphA7 is lost in lymphomas, where 
the gene is hypermethylated and repressed in germinal center B-cell 
non-Hodgkins lymphomas and this has a potential to influence tumor 
progression and spread [74]. In this study a soluble form of EphA7 
was shown to inhibit lymphoma in a mouse model, a chimeric protein 
consisting of soluble EphA7 and CD20 antibody had still greater 
therapeutic effect. Further studies show EphA7 as targeted tumor 
suppressor gene in T-cell lymphoblastic leukemia and lymphoma 
(T-LBL) and follicular B cell lymphoma [47,116]. 
EphB6 expression has been observed in normal human tissue and 
over-expression of EphB6 has also been reported in both myeloid 
[117] and lymphoid leukemias [82,118]. The expression level of EphB6 
decreases with maturation of the cells in T-cell derived leukemia-
cells, therefore suggesting that EphB6 expression regulates T-cell 
development but has less significant role in mature T cells [82].  To 
date there are no reports of experimental therapies targeting EphB6. 
Table 2 [110,119,120] represents the summary of Eph receptors used as 
therapy target in various malignancies. 
Summary
In summary, the aberrant expression of Eph receptors in 
hematopoietic tumors reflects the spectrum of functions of these 
receptors in all cancers. In some cancers these genes act as tumor 
suppressor, examples being EphA1 in colorectal cancer and EphA7 in 
follicular lymphomas. On the other hand these proteins can also have 
oncogenic effects, examples being the expression of EphA2 and EphA3 
in glioma and the over-expression of EphA3 in leukemia. In terms of 
therapy, the over-expression in certain tumors, taken together with the 
surface expression of these proteins, makes a strong case for targeted 
therapies. This is particularly the case when expression on normal 
tissues is minimal; this is exemplified by EphA3 and EphB4 where 
no toxicity was evident in pre-clinical testing of potential therapeutic 
antibodies. These studies reveal the therapeutic potential of targeting 
components of the Eph/ephrin system in leukemia and other cancers. 
These results should prompt further research into the specific roles 
of these proteins in different cancers as a prelude to designing and 
optimizing the therapeutic targeting of these proteins.
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